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This thesis describes development of organocatalytic methods for the synthesis of chiral 
organofluorine molecules with focus on nitrogen-containing species as potentially bioactive 
compounds or synthons towards bioactive scaffolds. The methodology relied on seeking 
suitable fluorinated substrates to achieve molecules containing novel -fluoro--amino core 
as well as -fluoro--amino core via organocatalytic enantioselective CC bond forming 
reactions.  
Chapter one describes the use of fluoronitroacetic acid esters as donors in organocatalytic 
Michael addition to nitroalkenes to achieve enantioenriched products, which were derived 
into novel -fluoro--amino ester, -fluoro-,-diamine precursors as well as -fluoroesters. 
Chapter two details the development of 1-fluoro-1-nitro-1-arylmethanes as prochiral donors 
which in enantioselective Michael addition led to direct precursors of -fluorinated diamines. 
The method was applied to synthesize fluorinated mono- and diamines and heterocycle - 
tetrahydropyrimidine. 
In the third chapter, route towards fluorinated phosphonates as phosphates mimics is 
presented. Application of racemic -fluoro--ketophosphonates in organocatalytic Michael 
addition resulted in highly enantioselective preparation of branched and functionalized -
fluoro--nitrophosphonates. Further manipulation of the product structure led to the 
preparation of pyrrolidine containing -fluorophosphonate, structure being analogue of 
recently developed endothelin-A receptor antagonist. 
Chapter four describes the further study on application of 2-fluoro-1,3-dicarbonyl compounds 
as Michael addition donors, which results in enantioselective preparation of compounds being 
direct precursors of fluoro-isosteres of glycerine. The facile reduction of the representative 
product led to trisubstituted 2-fluoro-1,3-diol with three tertiary stereogenic centers 
surrounding the fluorinated quaternary asymmetric carbon. 
X 
 
The last chapter in the results section - chapter five - shows how simple manipulations of 
enantiomerically enriched Mannich addition product led to valuable and potentially bioactive 
molecules such as -fluoro--amino ester, -fluoro--lactam and lactone. The following, 
studies on tandem mono-decarboxylation / asymmetric protonation of the fluoromoalonate 
Mannich adducts resulted in preliminary development of interesting methodology for 
enantioselective preparation of linear -fluoro--amino acids and -lactams.  
Section three provides a brief summary and conclusion, as well as preliminary results and 
future perspective. As an implication of studies towards decarboxylation/asymmetric 
protonation, decarboxylative addition of fluoromalonate halfesters was designed and in-
principle proven as an effective synthetic pathway towards linear -fluoro--amino acids, 
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I.1.Importance of organofluorine in medicinal chemistry 







I. Introduction: chiral organofluorine compounds 
 
The introduction is divided into two sections. In the first part, physicochemical properties of 
fluorine atom are briefly described, followed by a few selected examples of incorporating 
fluorine atoms into specific bioactive compounds to alter targeted properties. The second part 
summarizes synthetic methods for making fluorinated molecules: direct and indirect 
fluorination. The section on direct fluorination is further divided into organocatalytic and 
metal-catalytic methodologies.  
I-1. Importance of organofluorine in medicinal chemistry 
 
Fluorine is a unique atom in the periodic table and has a very special place in modern 
science.
1
  Even though human body contains an average of only 3 mg of this element,
2
 there 
has been much interest in selective introduction of fluorine into organic compounds in the last 
few decades. This section aims to describe the basic characteristics of fluorine atom and 
carbonfluorine (CF) bond, and briefly discuss the various effects of fluorination on the 
properties of bioactive compounds using specific examples; and in such a way explain and 
substantiate the interest in fluorine of life and chemical sciences. 
I-1.1. Properties of fluorine and the CF bond. 
 
Fluorine has an extreme electronegativity of  = 4 on Pauling‟s scale, with that of oxygen ( 
= 3.5) being the closest. In comparison, the next most electronegative halogen, chlorine, has 
the electronegativity of  = 3. Having the largest electronegativity of all elements, fluorine 
has a small size - its van der Waals radius is estimated as 1.47 Å, which is 0.27 Å more than 
hydrogen and 0.28 Å less than chlorine, while being very close to that of oxygen (1.52 Å). 
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The C-F bond length is estimated to be 1.35 Å and is only longer than C-H bond (1.09 Å) and 
shorter than all other C-X bonds, with C-O (1.43 Å) and C-N bonds (1.47 Å) being of the 
most similar length.
3
 The high electronegativity paired with small size results in a very low 
polarizability of fluorine atom. At the same time, the C-F bond has a very large dipole 
moment of 1.85 D for fluoromethane and 1.97 for difluoromethane, decreasing with further 
fluorination. It is the strongest of all covalent bonds in organic chemistry with dissociation 
energy calculated as 105.4 kcal/mol (in comparison, the second strongest bond C-H has 
dissociation energy of 98.8 kcal/mol). Interestingly, the C-F bond is hydrophobic despite its 
high dipole moment (polar hydrophobicity), and the effect translates to the whole molecule - 
the electron withdrawing character of fluorine decreases polarizability, and consequently 
increases hydrophobicity of the whole compound.  Despite the high dipole moment, which 
would favor H-bonding interactions, the low polarizability of the fluorine prevails, and as a 
result fluorine is a very weak hydrogen bond acceptor, yet during recent computational study 
of the protein database bank,
4
 hydrogen bonding interactions involving fluorine were found in 
18% of screened protein-ligand complexes, while coordination of metals to hydrocarbons 
through organofluorine is a fact.
5
  
These characteristics of fluorine result in its increasing applications in the fields of medicinal 
chemistry and biochemistry. Having the basic characteristics so close to those of oxygen, 
fluorine can mimic oxygen or hydroxy group in bioactive compounds (fluoro-isostere). 
Replacement of C-H with a stronger C-F bond results in minimal steric but dramatic 
electronic alteration, which understandingly became a useful tool in drug design and 
biochemistry. The high electronegativity of fluorine with its minimal steric effects are utilized 
to tune acidity and basicity of neighboring functional groups, thus influencing lipophilicity, 
tuning potency and modifying pharmacokinetic properties of a compound. For example, the 
pKa values of acetic acid and its fluorine-incorporating analogues are as follows: 4.76 
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(CH3CO2H), 2.59 (CH2FCO2H), 1.24 (CF2HCO2H) and 0.23 (CF3CO2H); pKb values for 
ethylamines increase with fluorination: 3.3 (CH3CH2NH2), 4.03 (CH2FCH2NH2), 6.48 
(CF2HCH2NH2) and 8.3 (CF3CH2NH2).
6
 Moreover, due to the rarity of occurrence of fluorine 
in natural peptides and proteins, as well as its very low background signal, high sensitivity 
and large chemical shift, 
19
F NMR is a powerful tool in peptide analysis and could also be 
used to elucidate reaction mechanisms. Fluorine‟s unnatural isotope 
18
F is the most widely 
used isotope in positron emission tomography (PET) – a now common method in medical 
diagnostics, because of its low positron energy (safe for patient) and relatively long half-life 
(110 mins) to allow sophisticated measurements (yet short enough to conduct kinetic studies). 
The characteristics of fluorine listed above are the reason why this element found application 
in “rational” drug design. In the following section, some specific examples will be reviewed, 
where certain effects were observed after selective incorporation of fluorine into the 
molecular structure. 
I-1.2. Altering characteristics of molecules by selective incorporation 
of fluorine.  
 
Campothecin (CPT, Figure 2) is a pentacyclic alkaloid isolated from Camptotheca Acuminate 
and was found to possess high antitumor activity by inhibiting topoisomerase I (Top1). 
However the potential applications of this compound was hampered by its instability, 
attributed to the vulnerability of the lactone moiety. Moreover, this compound was also 
hepatoxic. In fact, lactone is a common motif in bioactive compounds, therefore, improving 
the stability of CPT could help resolve similar issues with other leads. It was proposed that 
substitution of carbonyl oxygen with fluorine would increase hydrolytic stability of the 
compound, without generating excessive steric hindrance.
7
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Figure 2. The structure of Campothecin and the proposed alteration by fluorination. 
Indeed, upon fluorination, the stability was dramatically improved; after 6 hours the CPT 
analogues (I-2) and (I-3l, R1 = c-hex, R2 = R3 = H) were both hardly affected (96% in original 
form), while only 42.7% of CPT remained intact (Figure 3, C). Understandably, fluorination 
affected other features of the compound as well, and not all in a positive way. It was found 
that fluorocampothecin was less active against common cancers. This problem was resolved 
by structural optimization and eventually highly potent compound I-3l was identified as a 
potential lead, exhibiting the same potency as the clinically relevant reference - Topotecan 
(TPT, Figure 3, A - inhibition of tumor growth), while at the same time causing almost no 
loss in mice body weight - which can be approximated to low toxicity - as compared to 
significant weight loss caused by TPT (B, Figure 3). 
 
Figure 3. A) Potency of compound I-3l (1-3l: purple-2 mg/kg, pink-4 mg/kg; green-TPT-0.5 mg/kg; 
blue-control; B) Weight loss of mice (8l: green-2 mg/kg, violet-4 mg/kg; red-TPT; blue-control); C) 
Hydrolytic stability of CPT (green) and its two fluorinated analogues at pH = 7.4: 1-2 (blue), 1-3l (red). 
Lipophilic compounds are thought to be metabolized by liver enzymes (especially 
cytochrome P450). Two strategies are: increasing polarity of the compound (however, 
6 
 
decreasing membrane permeation) or blocking metabolically vulnerable points with fluorine 
(however, some other effects may also emerge). The latter strategy was successfully 
employed to reinforce the stability of SCH48461 (I-4, Figure 4) - a cholesterol absorption 
inhibitor. Incorporation of fluorine into the phenyl ring of SCH48461 prevented its oxidation 
to phenol, while substitution of labile methoxy with fluorine prevented its dealkylation. As a 
result, Ezetimib (I-5), which is a stable compound and is 55 times more potent than I-4, has 




Figure 4. Development of Ezetimib I-5 - a more stable and potent version of lead SCH48461. 
 
Sugar nucleosides play multiple roles in biological systems such as neurotransmission, 
regulation of cardiovascular activity and signaling, in addition to being key compounds in 
cellular biosynthesis. As such, they constitute an important pool for development of antiviral 
and antitumor agents in medicinal chemistry. Since fluorine is an excellent hydroxyl 
surrogate, incorporation of fluorine atom into nucleoside structures has become an important 
approach in drug development. The most profound effects of fluorine incorporation include: 
strengthening of glycosyl bond and consequently increasing stability against phosphorylases, 
increasing lipophilicity and decreasing polarizability of nucleoside (polar hydrophobicity) and 
inducing strong stereoelectronic effects due to fluorine‟s preference for gauche and 
antiperiplanar orientation.  Following the discovery of novel carbocyclic-, thio-, phospha- and 
azanucleosides, and their potent antiviral activities, a series of nucleosides either directly 
fluorinated at 2‟, 3‟, 5‟, 6‟ positions, or substituted with various fluoroalkyl substituents have 
been prepared and evaluated for their antiviral properties. For instance, FdC (I-6, Figure 5) 
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 and FIAC (I-8)
8c
 were found very active against herpex simplex, varicella 
zoster (VZV), cytomegalovirus (CMV), and Epstein–Barr (EBV) viruses; Gemcitabine (I-9) 




Figure 5. Fluorinated nucleosides with biomedical applications. 
The development of fluoroquinolone antibiotics began with the discovery of nalidixic acid (I-
10, Figure 6) as an impurity in quinine, and its following application in treating urinary tract 
infection.
9
 After 25 years, during which period occasional research eventually shed light on 
the effects of fluorination on properties of quinolones, several antibiotic agents have been 
developed, such as: perfloxacin (I-11), ciprofloxacin (I-12), levofloxacin (I-13), moxifloxacin 
(I-14) and the newest - sitafloxacin (I-15). Notably, all the compounds bear a fluorine atom at 
C6 of the aromatic ring. This substitution was found to dramatically increase potency of the 
leads (2  17-fold increase in DNA gyrase-inhibitory and 2 100-fold increase in cellular 
potency).  These observations are rationalized and attributed to the effects of fluorine on 
binding, cell penetration and pKa modulation.
1a
 Interestingly, the unusual fluorocyclopropyl 
substituent on sitafloxacin was found to decrease the overall lipophilicity and improve 
selectivity against mammalian topoisomerase II.
10
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Figure 6. Fluoroquinolone antibiotics. 
Strategic incorporation of fluorine to modify pKb was used as a tool in the development of 
MK-0731 (I-17, Figure 7), a taxane-refractory antitumor agent, currently in clinical trials.
11
 
The lead compounds (I-16a-c) were found to exhibit promising kinesin spindle protein 
(KSP)
12
 inhibiting properties. It was found that the basicity of the piperidine ring was crucial 
in further optimization. In order to bring the pKb to the envisioned optimum range (6.5-8.0), 
installation of substituents on piperidine nitrogen was attempted. N-Cyclopropyl substituent in 
I-16a resulted in unintentional time-dependent cytochrome P450 inhibition; fluoroalkyl group 
on the piperidine nitrogen in I-16b was found to transform into I-16c and produce 
fluoroacetic acid as highly toxic metabolite. On the other hand, introduction of fluorine into 
the piperidine ring resulted in achieving the desired pKb range, while not causing any major 
additional side effects. Interestingly, the effect of fluorination on pKb was found to depend on 
configuration; the diastereomer with equatorial (or trans) fluorine (I-18) had pKb = 6.6 
(brought down from 8.8 in parent compound), while (1-17) with axially installed fluorine (cis) 
exhibited pKb of 7.6 and was eventually advanced into clinical trials.     
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Figure 7. Modulating pKb by fluorination in the development of MK-0731 (I-17). 
 
The structural motif of fluorinated cyclic amine is established as a valuable component in 
drug design.
13
 Variations of such fluorinated cyclic-amines were targeted during the course of 
our research and resulted in the development of general route towards -fluoro-
tetrahydropyrimidines (see Chapter II-2) and phosphonate-containing pyrrolidines (Chapter 
II-3).  
Amino acids are the basic building blocks of peptides, which in turn are larger building units 
for a variety of biomolecules, e.g. proteins. The development of functional peptides is a 
daunting challenge, suffering from limited structural variation within the pool of 
proteinogenic amino acids, as well as poor metabolic stability, bioavailability and lacking 
potency of peptides consisting of natural amino acids units. On the other hand, fluorinated 
amino acids are interesting analogues of natural and synthetic amino acids, with some unique 
properties attributed to fluorination. However, due to the complexity of biological systems, 
specific applications of fluorinated amino acids are rare and underdeveloped. Given the 
unique properties of fluorine, this will certainly emerge with further advancements in life 
sciences and synthetic chemistry - broadening the pool of tunable, fluorinated molecules. 
Electronic properties of fluorine could be used to alter pKa and pKb values and lipophilicity 
of individual amino acids or the whole peptide, increasing membrane permeation, affecting 
metabolism, or binding to molecular plasma.  Fluorine also affects the stability, flexibility and 
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conformation of peptides, their higher order structures and interactions with proteins.
14
 
Furthermore, interesting reactivity may also emerge. For example, elimination of hydrogen 
fluoride from fluorinated amino acids and formation of active -carbanion Michael acceptors 
could inactivate decarboxylases or transferases (suicide inhibitors).
15
 
The effect of fluorination on interactions between peptide and receptor was studied on a 
model example of chemotactic peptide For-Met-Leu-PheNH2 (fMLF) from Escherichia coli. 
The role of the chemoattractant is to bind to the hydrophobic receptor of neutrophil, which 
initiates chemotaxis, as a response to infection. Therefore, it is a good system to study the 
effects of fluorination on hydrophobicity versus polarity and sterics.
16
 The analogues of fMLF 
were prepared in which leucine was replaced with (R) or (S) difluoro- or trifluoro- glycines or 
alanines.  In general, it was found that all new peptides were active, however their activities 
were lower than that of the native peptide. Moreover, the R/S configuration was crucial and 
brought 100% increases or decreases in binding affinity. The steric demands of 
trifluoromethyl group were confirmed and found favorable in this case, while the polarity of 
difluoromethyl group was detrimental. This example illustrated complexity that may arise 
from fluorinated analogues of peptides. Similarly complex, favorable effects were observed 
for a similar complex. Enkephalins - one of native peptide ligands of opioid receptors, play an 
important part in regulation of central nervous system pathways.
17





]enkephalin (DPDPE) was modified by introducing either (D) or (L) 
4,4-difluoro-2-aminobutyric acid ((D) or (L)-DFAB, I-19, Figure 8). The analogues showed 
unexpected selectivity patterns compared to the non-fluorinated modifications, and improved 
selectivities were observed for (D)-fluorinated amino acids (as compared to preference for 
(L)-natural amino acids).   
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Figure 8.Modification of encephalin -opioid peptide DPDPE (I-20). 
At the same time, a pronounced fluorine effect was observed and the newly developed peptide 
(I-20) displayed 100-fold higher  agonist potency than its non-fluorinated counterpart. The 
increase in potency and reversed configuration/selectivity pattern was rationalized as increase 
in hydrophobic contact, hydrogen bridges with fluorine, modified electrostatics via polarized 
C-F bonds as well as displacement of water molecules from the binding site.  
The complexity and the scale of the observed effects caused by incorporation of fluorinated 
amino acids into bioactive molecules, motivate the search and development of general 
synthetic routes towards those molecules. Such studies were undertaken during the course of 




I-2. Synthesis of chiral fluorinated molecules 
 
This section summarizes the synthesis of organofluorine compounds with focus on the classes 
of chiral, functionalized molecules, relevant to the overlapping fields of synthetic, medicinal- 
and bio-chemistry. Due to constrain as to the volume of this chapter, racemic perfluorinated 
molecules and asymmetric trifluoromethylation, will not be discussed. The section is divided 
into two parts: direct fluorination (organocatalytic and metal-promoted methodologies) and 
indirect fluorination (the use of fluorinated prochiral donors).  
I-2.1. Direct asymmetric fluorination  
The most straightforward method to access chiral fluorinated molecules is enantioselective 
fluorination. It is a difficult synthetic task that requires addressing several challenges such as: 
chemo- and enantioselectivity, activation of unreactive substrates while avoiding bis- or 
perfluorination. Due to the characteristics of fluorine atom, the fluorinating reagents in 
general are reactive and can breakdown functionalized molecules. Therefore, preparation of 
fluorine-containing substrates or target molecules via direct fluorination has been and will 
remain a challenge for many years to come. The practical enantioselective methods for 
enantioselective installation of fluorine employ electrophilic N-F reagents, such as: 
Selectfluor
®
, NFSI (N-Fluorobenzenesulfonimide) as well as N-S-F reagents such as: DAST 
(Diethylaminosulfur trifluoride), morpho-DAST (Morpholinosulfur trifluoride) or metal or 




 (Figure 9). This introduction will explore and present 
the most practical enantioselective fluorination methodologies based on the application of 
common mild electrophilic fluorinating reagents and activation by metal or metal-free 
catalysts, with focus on the scope and diversity of synthetic molecules
18
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Figure 9. Common fluorinating reagents. 
 
I-2.1.1. Organocatalytic enantioselective fluorination  
 
In the late 1980s, attention was given to the development of chiral, stoichiometric fluorinating 
agents, such as N-fluorocamphorsultams
19
 and N-F sulphonamides.
20
 These fluorinating 
agents will not be covered in this introduction, as their synthesis require multistep procedure 
and the usage of elemental fluorine or perchloryl fluoride, while the ee values of products 
were usually low to moderate and substrate scope was limited. In the early 2000s, improved 
chiral fluorinating agents (I-30 – I-32, Figure 10) were prepared from Cinchona alkaloids or 





Figure 10. Cinchona alkaloid-derived enantioselective fluorinating agents. 
These chiral N-fluoroammonium salts were used as pure compounds, or generated in situ, in 
enantioselective fluorinations of enolates of selected ketones (I-35a - I-35e, Figure 11), a few 
-ketoesters (I-33 - I-34) and -cyanoesters (I-43 - I-47) as well as oxindoles with moderate 
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to high ee values of 37% ee – 91% ee and good to excellent yields of 55 (12)% - 99% (I-37 - 
I-42) and later on - nitroesters with poor enantioselectivities of up to 40% ee and substrate-
dependent yields of 8% - 85% (I-48 - I-51).
21
 Notably, the special oxindole derivative 
prepared in 5 steps from 3-trifluoromethylaniline was efficiently fluorinated with these 
reagents by two groups independently, leading to (S)-BMS-204352 in 88% ee or 84% ee with 
enantiopure form attainable after recrystallization (I-52); (S)-BMS-204352 is an anti-ischemic 






Figure 11. Products attainable via fluorination with Cinchona alkaloid-derived 
enantioselective fluorinating agents 
In a similar fashion, fluorination with in situ generated N-fluoroammonium salts of pseudo-
enantiomeric bis-Cinchona alkaloid ((DHQ)2PHAL), both enantiomers of 20-deoxy-20-
fluorocamptothecin were obtained with 88% ee (R enantiomer) and 81% ee (S enantiomer) by 
Shibata and coworkers (I-54, Scheme 1; an isosteric analogue of camptothecin).
23
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Scheme 1. Enantioselective fluorination of 20-deoxycamptothecin. 
Attempts to enantioselectively fluorinate amino acids analogues are rare, due to the basicity 
of the amino function and the difficulty in controlling the stereoselectivities. To date, there is 
only one report by the group of Cahard on fluorination of N-phthaloylphenylglycine (I-56a, 
Scheme 2) and its nitrile analogue (I-56a) achieving 76% ee (94% ee for nitrile).
24
 However, 
hydrolysis to free the amino group (and/or hydrolyze nitrile to acid) was not attempted and 
doubtful (harsh and/or acidic conditions usually lead to de-fluorination; unsuccessful cleavage 
of N-phthaloyl protecting group to free fluorinated glycine derivative was reported ten years 




Scheme 2. Fluorination of N-phthaloylphenylglycine. 
Semi-pinacol rearrangement, a different type of transformation, yet still based on the same in 
situ-generated N-F Cinchona alkaloid-derived salts, was reported by the group of Tu (Scheme 
3).
26
 The results, however were far from practical, with yields ranging from 33 % - 50 % and 
enantioselectivities from 54 % to 74 %.  
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Scheme 3. Semi-pinacol rearrangement with chiral N-F salt. 
The major drawback of the methodology is the requirement for stoichiometric amount of 
chiral promoter. The use of catalytic amount of chiral inductor in fluorination of silyl enol 
ethers of selected ketones (I-35aI-35e) led to expected products in racemic form. 
Racemization was due to the background fluorination by Selectfluor
®
 and not chiral 
Cinchona-derived N-F salt; which was later overcome by employing acyl enol ethers, which 
were unreactive towards Selectfluor
®
 alone, leading to improved enantioselectivities of up to 
54 %.
27 
Efforts were put into developing polymeric or polymer-supported Cinchona alkaloid-
based N-fluoroammonium salts as a practical and industry-friendly approach. The application 
of one of the polymeric fluorinating agents was demonstrated on the enantioselective 
fluorination of silyl enol ether of aromatic bicyclic ketone (Scheme 4), where good 
enantioselectivity of 84 % was obtained, and the promoter was recycled three times without 




Scheme 4. Fluorination with polymer-supported N-F salt. 
 
Apart from the application of stoichiometric chiral N-F reagents, other methods were recently 
developed, based on the application of organocatalysts in combination with NFSI and 
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. One of the first reported organocatalytic methodologies relied on phase-trasfer 
catalysis (PTC), as demonstrated by several contributors following the first report by Kim and 
Park.
29
 Enantioselective fluorination on simple substrate - cyclic -ketoesters (I-63ae, 
Scheme 5) was performed by using Cinchona alkaloid-derived PTC catalyst (I-67), and very 
good yields (78 % - 92 %) and modest enantioselectivities of up to 69% were achieved. Later, 
the scope of substrates was expanded to -cyanoesters (I-64ae), from which the 





Scheme 5. PTC fluorination of keto- and cyanoesters by Kim and Park. 
Shortly after, reports appeared on the development of simple organocatalysts for the 
enantioselective fluorination of aldehydes by three groups independently and almost 
simultaneously, all applying enamine catalysis. Barbas and co-workers demonstrated the 
application of prolinol derivatives as catalysts for arrange of aldehydes (I-68a – j, Scheme 6) 
achieving up 96 % ee.
31
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Scheme 6. Fluorination of aldehydes by Barbas and coworkers. 
Jorgensen and coworkers reported similar fluorination of simple aldehydes mediated also by 
prolinol derivative (I-76, Scheme 7), with subsequent reduction yielding sterically stable 




Scheme 7. Jorgensen‟s fluorination of simple aldehydes. 
The same methodology was later applied by the Yamamoto group in the synthesis of highly 
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Scheme 8. Synthesis of chlorofluorohydrins and functionalized ketones. 
Equally effective results were obtained by the MacMillan group (however with higher 
catalyst loading to that of Jorgensen‟s) – aldehydes were fluorinated and reduced to 
corresponding 2-fluoro alcohols in good to excellent yields and with excellent enantiomeric 
control (91 % ee – 99 % ee, Scheme 9).34  
 
Scheme 9. MacMillan‟s organocatalytic fluorination of aldehydes  
The same group also demonstrated formal addition of HF in the tandem transfer 
hydrogenation / fluorination of an ,-unsaturated aldehyde (I-80, Scheme 10), in good yields 
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Scheme 10. Formal addition of HF by tandem transfer hydrogenation / fluorination. 
Fluorination of -branched aldehydes is much less common. One example was demonstrated 
by Barbas (Scheme 6). More extensive study was undertaken by the Jorgensen group, and 
resulted in the development of atropoisomeric catalyst (I-76b, Scheme 11).
36
 The 
methodology was found applicable mostly to aldehydes with one aromatic substituent 
(36%60%, 78% ee - 90% ee), while aldehydes with all aliphatic substituents were found 
unreactive (10% - 29%, 7% ee - 31% ee).  
 
Scheme 11. Fluorination of branched aldehydes by Jorgensen. 
Fluorodesilylation reactions are of practical interest as these methods leading to allylic 
fluorides. One such organocatalytic transformation was reported by the group of Gouverneur; 
allyl fluorides were obtained, with substrate dependent enantioselectivities ranging from 22 % 
to 96 % (Scheme 12, X = CH2 only).
37
 The original method requiring an equivalent amount of 
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alkaloid was later improved by Shibata and coworkers, who achieved similar transformation 




Scheme 12. Fluorodesilylation by Gouverneur and coworkers. 
Fluorination of silyl enol ether was also realized in a desymmetrization process with chirality 
induced by C2-symmetrical base (I-89, Scheme 13).
39
 The interesting bicyclic fluorinated 
ketone (I-88) was obtained in 55% yield and with 60 % ee. Unfortunately the transformation 
required an equivalent amount of chiral base. 
 
Scheme 13. Fluorination of  bicyclic ketone mediated by chiral base. 
Biologically-relevant fluorinated flavones were synthesized in a tandem process developed by 
Zhao and co-workers (Scheme 14).
40
 Extensive investigation of scope revealed the reaction 
was general and highly effective for substrates with aromatic substituents (R2, I-90a-v) - 86% 
ee – 93% ee and high yield, but less stereoselective for substrate with heterocyclic substituent 
(73% ee) and hardly enantioselective for substrate with two aliphatic substituents (R1 and R2 – 
only 17% ee).  
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Scheme 14. Tandem Michael addition/fluorination leading to fluorinated flavones. 
The transformation is believed to be a stepwise process – oxa-Michael intramolecular 
cyclization with diastereoselective fluorination of the intermediate enolate. 
Until recently, effective enantioselective fluorination of ketones has not been realized by 
means of organocatalysis, due to low reactivity (slow enamine formation) and existence of 
rotational isomers of enamine active species. The breakthrough report came recently from 
MacMillan‟s group communicating the first organocatalytic fluorination of simple cyclic 
ketones, catalyzed by dihydroquinidine (I-92, Scheme 15), with extension to three 
heterocycles (I-91m – n).41 
 
Scheme 15. Organocatalytic fluorination of cyclic ketones. 
This method was only applicable to cyclic ketones, mostly cyclohexananone derivatives, with 
no advancement or further development to date. Practical extension of Jorgensen‟s 
enantioselective fluorination of aldehydes was developed by the same group - one pot 
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synthesis of propargylic fluorides.
42
 The first step in the process was asymmetric fluorination 
of aldehydes as reported by Jorgensen earlier (see Scheme 7), followed by Seyferth–Gilbert 
reaction (with Ohira–Bestmann modification – to avoid racemization), leading to the desired 
propargylic fluorides in fair yields and with excellent enantioselectivities (up to 99%, Scheme 
15).  
 
Scheme 16. One-pot synthesis of propargylic fluorides. 
In the young field of organocatalytic enantioselective fluorination, the single most general 
methodology is to carry out fluorination of aldehydes via iminium/enamine-catalysis, 
followed by reduction. The obtained fluorinated alcohols could then be used in target 
synthesis. Of practical importance is synthesis of fluorinated propargylic fluorides - class of 
compound directly applicable to further coupling. Further advancement of ketone 
fluorination, would be of great importance, as such stable synthons could later be transformed 
into fluorinated nitrogen-containing species.    
                                                          
42
 a) For a review on propargylic fluorides and their importance see: M. C. Pacheco, S. Purser, V. 
Gouverneur, Chem. Rev., 2008, 108, 1943; b) H. Jiang, A. Falcicchio, K. L. Jensen, M. W. Paixao, 
S.Bertelsen, K. A. Jørgensen, J. Am. Chem. Soc., 2009,131, 7153. 
24 
 
I-2.1.2. Transition metal-catalyzed enantioselective fluorination 
 
The very first enantioselective fluorination was achieved with titanium-taddol complex (I-
100, Scheme 17) and reported by Togni and Hintermann on linear -ketoesters, with 
Selectfluor
®
 as a fluorine source.
43
 Since then, similar methodologies employing various 
transition metals and ligands appeared, with -ketoesters as model substrates - owing to their 
acidic -proton and two carbonyl groups capable of coordination with the transition metal to 
form stable 6-membered ring intermediate. 
 
Scheme 17. The first enantiocatalytic fluorination by Togni and Hintermann. 
In 2002 Sodeoka et al. disclosed the use of Pd-BINAP catalytic systems for highly 
enantioselective fluorination with NFSI (Scheme 18).
44
 Cyclic and linear fluorinated -
ketoesters (I-101a-e) were obtained in very good yields and with high enantioselectivities 
(83% to 92% ee). Later on, the scope of the reaction was expanded to include lactone and 
lactams (I-102f-k).
45
 In the case of lactone, more sterically demanding solvent (isopropanol) 
was found advantageous for high level of stereo-control (98% ee eventually), while less 
reactive lactams (less acidic -proton) required the addition of 0.5 equiv. of organic base (2,6 
lutidine) to facilitate formation of palladium enolate and bolster the yields of desired products 
to 45% - 89%, while retaining excellent enantioselectivities of 94% to 99%.   
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Scheme 18. Sodeoka‟s fluorination of -ketoesters. 
Similar results were later obtained for enantioselective fluorination of similar -ketoesters 
using chiral oxazolidine-featuring complexes (I-105, Figure 12) with copper as metal 
promoter (up to 96% yield and 85% ee),
46
 and copper and nickel in the study by Shibata and 
Toru (I-105 and I-106, up to 93% yield and 99% ee).
47
 Improved results for the same 
reactions were achieved subsequently by employing tridentate oxazoline-incorporating 
ligands (I-107 and I-108) with nickel, as reported by Shibatomi and Iwasa (up to 99% yield 
and 99% ee).
48
   
 
Figure 12. Oxazoline-featuring ligands in enantioselective fluorination of -ketoesters. 
-Ketoesters, so thoroughly explored by numerous groups, were shown to be suitable 
substrates for one-pot sequential chlorination-fluorination or fluorination-chlorination 
reactions. This was first reported by the Togni group in 2003, utilizing their previously 
employed Ti-taddol complex (I-100, Scheme 17); however only moderate enantioselectivities 
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were obtained (up to 65%).
49
 Later the same reaction was reported by Kim and co-workers, 
achieving similar results with palladium aqueous complexes (I-111a-d, Scheme 19),
50
 while 
slightly better results (up to 77% ee) were obtained when pre-formed -chloro--ketoester 
was fluorinated using the same palladium complexes (Scheme 19).  
 
Scheme 19. Fluorination of -chloro--ketoesters. 
Other 1,3-dicarbonyl compounds were also found suitable for enantioselective fluorination – 
such as malonates and -ketophosphonates. Asymmetrical tert-butyl-methyl malonate was 
enantioselectively fluorinated using NFSI and zinc complex analogical to one used previously 
by Kanemasa and Shibata and Toru (I-106, Figure 12).
51
 Notably, the protocol is tolerant of 
several functional groups such as thio-, ether and tert-amine (I-112a-I, Scheme 20); however 
unsubstituted (R = H) malonates have not been reported, presumably due to bis-fluorination.  
 
Scheme 20. Enantioselective fluorination of malonates. 
Synthetic utility of the fluorinated malonates was explored thoroughly, and simple yet lengthy 
routes towards valuable molecules were demonstrated: -fluoro--amino acid (I-113m, 
Scheme 21), fluorinated -lactam and fluorinated drug analogue - fluoroalacepril (I-113o). 
                                                          
49
 R. Frantz, L. Hintermann, M. Perseghini, D. Broggini,A. Togni, Org. Lett., 2003, 5, 1709. 
50
 M. J. Cho, Y. K. Kang, N. R. Lee, D. Y. Kim, Bull.Korean Chem. Soc., 2007, 28, 2191. 
51





Scheme 21. Transformations of fluorinated malonate into amine, lactam and drug analogue.  
An interesting example of 1,3-dicarbonyl compounds which have been efficiently fluorinated 
with the use of transition metal complexes are -ketophosphonates. Previously reported 
complexes were successfully employed with this class of compounds as well. The Sodeka 
group reported BINAP complex (I-103, Scheme 18) to catalyze enantioselective fluorination 
of cyclic and acyclic -ketophosphonates with excellent enantiocontrol (up to 96% ee), and 




Scheme 22. Enantioselective fluorination of -ketophosphonates by Sodeoka and coworkers. 
Similar results were obtained by Kim utilizing cationic palladium complexes,
53
 and also in 
ionic liquids with recycled catalyst (after seven cycles, only insignificant effect on yields and 
enantioselectivities was observed).
54
 In addition to abovementioned -ketophosphonates, -
cyanophosphonates were shown to undergo enantioselective fluorination as well. However, 
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significantly lower acidity of -proton, as compared to -ketophosphonates, required the use 
of additional base to facilitate deprotonation. This could have resulted in lower 
enantioselectivities observed by the groups of Kim (81% ee – 91% ee, Scheme 23)55 and 
Sodeoka (24% ee – 78% ee)56 in reactions catalyzed by previously reported palladium 
complexes (I-111c and I-104). 
 
Scheme 23. Kim‟s fluorination of -cyanophosphonates. 
Kim and co-workers have further extended their methodology to -cyanoacetates (I-118a-f, 
Scheme 24),
55b,57
 obtaining excellent results (62%  94% and 85% ee – 99% ee). In this case, 
the use of external base was unnecessary. 
 
Scheme 24. Enantioselective fluorination of -cyanoesters. 
Apart from acidic 1,3-dicarbonyl compounds, efforts were devoted to fluorination of more 
challenging (less acidic -proton) -arylacetic acid derivatives. Sodeoka devised a catalytic 
system consisting of Ni-BINAP complex (I-102, Scheme 25) with addition of 2,6-lutidine and 
triethylsilyl triflate, for effective fluorination of -arylacetic acid derivatives (I-100a-h).58 
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Very good yields and enantioselectivities were attainable with aromatic substrates, while only 
very low yield (15%) and hardly any enantiocontrol (11% ee) were attainable for aliphatic n-
butanoic acid thiazolidin. 
 
Scheme 25. Sodeoka‟s fluorination of arylacetic acid derivatives. 
Later, these results were improved by Shibata and Toru – their system consisting of 
oxazoline-containing ligand (I-86, Figure 12), nickel perchlorate, 2,6-lutidine and importantly 
- 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) as additive, lead to products (with slightly 
extended scope as compared to I-100a-h) with excellent enantioselectivities of 92% - 98% 
and yields (87% - 96%), albeit missing any aliphatic example.
59
 In the same paper, the authors 
presented an extension to disubstituted arylvinyl-containg thiazolidin derivatives (I-103a-g, 
Scheme 26) and indole-containing substrates (I-103h-k), the former obtained with up to 86% 
ee, the latter with excellent, up to 99% ee.   
 
Scheme 26. Enantioselective fluorination of other arylacetic acid derivatives and indoles. 
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The lower acidity of -proton in substrates other than 1,3-dicarbonyls required the addition of 
external base. The other limiting requirement remained - the use of substrate with carbonyl 
group for facile coordination to metal promoter. The bidentate manner of binding of the two 
carbonyl groups in -ketoesters was translated here to analogous binding of one carbonyl of 
the substrate and the other from the auxiliary – thiazolidin, and found indispensable for 
enantiocontrol. 
 Later on, -ketoesters (as another example of substrates with bidentate binding capabilities to 
the metal) were reported as suitable substrates for enantioselective fluorination with the use of 
previously developed DBFOX nickel complex, as reported by Sodeoka and coworkers 
(Scheme 27).
60
 The products were obtained in high chemical yields, and with high to 
excellent ee values, with low to decent diastereoselectivities (1.4:1  7.6:1). Despite the 
narrow substrate scope, this first example of direct fluorination of -ketoesters stood as a 
useful method for the synthesis of linear -fluoro--amino acids (I-126e-f).  
 
Scheme 27.Sodeoka‟s fluorination of -ketoesters. 





Initial reports involved N-Boc protected oxindole substrates 
being fluorinated with the aid of aqueous palladium BINAP complex (I-103, Scheme 18). 
Good to excellent yields (up to 97%) and decent to very good enantioselectivities (up to 90%) 
were achieved, as reported by Sodeoka‟s group (Scheme 28).61 This protocol was employed 
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for the synthesis of MaxiPost, leading to 57% yield of the enantio-pure compound (after 
recrystallization). 
 
Scheme 28. Sodeoka‟s fluorination of N-Boc protected oxindoles. 
 
Interestingly, the authors also disclosed a strategy for monofluorination of unsubstituted 
oxindole (I-129) avoiding bisfluorination by in situ solvolysis of oxindole moiety, resulting in 
generation of monofluorinated -arylacetic acid ester (I-130) with 93% ee and 53% yield.  
 
Scheme 29. Fluorination of unsubstituted oxindole leading to arylacetic ester. 
Similar results for substituted N-Boc-oxindoles were independently reported by Shibata and 
Toru (and also MaxiPost synthesis), who described enantioselective fluorination employing 
their oxazoline-containing nickel DBFOX complex (I-106, Figure 12), achieving up to 73% 
yield and up to 93% ee.
62
  
Investigations on fluorination of compounds not capable of H-bonding to catalyst or ligand 
are less common. One method would be to utilize the ability of palladium (0) to form 
complexes with alkyl/aryl halides in an oxidative process; a truly complementary approach to 
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organocatalysis. One such methodology was developed by the Doyle group, where cyclic 
allyl chlorides (I-131a - g, Scheme 30) were transformed into corresponding fluorides in a 
palladium catalyzed reaction in the presence of the Trost ligand (I-133).
63
 Decent yields (56% 
- 85%) and high enantioselectivities (85% ee – 93% ee) were achieved for various substrates 
containing carbocyle, as well as oxygen- or nitrogen-containing heterocycles, and several 
functional groups such as: alcohol, ester, amide.  
 
Scheme 30. Pd-catalyzed enantioselective formation of cyclic allyl fluorides. 
This methodology was later extended to allylic fluorination of linear allyl chlorides (I-134a–
g, Scheme 31), leading to formation of branched products, rather than linear isomers.
64
 
Reasons for such preference (branched:linear > 20:1 for most examples) were unclear, 
however it was suggested that the fluoride anion is involved in H-bonding interactions with 
the ligand and results in its subsequent stereo-directed delivery to the reactant. 
Enantioselectivity of the reaction is highly substrate dependent and can range from 0% to 
97%.  
 
Scheme 31. Asymmetric allylic fluorination by Doyle and coworkers. 
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Simple, general method to access diverse fluorinated alcohols from easily available sources 
would be of interest to both academia and industry. Such alcohols can be obtained via two-
step one-pot procedures based on aldehyde fluorination/reduction process utilizing 
organocatalysts or transition metal-based catalysts (see above). Another subarea of research 
capable of such output would be enantioselective epoxide opening with fluoride anion 
(Scheme 32). Significant efforts were put towards this goal, however up to date results 
inferior to those offered by aldehyde fluorination/reduction were obtained.  
 
Scheme 32. Epoxide opening with nucleophilic fluoride. 
Salen complexes were used as catalyst or promoter to desymmetrize meso epoxide in a 
pioneering report by Bruns and Haufe in 2000, achieving 55% ee (1 eq. of catalysts) or 11% 
ee in the catalytic version,
65
 while salen-promoted opening/fluorination of styrene oxide 
afforded the desired product in up to 90% ee. This methodology was than reinvestigated by 
Mazzetti and coworkers,
66
 without significant improvement. Eventually, breakthrough came 
when Doyle and Karlow used a similar approach to achieve the desired epoxide 
opening/fluorination products in good yields (55% - 88%) and enantioselectivities (58% ee - 
95% ee) under catalytic protocol, with kinetic resolution involved in some cases (90% ee - 
99% ee).
67
   
Interestingly, excellent results were obtained in reactions performed via cooperative catalysis 
involving organocatalyst (chiral organic base) and metal complex (Lewis acid). This was 
demonstrated in -fluorination of acyl chlorides (I-140, Scheme 33) via a process involving 
dually activated enolate (by chiral tert-amine I-142 and achiral metal complex I-143 or I-
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144). Release of the final product is done by subsequent reaction of fluorinated intermediate 
with nucleophile of choice - water, thiol, amine or alcohol, giving  rise to a range of diverse 
products with excellent optical purity (up to 99% ee) in very good yields (up to 91%).
68
 This 
methodology was later applied to a two-step fluorofunctionalization of nuclephilic, large and 
complex molecules such as: artemisinin lactol, mitomycin C, taxol, cholesterol,  vitamin D3 
and aminoglutethimide, providing the selectively monofluorinated products with excellent 
sterocontrol (all 99% de, one example 81% de) with acceptable to excellent yield (43% - 
98%).
69
 The novelty lies in using nucleophilic macromolecules to quench sulphonamide - an 
intermediate arose form addition of one molecule of NFSI to ketene.   
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Scheme 33. -Fluorination via cooperative catalysis.69 
Similarly to organocatalytic methodologies, transition-metal involving procedures also give 
rise to variety of fluorinated quaternary carbon-containing molecules. Such adducts can be 
manipulated to yield general synthons in certain cases, e.g. malonates (Scheme 20 and 
Scheme 21). Further manipulation of fluorinated malonates - namely decarboxylation/ 
asymmetric protonation would be desired, as it would yield linear -fluoro--amino acids. 
Such transformation was investigated during the course of our research and results are 
reported in chapters II-5 and the future perspectives section. Notably, there has been several 
reports where more challenging substrates were successfully fluorinated, yielding linear 
molecules such as allylic fluorination (Scheme 30), fluorination of chloroketoesters (Scheme 
18), cyanoesters or cyanoposphonates (Scheme 22 and Scheme 23). Further development of 
36 
 
fluorination of -ketoesters (Scheme 27) and arylacetic acid derivatives (Scheme 25 and 
Scheme 26) would greatly broaden the pool of useful synthons. Lastly, advancement of 
Lectka‟s cooperative catalytic system for fluorination/addition of small fluorinated synthons 
to complex molecules (Scheme 33) would be very beneficial to the development of practical 
approaches in fluoro-modifcation of large bioactive molecules, perhaps harnessed from 
natural sources.  
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I-2.2. Indirect fluorination 
 
While direct fluorination remains as an important method for synthesis of fluorinated 
molecules, alternative approaches for construction of chiral fluorinated species can also be 
employed - namely CC or CX bond formation using pro-chiral fluorinated synthons (i.e. 
indirect fluorination). This methodology presents truly complementary approach to the above 
mentioned direct fluorination, as some functional groups are rather sensitive or could quench 
fluorinating reagents. In such cases, fluorinated synthon may be prepared and subsequently 
reacted with the more sensitive substrate, yielding the desired functionalized and fluorinated 
molecule. Furthermore, in some cases, cheaper non-selective fluorinating agents for the 
preparation of substrates may be used, while some fluorine-containing starting materials may 
be commercially available. At first glance, it may seem that general methods for 
enantioselective CC or CX bond forming reactions could be employed straightforwardly to 
analogous reactions with fluorinated substrates. However, the presence of fluorine in one of 
the substrates usually influences the reactivity and selectivity greatly, thus requiring 
elaboration of reaction conditions. The most appealing cause of such altered reactivity may be 
the electron withdrawing properties of fluorine, together with its small size, which on one 
hand presents new possibilities and enhanced reactivity in sluggish reactions between non-
fluorinated reaction partners; on the other hand, it may cause over-stabilization of anions or 
anionic transition states - slowing down, inhibiting or directing reactions to new, unexpected 
routes. Therefore organofluorine chemistry is of importance not only with regards to 
preparation of important or alternative compounds but also for broadening the general 
knowledge and understanding of organic chemistry, including elucidation of reaction 
mechanisms and biotransformation pathways. 
This section aims to present the currently available methods for enantioselective CC, CN 
and CH bond forming reactions involving pro-chiral, fluorinated substrates, as well as 
cascade or domino processes consisting of fluorination and CC or CN bond forming 
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reactions. Similar to the above introduction on direct fluorination, the focus will be on the 
scope of attainable chiral fluorinated molecules. General class of substrates, regardless of 
activation mode, be it organocatalytic or via metal-containing catalysts will be discussed 
below. 
The simplest pro-chiral fluorinated substrates used so far are fluorinated alkenes in 
enantioselective hydrogenation. Such transformations lead to simple and usually linear, chiral 
fluorinated products which are quite unique in reactions employing fluorinated synthons (in 
most cases branched molecules are the reaction outcome). Employing simple ruthenium-(R)-
BINAP complex, Uchida and co-workers achieved enantioselective hydrogenation of 2-





Scheme 34. Enantioselective hydrogenation of (Z) or (E) alkenes.
Besides the one isolated report on hydrogenation of monofluorinated compounds, there were 
several reports on enantioselective hydrogenation of trifluoromethyl-containing alkenes and 
ketones, which will not be covered herein. Much more common are methodologies for 
carbon-carbon bond formation between two reaction partners, one of which contains fluorine, 
such as aldol, Mannich, Michael additions or, in broader sense, alkylations.  
Mukayama aldol reaction of pre-formed ketene silyl acetals with simple aldehydes was 
developed by Kobayashi and co-workers (Scheme 35).
71
 When the reaction was performed at 
-78 
o
C in the presence of 20 mol% Masamune‟s catalyst (I-150), a range of aldol products 
was obtained in high yields and with excellent enantioselectivities, albeit with very poor 
diastereoselectivities.   
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Scheme 35. Mukayama-aldol addition of fluorinated ketene silyl acetals to aldehydes. 
General and simple monofluorinated substrate for aldol reaction - fluoroacetone - has been 
studied by several research groups. Fluoroacetone, represents one type of substrate where 
fluorination causes additional selectivity issues - the reaction can occur on either one of the -
carbons - the fluorinated or the non-fluorinated. Barbas and co-workers reported a simple 
addition of fluoroacetone to aliphatic and aromatic aldehydes catalyzed by prolinol (I-155, 
Scheme 36).
72
 High catalyst loading of 35 mol% was necessary to maintain moderate yield of 
the reaction, which ranges from 29% to 82%, with good enantiomeric control (79% to 87%), 
and regioselectivity ranging from 4:1 to 11:1. Similar method was later reported by Guillena 
and co-workers, achieving up to 80% ee in analogous aldol addition to fluoroacetone 




Scheme 36. Aldol reaction of fluoroacetone catalyzed by prolinol. 
Gong and co-workers reported the utilization of fluoroacetone in similar aldol addition to 
aromatic aldehydes (I-150a  c, Scheme 37) catalyzed by proline-amide catalyst (I-158).74 
Although high enantioselectivity (95%  98% ee) and excellent chemical yields (89% - 96%) 
were attainable, the diastereoselectivity remained poor (2:1 - 4:1), and the regioselectivity 
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ranged from 5:1 to 49:1. This reaction was narrow in substrate scope - only aromatic 
aldehydes with electron-withdrawing substituents were found to be suitable.  
 
Scheme 37. Aldol addition of fluoroacetone to aromatic aldehydes catalyzed by proline-amide. 
Notably, the major diastereomer in such aldol addition had anti configuration. However, 
similar type of dipeptide catalyst developed later by the Gong group (I-160, Scheme 38) was 
shown to direct the aldol addition to fluoroacetone towards the challenging syn products (I-
159d-f).
75
 The three products were obtained in moderate to good yields (45%  82%), with 
excellent enantiomeric control (93% ee - 99% ee), and high to excellent diastereoselectivity 
(5:1 to 15:1). However, once again the reaction suffered from very narrow scope of suitable 
aldol acceptors.  
 
Scheme 38. Syn-selective aldol addition of aromatic aldehydes to fluoroacetone. 
Fluoroacetone was also found suitable for three-component Mannich reaction catalyzed by 
simple proline-derived catalyst (I-163, Scheme 39).
76
 Regioselectivity of the reaction was 
studied and it was unexpectedly found that polar solvents directed the reaction towards the 
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formation of products of addition of non-fluorinated side of fluoroacetone (I-161), while in 
non-polar solvents - no selectivity was observed.  
 
Scheme 39. Three-component Mannich reaction with fluoroacetone.
Much more common was to use fluorinate ketoesters and malonates in Mannich-type 
additions. Generally, -fluorinated 1,3-dicarbonyl compounds are good and convenient 
substrates for enantioselective reactions as deprotonation of the acidic -proton require the 
use of only mild bases, while carbonyl groups possess strong H-bond acceptor properties, 
rendering possible interactions with suitable H-bond donors in the catalysts. Direct 
fluorination of 1,3-dicarbonyl compounds yields linear fluorinated molecules, whereas the use 
of these substrates in C-C or C-N bond forming reactions leads to branched compounds. On 
the other hand, further manipulations of the products were troublesome, due to high degree of 
functionalization of the relatively small carbon core. As such, decompositions or 
defluorinations during even fundamental functional group transformations, such as reductive 
amination, are common. Nevertheless, some successful methods for effective handling of 
such compounds have been demonstrated. A highly enantioselective Mannich addition of 
fluorinated ketoesters to N-Boc imines leading to synthetically useful adducts has been 
developed (Scheme 40)
77
 and the reaction and manipulation of the products will be discussed 
in chapter II-5.  
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Scheme 40. Mannich addition of fluorinated ketoesters to N-Boc imines. 
Identical reaction was later reported by a Korean group,
78
 with following extension to 
fluorinated malonate as a donor (Scheme 41); however no manipulation of the generated 
adducts was demonstrated.
79 
In parallel, the same transformation together with studies on 
mono-decarboxylation/asymmetric protonation, leading to linear -fluoro--amino esters, 
were the subject of our research; preliminary results will be described in chapter II-5 and in 
the future perspectives section of this thesis.  
 
Scheme 41. Mannich addition of fluoromalonate to N-Boc aldimines. 
Structurally similar dicarbonyl compounds, -keto-acetyloxazolidinones (I-173, Scheme 42) 
were found suitable in Mannich reaction with N-Eoc imines (I-174), yielding the desired 
products with excellent levels of stereo-chemical control (>95% ee & >11: 1 dr) and yields 
(>90%).
80
 More importantly, useful structural manipulations of the obtained products were 
demonstrated; decarboxylation leading to two diastereomeric fluorinated ketoamines (I-
176a,b) and deacylation, being one possible route to linear -fluoro--amino esters (I-177).  
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Scheme 42. Mannich addition of -keto-acetyloxazolidinones. 
Bicyclic -fluorotetralones (I-179, X=C, Scheme 43) and -fluorochromanones (I-179, X=O) 
were all found to be suitable substrates for bicyclic guanidine (I-178) catalyzed Mannich-type 
addition to aromatic N-mesyl imines (I-180), affording the corresponding products with 
excellent enantioselectivities (>95%), good yields (70% - 94%) but low diastereoselectivities 
(2:1  5:1).81 
 
Scheme 43. Mannich addition of tetralones. 
The other good fluorinated donors for Mannich-type additions are fluorinated 
phenylsulfonylmethanes: 1-fluorobis (phenylsulfonyl)methane (FBSM), fluoro-
(phenylsulfonyl)methane (FSM) and its derivatives: 1-fluoro-1-nitro(phenylsulfonyl)methane 
(FNSM) and ester-incorporating (I-186, Scheme 45), also described as monofluoromethyl- 
(monofluoronitromethyl-) equivalents. Addition of FBSM to air- and moisture-stable N-Boc 
imine precursors (II-150, Scheme 44) via PTC methodology was demonstrated as a 
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stereoselective 2-step route towards monofluoromethylated amines (I-184), involving 




Scheme 44. Mannich-type addition of FBSM leading to monofluoromethylated amines. 
Similar work, this time with FSM derivatives (FNSM and I-186, Scheme 45) and pre-formed 
N-Eoc imines was later demonstrated by Tan and co-workers.
80
 Unfortunately, cleavage of 
phenylsulfonyl- moiety was not shown, presumably due to de-fluorination or decomposition 
of products. Therefore practical applications of such adducts remain unexplored and 
somewhat dubious.   
 
Scheme 45. Mannich-type addition of FSM derivatives.  
The same fluorinated donors found application in numerous Michael additions. We and two 
other groups have reported organocatalytic coupling of the same fluorinated ketoesters (I-165, 
Scheme 46) with nitroalkenes (I-169).
83
 The best results in terms of stereocontrol were 
obtained by using bifunctional Quinidine-derived organocatalysts (I-194b): 95% - 99% ee, 
and 5:2 - 19:1 dr. The adducts were then transformed into chiral amide (I-191), pyrrolidine (I-
192) and cyclic iminoester (I-193).
83a
 The same ketoesters were also employed in analogous 
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reaction with N-alkyl maleimides, catalyzed by guanidine (I-178) yielding complex structures 
under excellent stereocontrol but with no apparent application.
84
    
 
Scheme 46. Michael addition of fluorinated ketoester to nitroalkenes. 
-Fluoromalonate (Scheme 47) was also shown to be an excellent Michael donor in reactions 
with nitroalkenes,
85
 ,-unsaturated aldehydes86 and MBH carbonates,87 leading to seemingly 
useful products. However no manipulations of those structures obtained were described and 
therefore it was difficult to assess the practical utility of such adducts. 
 
Scheme 47. Michael additions of fluoromalonate. 
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 were also employed in Michael addition, leading to a range of 
enantioenriched adducts (I-203 and I-208, Scheme 48). However, only FBSM addition 
products were demonstrated as useful intermediates, yielding monofluoromethylated 
aminoalcohols (I-204), alcohols (I-205), ketones (I-207) and amines (however, still bearing 
the uncleaved sulfonyl moieties, I-206).   
 
Scheme 48. Michael addition of phenylsulfonylmethanes.  
Alkylations of fluorine-containing prochiral nucleophiles have also been achieved by means 
of organo- and metal catalysis,
90
 one representative example being organocatalytic alkylation 
of -fluorotetralone (I-179, Scheme 49).91 Chemical yields of 33%  83%, fair to very good 
enantioselectivities (70%  91%) were achieved under PTC catalysis with I-211. Similar 
alkylation was also reported by Maruoka and coworkers,
92
 however, the substrates were more 
challenging with regards to stereocontrol - linear -fluoro--ketoester (I-165). Under similar 
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Lett., 2009, 50,4896. 
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Cahard, Synthesis, 2001, 1742. 
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phase-transfer organocatalysis, the corresponding products were obtained with modest 
enantioselectivities (up to 88% ee).  
 
Scheme 49. Alkylation of fluorinated tetralones. 
Fluorinated flavanones (I-214, Scheme 50) were prepared in tandem oxa-Michael 
addition/diastereoselective fluorination, catalyzed by simple de-methylated Cinchona 
alkaloid-derived catalyst (I-215). Excellent results were reported for this transformation; very 
high ee values (88% ee - 99% ee), yields over 86% were attainable with single examples 
where lower level of stereocontrol was observed (heterocyclic and aliphatic substituents).
93
   
 
Scheme 50. Tandem intramolecular oxa-Michael/fluorination. 
Much simpler substrates were used in the synthesis of functionalized cyclohexanones, 
featuring -fluoroester moiety; diastereomers of -fluoro--diketoester (I-220, Scheme 51) 
in intramolecular aldol reaction, or prochiral, unsaturated -fluoro--ketoester (I-216) and 
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,-unsaturated methyl ketone (I-217) in Robinson annulation.94 The tryptophan-derived 
diamine (I-221) could control the stereoselectivity well, leading to products with excellent 
enantioselectivities (98%  99%), good to excellent diastereomeric ratios (6:1 99:1) and fair 
to good yields (44% 80%). 
 
Scheme 51. Synthesis of fluorinated cyclohexanes with -fluoroester core. 
Stereoselective methods, towards bi- or tricyclic fluorinated structures are rare. Besides the 
two rather limited methods (oxa-Michael and alkylation of tetralones), there is one emerging 
methodology of great potential - fluorocyclization. To date there is only two reports on its 
enantioselective version, both by Gouverneur and co-workers.
95
 In the presence of 1.2 
equivalent of commercially available Cinchona alkaloid-derived chiral promoter 
((DHQ)2PHAL, the fluorinated hetero-tricycles (I-223I-226, Scheme 52) were obtained in 
moderate to high ee values, and fair to very good yields. The reaction could also be performed 
using 20 mol% catalyst, the chemical yields of the reaction were maintained, but the 
enantioselectivities dropped by 10% on the average. Further development of this method is 
desirable, as it would significantly bolster access to fluorinated heterocycles from simple 
starting materials.  
                                                          
94
 (a) H.-F. Cui, Y.-Q. Yang, Z. Chai, P. Li, C.-W. Zheng, S.-Z. Zhu, G. Zhao, J. Org. Chem., 2010, 75, 
117; (b) H.-F. Cui, P. Li, X.-W. Wang, Z. Chai, Y.-Q. Yang, Y.-P. Cai, S.-Z. Zhu, G. Zhao, 
Tetrahedron, 2011, 67, 312. 
95
 a) for a review see: S. C. Wilkinson, R. Salmon, V. Gouverneur, Future Med. Chem., 2009, 1, 847; 
b) O. Lozano, G. Blessley, T. M. del Campo, A. L. Thompson, G. T. Giuffredi, M. Bettati, M. Walker, 
R. Borman, V. Gouverneur, Angew. Chem. Int. Ed., 2011, 50, 8105; c) S. C. Wilkinson, O. Lozano, M. 




Scheme 52. Asymmetric fluorocyclization. 
In addition to CC bond forming reactions, some CN bond formations via amination were 
also reported. However, practical applications of such molecules are limited due to lack of 
methods for cleaving the NN bond to free the amino functionality. Enantioselective 
aminations were achieved by means of metal catalysis,
96
 phase-transfer organocatalysis (one 
example)
97
 and organocatalysis (Scheme 53).
98
 Quinidine-derived guanidine (I-230) was 
found effective in amination of fluorinated ketoesters (I-165) achieving up to 92% ee with 
aromatic ketoesters and 47% - 87% ee for aliphatic substrates,
98a
 while simple bicyclic 
guanidine (I-178) led to amination of -fluorotetralones and -fluorochromanones (I-179, X 




Scheme 53.Amination of -fluoro--ketoester. 
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An interesting variation of the above methods is tandem formation of CF and CN bonds 
through fluoroamination of alkenes. Cyclic -fluoroamines (I-233, Scheme 54) were obtained 
as racemate via palladium catalysis 
99a 
or as enantio-enriched mixture in reaction promoted by 
an interesting C-2 symmetric hypervalent iodine catalyst (up to 81% ee).
99b 
Linear fluorinated 
hydroxyamines (I-234) were attainable from simple -unsaturated aldehydes, using 
prolinol-derived organocatalysts (with excellent 98% - 99% ee (80% ee - one example) and 
6:1 - 49:1 dr)
99c
, while aromatic -fluoroamines (I-235) were obtained from simple, 
unactivated styrenes, by Pd-catalysis.
99d
 Further development of enantioselective 
fluoroamination would certainly offer new opportunities for generation of valuable 
fluorinated precursors of bioactive compounds from simple starting materials. 
 
Scheme 54. Fluoroamination of olefins. 
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Given all the unique properties of fluorine, its small size alongside the extreme 
electronegativity, and resulting significant (frequently beneficial) influence of selective 
fluorination on activities and characteristics of bioactive compounds, it is easily 
understandable that the utility of fluorine in pharmaceutical research, biological sciences and 
medicinal chemistry is expanding. Approximately 20% of today‟s pharmaceuticals are 
fluorine-containing compounds, whereas in 1957 there was none. However, two major 
challenges have to be met to further advance the applications of fluorinated compounds, 
namely: insufficient understanding of complex biological systems, pathways and molecular 
interactions, as well as lacking methodology to access selectively fluorinated, chiral 
compounds in a practical way. The shortcomings include: substrate scope, resolution of 
diastereomers, laborious catalyst preparation and necessity for multistep transformations to 
access precursors of practical synthetic value. As much as general methods are highly 
desirable, one must think realistically, that generalization may be possible only to a certain 
extent. Therefore, one must consider the limits, benefits and mutual complementarity of all 
methods, be it organo- or metal-catalytic, with direct or indirect incorporation of fluorine, 
when designing routes towards target molecules. Undoubtedly, invention of mild N-F 
fluorination agents such as NFSI and Selectfluor
®
 had a great impact on advancing the field 
of preparation of chiral organofluorine compounds. The two fluorinating agents are nowadays 
almost sole agents used in enantioselective fluorine incorporation. Direct, enantioselective 
fluorination offers straightforward approach towards fluorine-containing compounds usually 
at very low catalyst loadings. However the common disadvantage is restriction to generation 
of quaternary fluorine-containing centers, to avoid bis-fluorination, e.g. fluorination of -
ketoesters (Scheme 17). Of course in certain cases, this is favorable - whenever fluorinated 
quaternary carbon is the synthetic aim itself (see for example fluorination of oxindoles 
leading to MaxiPost® analogues, Scheme 28). However, it may also be seen as a significant 
restriction. Additionally, influence of fluorination on neighboring groups (which is a desired 
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property) is tuned down by the presence of substituents with electron-donating capabilities at 
the fluorinated, quaternary carbon (common are alkyl or aryl groups). Therefore, some 
strategies emerged to nullify or at least temper this limitation; for example: a tunable 
substituent was installed on the fluorinated quaternary carbon prior to reaction, or in tandem 
process, to block bis-fluorination and later exchanged to other functional group with retention 
of optical purity (e.g. the fluorination of -chloro--ketoester, Scheme 19; the chlorine could 
later be substituted by azide - however reduction to amine was unsuccessful). Some practical 
methodologies leading to linear fluorinated molecules (without quaternary fluorinated carbon 
center) have emerged in more or less optimized forms, such as: fluorination of arylacetic 
acids (Scheme 25), fluorination of -ketoester with successful conversion to linear -fluoro-
-aminoesters (Scheme 27), allylic fluorination (Scheme 31) or brilliant fluorination of acyl 
chlorides via cooperative catalysis through in-situ generated ketenes,  leading to a range of 
products -  acids, esters, thioesters, amides - depending on the quenching reagent (Scheme 
33), with following extension to the state of the art chemo selective fluorination of 
macromolecules,
69
 a strategy certainly worth further development. Alternatively, activation 
via imine-enamine organocatalytic systems was broadly successful in monofluorination of 
aldehydes (Scheme 6 - Scheme 9), with emerging fluorination of ketones (Scheme 15).  
Apart from direct fluorination - another practical approach towards chiral, fluorinated 
molecules is based on application of prochiral fluorine-containing substrates or tandem 
processes. Multitude of interesting and valuable synthons can be accessed via this 
methodology, however, the generation of branched molecules with quaternary fluorinated 
centers is favored, lacking routes towards linear synthons. Unarguably, generation of such 
branched molecules is desired - see for example route towards fluorinated tri-heterocycles in a 
tandem process (Scheme 52) or bio-relevant fluorinated flavanones (Scheme 50). 
Nevertheless, the development in the direction of practical preparation of chiral, linear, 
fluorinated molecules is certainly also of great importance. Isolated examples of such 
methods include: monofluoromethylation (Scheme 44 and Scheme 48, with troublesome 
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removal of phenylsulfonyl moieties), Mannich and aldol additions of fluoroacetone (Scheme 
36  Scheme 39; low stereocontrol) and fluoroaminations of olefins and simple styrenes 
(Scheme 54; low stereocontrol). On the other hand, skillful manipulation of branched adducts 
can also lead to optically enriched, linear product (e.g. deacylation or decarboxylation of 
Mannich adduct (Scheme 42)). A good alternative would also be, selective mono-
decarboxylation of fluoromalonate adducts, which is unknown to date and has been tackled 
during the course of our research (results are presented in chapter II-5 and the future 
perspective section). The remaining, long-standing challenge - cleavage of NN bond in 
amination products, retaining the CF bond intact (e.g. Scheme 53), to yield -fluoro--
amino acid core is of great interest and one alternative approach towards it is described in 
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II-1. Towards the enantioselective synthesis of functionalized -
fluoro--amino acids: organocatalytic Michael 
addition/hydrogenation of ethyl fluoronitroacetate 
 
In search for practical methodologies for preparation of fluorinated bioactive molecules, 
attention was given to the very basic bio-compounds - amino acids. There are several 
examples in the literature of methodologies leading to -fluoro--amino acids via multiple-
step synthesis, but no method for the preparation of -fluoro--amino acids. Being interested 
in developing a general methodology towards fluorinated amino acids, we envisioned 
designing a donor containing the -fluoro--amino acid core for Michael and Mannich 
additions. In this chapter, the work on the use of fluoronitroacetate as a synthon for the 
preparation of -fluoro--amino acids is disclosed. 
II-1.1. Introduction 
Alteration of amino acids, the very basic bioactive molecules and building units of peptides 
and enzymes, by fluorination is especially sought-after, due to the little steric disruption 
caused, while greatly affecting compound‟s properties in a predictable manner.100 Despite the 
great efforts to date, stereoselective synthesis of fluorinated amino acids remains a formidable 
task requiring multistep procedures, while allowing only for generation of specific 
compounds with no structural variation.
101
 The common approach towards fluorine-
containing amino acids derivatives is through enantioselective Mannich reactions with 
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fluorinated ketoesters (I, Figure 13) or malonates.
102
 This methodology leads to molecules 
with amino- and fluoro- functionalities installed on the neighboring carbon atoms (II), while 
the strongest effects of fluorination on the amine and carboxylic acid functionalities would be 
observed if fluorine is attached to the -carbon in amino acid (III).  
One straightforward method to access such motif would be the amination of -fluorinated 
ketoesters,
103
 however all attempts to cleave the N-N bond and free the amino- functionality 
failed. Thus -fluro--amino acids were never achieved before in enantioselective fashion, 
except via the resolution with chiral amines,
104
 and for a single example of fluorination of N-
phthaloylphenylglycine derivative with stoichiometric amounts of chiral Cinchona alkaloid-
derived N-fluoroammonium salts, sadly with no follow up or any extension of scope.
105
 
Notably, it was reported that removal of the phthaloyl amino protecting group while retaining 
C-F bond intact is not possible, due to de-fluorination.
106a
 We envisioned that a general 
method for asymmetric construction of the -fluoro--amino acid scaffold would be of great 
interest in the overlapping areas of synthetic, bio- and medicinal chemistry. 
 
Figure 13. Construction of fluorinated amino esters. 
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Nitroacetic acid esters have been recognized as valuable intermediates leading towards -
amino acids and heterocycles,
107
  with little attention paid to fluoronitroacetic acid esters,
108
 
the latter being the simplest and easy accessible synthon towards -fluoro--amino acids.106 
To date, there are four reports on the use of prochiral fluorinated donors for the construction 
of -fluoro--nitrogen-containing compounds. Two methodologies utilize pro-chiral 
fluorinated donors (Scheme 55), while the two other describe direct fluorination (Scheme 56). 
Fluorinated ketoesters were used in amination, leading to adducts I-229a-m (Scheme 55) 
effectively and with enantioselectivities ranging from 47% to 93%.
109
 The other example 
utilizes ethyl fluoronitroacetate in Michael addition to ,-unsaturated ketones, leading to 
products II-1.4al in good to excellent yields (75%  95%) and excellent enantioselectivities 
(93%  99% ee).   
 
 
Scheme 55. Preparation of -fluoro--nitrogen-containing core via the use of fluorinated donors. 
Enantioselective fluorination of nitroacetic ester was reported with the use of Cinchona 
alkaloid-derived chiral stoichiometric fluorinating agents (I-10I-12, Scheme 56) affording 
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the products (II-1.9ad) in good yields (78%  85%) but low enantioselectivities (23% 
40% ee). The other methodology is based on copper-catalyzed gem-chlorofluorination, 
followed by substitution of chlorine with azide. The -fluoro--azidoester (II-1.7) was 
obtained in excellent yield (97%) and high ee (91%).  
 
Scheme 56. Preparation of -fluoro--nitrogen-containing core via enantioselective fluorination. 
Despite the attempts shown above, the -nitrogen-containing group was never successfully 
transformed to the amino functionality; de-nitration was observed for -fluoro--nitro 
compounds, while de-fluorination under palladium catalyzed azide reduction was anticipated. 
Hence the potential applications of -fluoro--amino acid scaffold in medicinal chemistry 
together with the unchallenged attempts of their synthesis prompted us to investigate a 
general and tunable method to access such compounds. Furthermore, the the use of 
fluoronitroacetate as Michael donor instead of non-fluorinated ethyl nitroacetate has several 
advantages. Firstly, Michael addition product of ethyl nitroacetate would contain highly 
acidic -proton, which would lead to racemization (Figure 14). Secondly, fluorination of 
Michael addition product of ethyl nitroacetate would be difficult due to selectivity issues 
(possible side products marked in red). Lastly, asymmetric fluorination is in general 




Figure 14. Two alternative Michael addition-fluorination sequences. 
II-1.2. Organocatalytic Michael addition of ethyl fluoronitroacetate 
to nitroalkenes - reaction optimization 
We were intrigued, whether the easily accessible ethyl fluoronitroacetate would be a viable 
precursor for -fluoro--amino acids, through Michael or Mannich additions. Nitroalkenes, 
which are stable and excellent acceptors, were chosen as model reaction partners for Michael 
additions, allowing for diverse structural manipulations of the products via the chemistry of 




To validate our hypothesis, the substrate was prepared by fluorination of commercially 
available ethyl nitroacetate, using sodium hydride as base and THF as solvent (Scheme 57).  
 
Scheme 57. Preparation of ethyl fluoronitroacetate. 
The isolated yield of the product was only 36%, even though the reaction was clean and the 
crude 
1
H NMR indicated up to 60% conversion of ethyl nitroacetate to the desired 
monofluorinated product. Notably, ethyl fluoronitroacetate was found to be stable at room 
temperature a few hours, therefore it was freshly prepared before each batch of reactions. 
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Optimization of the fluorination was attempted; however no better method was found, with 
the microwave-assisted fluorination under neutral conditions leading to conversions not 
exceeding 40%. The nitroalkenes - were prepared from the respective aldehyde and 
nitromethane, according to the known procedures. 
Reaction optimization 
With the substrates in hand, we began our studies on the model reaction of ethyl 
fluoronitroacetate with (E)--nitrostyrene. Firstly, the common Quinine-derived thiourea 
catalyst was screened (I-194a, Table 1), leading to poor enantio- and diastereoselectivities 
(19% ee & 5:2 dr), with excellent yield (97%, entry 1). To our satisfaction, the catalyst 
previously developed in our laboratory, incorporating L-tert-leucine unit in-between the 
alkaloid core and the thiourea moiety (II-1.11),
111
 led to the desired product with dramatically 
increased enantioselectivity (89% ee, entry 2), while retaining the very high yield (95%). 
Further fine-tuning of the catalyst structure by modifying the silyl protecting group (TBS in 
II-1.12a and TBDPS in II-1.12b) on the L-Threonine unit, led to the identification of II-
1.12b as the optimum catalyst, affording the product with 97% ee and excellent yield (entry 
4). Next, we attempted to further optimize the reaction by lowering or increasing the reaction 
temperature (entries 56) but observed only 10% decrease in ee values in both cases. The 
addition of 4 Ǻ molecular sieves resulted in significant decrease of ee value to 72% (entry 6), 
while 10 equiv. of water as additive, caused a slight decrease in enantioselectivity by 5% 
(entry 7). The subsequent, screening of solvents (entries 810) reassured us that toluene is the 
preferred solvent with xylene being the second best in terms of enantioselectivity (94% ee), 
while yields and dr values were unaffected in all cases. In a final attempt to increase the 
diastereoselectivity of the reaction, the ethyl ester of the fluoronitroacetate was changed to 
iso-propyl. Unfortunately a slight decrease in ee value and the lack of dr improvement was 
                                                          
111
 Q. Zhu, Y. Lu, Angew. Chem. Int. Ed., 2010, 49, 7753. 
62 
 
observed (entry 11), and we decided that the troublesome transesterification of the 
commercially available ethyl ester would unlikely yield any benefits to the reaction.
112
 
Table 1. Michael addition of ethyl fluoronitroacetate II-1.5 to (E)-nitrostyrene I-
189a catalyzed by organocatalysts.
a 
 






1 Et I-194a Toluene 97 19 5:2 
2 Et II-1.11 Toluene 95 89 3:1 
3 Et II-1.12a Toluene 96 88 3:1 
4 Et II-1.12b Toluene 96 97 3:1 
5
e 
Et II-1.12b Toluene 94 88 3:1 
6
f 
Et II-1.12b Toluene 96 87 3:1 
6
g 
Et II-1.12b Toluene 95 72 5:2 
7
h 
Et II-1.12b Toluene 95 92 5:2 
8 Et II-1.12b CHCl3 92 87 5:2 
9 Et II-1.12b Et2O 94 87 3:1 
10 Et II-1.12b Xylene 95 94 3:1 
11 i-Pr II-1.12b Toluene 95 86 3:1 
a
 Reaction conditions: II-1.5a or II-1.5b (0.1 mmol), the catalyst (0.01 
mmol) in the solvent (1ml) with nitrostyrene (0.11 mmol) at 0 
o





 Determined by HPLC analysis on a 
chiral stationary phase. 
d
 Determined by 
1
H NMR analysis of the crude 
reaction mixture. 
e




 Reaction in rt. 
g
 Reaction in the 
presence of 4Ǻ molecular sieves (10 mg). h 10 equiv. of H2O added.  
  
In fact, the easy separability of diastereomers of the products provided routes towards both 
geometrical isomers of the molecules of interest (the dr value corresponds to configuration on 
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the fluorinated carbon, while ee value corresponds to the centre of asymmetry originating 
from nitroalkene - see the next section). Furthermore, we have found that the reaction 
proceeded in the absence of catalyst as well, which implied that the optimum stereocontrol of 
the process depends on the ratio of catalyzed versus the unanalyzed reaction‟s rates, which 
could explain our findings on the preferred moderate temperature for high ee.     
II-1.3. Scope of the reaction and determination of the absolute 
configuration 
 
With optimum conditions in hand, reaction scope with regards to the nitroalkenes was 
investigated (Table 2). When 2-napthalene replaced phenyl ring in our model nitrostyrene, the 
enantioselectivity dropped to 82% but the excellent yield and dr of 3:1 was maintained (II-
1.10c). Electron withdrawing substituent at para- orientation on aryl ring was found to be 
advantageous as the corresponding product II-1.10d was obtained in very high yield with 
96% ee and 3:1 dr. On the other hand, installing a methyl group in para position resulted in a 
drop in enantioselectivity to 82% (II-1.10e). 3-bromonitrostyrene was found to be the best 
substrate, leading to the corresponding product II-1.10f in enantiopure form in excellent yield 
and dr maintained at 3:1. Substitution of the aryl ring in nitrostyrene with fluorine in ortho 
orientation resulted in a large drop in enantioselectivity to 63% for the major diastereomer II-
1.10g, obtained in 2:1 dr ratio, with overall high yield of 94%. Bis-substitution of the aryl ring 
with either halogen (II-1.10h) or methoxy- group in 3,4- orientation (II-1.10i) was well 
tolerated and the corresponding products were obtained with very high yields and good 
enantioselectivities of 83% and 85% respectively. However, when two fluorine atoms were 
installed in both meta positions on the nitrostyrene aryl ring, the enantioselectivity was found 
to drop to 77% and dr to 2:1, while very high yield was maintained (II-1.10j). We next 
examined heterocyclic (II-1.10k) as well as two aliphatic nitroalkenes (one linear (II-1.10l) 
and one branched (II-1.10m)) and found the high yield maintained with enantioselectivity 
remaining at decent 80%  81% level, albeit lower diastereoselectivity (2:1  3:2). 
64 
 
Table 2. Scope of the Michael addition of ethyl fluoronitroacetate to nitroalkenes I-189b-l.a 
 
a
 Reaction conditions: II-1.5a (0.1 mmol), II-1.11b (0.01 mmol) in toluene (1ml) with nitroalkene I-
189bl (0.11 mmol) at 0 oC. b Determined by 1H NMR analysis of the crude reaction mixture. c 
Determined by HPLC analysis on a chiral stationary phase. 
The configuration of the major products was assessed as (S, S) by X-ray analysis of single 
crystal of II-1.10a (Figure 15). 
 
Figure 15. Single crystal X-ray structure of II-1.10a. 
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II-1.4. Synthesis of -fluoro--amino acid 
 
Aware of the reaction potential and limitations, we then investigated the synthetic utility of 
the products obtained. Our main goal was to reduce the nitro group on the -carbon, with 
regards to ester moiety, to access the unprecedented -fluoro--amino acid ester (II-1.12, 
Scheme 58). As expected, the reduction of the nitro group turned out to be difficult. Common 
methods, such as Fe/AcOH, Zn/AcOH/Ac2O, nickel boride (NiCl2/NaBH4) and H2/Pd(C) 
resulted in defluorination in addition to reducing both of the nitro groups. Zirconium boride 
(ZrCl4/NaBH4), which has been reported as effective in reducing aliphatic nitro compounds, 
113
  did not induce any reaction of our substrate II-1.10a.  
 
Scheme 58. Reduction of nitro group leading to -fluoro--amino acid ester. 
In our search for suitable conditions, we turned our attention to poisoned palladium catalysts 
for catalytic hydrogenation, varying the hydrogen pressure as well (autoclave was used). 
Lindlar‟s catalyst (Pd/CaCO3, lead poisoned) was ineffective at 1 atm of hydrogen, while at 12 
atm of hydrogen led to defluorination and reduction of the -nitro moiety. Finally, it was 
found that employing 3 mol% of palladium on barium sulphate, the nitro group can be 
reduced, while retaining fluorine on the -carbon and the desired -fluoro--amino acid (II-
1.12) was isolated in 20% yield together with 65% yield of defluorinated amino acid 
(identical yield of II-1.12 was achieved in a reaction with 1 atm of hydrogen over 3 days). 
While we believe that the yield of the catalytic hydrogenation could be further improved by 
optimization of the conditions, our synthesis of compound II-1.12 marks the first asymmetric 
synthesis of -fluoro--amino acid ester in a simple two step procedure from accessible 
fluoronitroacetate. Importantly, the methodology is general as the alkyl/aryl substituent at  
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position is easily tunable by employing different nitroalkenes in the Michael reaction, while 
additional function at  position could be further derived into other functionalities leading to 
sought-after fluorinated diaminoacids and amino diacids.
101c
 Such a general methodology was 
not reported before.  
II-1.5. Denitration and decarboethoxylation of the Michael adduct 
 
Next, we further explored synthetic applications of our products. Firstly, noticing the facile 
decarboethoxylation under reductive conditions, we investigated the issue finding out that 
sodium borohydride in THF at 0 
o
C can afford the transformation with ease, leading to 2:1 
ratio of diastereomeric -fluoro--dinitro compounds II-1.13a and II-1.13b (Scheme 59), 
regardless whether pure diastereomers of II-1.10a or crude Michael reaction mixture was 
used.  
 
Scheme 59. Monofluoronitromethylation via Michael addition/decarboethoxylation.  
DIBALH as well as L-selectride (both reactions at -35 
o
C) were found to lead to the mixture 
of diastereomeric compounds II-1.13 in the same ratio. Surprisingly, the addition of 10 mol% 
of palladium on carbon to the reaction with NaBH4 in THF at 0 
o
C, resulted in an increase in 
the diasteromeric ratio of decarboethoxylated products to 3:1. The -fluorinated dinitro 
compounds II-1.13 synthesized represents direct precursors of fluorinated 1,3 diamines.  
Secondly, understanding the value of simple -fluorinated esters, we quickly established a 
route towards this class of compounds by means of radical denitration (Scheme 60). Under 
the conditions employed, only the -nitro group was removed, with the other one intact. 
Notably, the crude Michael reaction mixture (after filtering off the catalyst) could be used 
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directly for the generation of the desired fluorinated esters (II-1.14a and II-1.14b) with 2:1 
diastereomeric ratio (diastereomers easily separable on silica gel column). Such esters were 





Scheme 60. Denitration of Michael addition adduct leading to -fluoroesters. 
Interestingly, compounds II-1.13 and II-1.14 represent the products of respectively - 
monofluoronitromethylation and monofluorocarboethoxymethylation of Michael acceptors 
(nitroalkenes) respectively. Such simple two-step procedures to install functionalized C1 or 
C2 synthons could provide valuable contributions in the field of total synthesis of target 
molecules. The observed reactivity of the -fluoro--nitroacetate, re-establishes this 
compound as an interesting alternative monofluoromethylation reagent, complementary to 
(fluoro-bis(phenyl)sulphonylmethane - FBSM), commonly used for the purpose.
115
 
II-1.6. Summary and future perspective 
 
In conclusion, fluoronitroacetate was successfully used as  a donor in Michael addition to 
nitroalkenes yielding functionalized adducts with tunable aryl/alkyl substituents in good to 
excellent enantioselectivities (63%  >99% ee) in very high yields (90%  98%) but low 
diastereoselectivities  (3:2  3:1). Catalytic hydrogenation of the Michael adduct led to the 
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first asymmetric synthesis of tunable -fluoro--amino acid ester, while denitration afforded 
functionalized -fluoroesters. Facile and diastereoselective decarboethoxylation led to 
fluorinated dinitro compounds being precursors of -fluoro-,-diamines. Thus ethyl 
fluoronitroacetate emerged as a convenient synthon for diverse range of fluorinated 
precursors of bioactive compounds and an alternative monofluoromethylation reagent. 
Future perspective 
The Michael addition of ethyl fluoronitroacetate and subsequent catalytic hydrogenation led 
to the first general synthesis of -fluoro--amino acids esters; however the yields for the 
reduction of the nitro moiety are far from being practical. Therefore, the reaction should be 
optimized and the yield improved. Perhaps variation of solvents, hydrogen pressure and 
temperature, which has not been explored, could result in finding more suitable reaction 
conditions. Additionally, hydrogen sources other than hydrogen gas could also be screened 
(e.g. ammonium formate), as well as other metal based reductive conditions. The major 
difficulty to tackle is to reduce the -nitro moiety without affecting the C-F bond. 
Ethyl fluoronitroacetate has emerged as an interesting synthon towards -fluoro(amino) 
acids, which could be applied in various stereo-controlled transformations, such as addition to 
N-Boc imines (ideally generated in situ from their stable sulphonates) leading to -fluoro--
amino acids (II-1.15, Scheme 61) or -fluoro-,-diaminoesters (II-1.16) upon successful 
hydrogenation of the -nitro group. Additions to vinyl sulphone, followed by 
diastereoselective alkylation could lead to a broad range of fluorinated amino acids (II-1.18a) 
including leucines after reduction of nitro group, or fluoroesters (II-1.18b) upon denitration. 
Sought-after bifunctional fluorinated amino acids,
101c
 other than abovementioned diamino 
acids, could also be accessed via addition of fluoronitroacetate to acrylates yielding alkylated 




Scheme 61. Utility of ethyl fluoronitroacetate in the synthesis of precursors of bioactive compounds. 
Furthermore, as mentioned in the results section, the facile decarboethoxylation or denitration 
render further exploration of ethyl fluoronitroacetate as a monofluoromethylating reagent. 
Addition and the following decarboethoxylation or denitration would be equivalent to 
stereoselective introduction of either fluoroester or fluoronitromethyl synthon onto the 




II-2. Organocatalytic Michael addition of -fluoro--nitro benzyls to 
nitroalkenes: facile preparation of fluorinated amines and 
pyrimidines 
 
In line with our research interests toward the synthesis of general molecules with -fluoro--
amino core, attention was given to very simple and accessible substituted nitrobenzyls. These 
compounds upon fluorination become potential donors for various additions and subsequent 
reduction of their nitro group if successful, would render them synthons for the generation of 
the sought-after -fluoro--amino core. In this chapter, development of -fluoro--
nitrobenzyls as Michael donors for the preparation of fluorinated nitrogen-containing linear 
and heterocyclic compounds is examined. 
II-2.1. Introduction 
One of the important class of synthons for the construction of biologically active molecules 
are fluorinated amines, which could be used in fluoro-peptidomimetics
116
 or preparation of 
fluorinated nitrogen heterocycles
117 
- especially fluorinated pyrimidines and uracils - a 
common motif in recently developed drugs (Figure 16),
118
 as well as piperidines - named 
“building blocks for medicinal chemistry”.117l  
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Figure 16. Selected drugs containing fluorinated amine or nitrogen-heterocycle scaffold. 
Synthesis of fluorinated amines is accomplished via two step procedure involving reductive 













Figure 17. Key intermediates towards fluorinated nitrogen species. 
One common feature of these methodologies is that they lead to -fluoroamines. Fluorination 
is a known way to modulate pKb of nitrogen-containing species, and it is somewhat surprising 
that to the best of our knowledge, the stereoselective construction of molecules containing -
fluoro--amino core (fluorine and amine installed on the same carbon) has not been reported 
even though the effect of fluorine on amino functionality would be the most profound in such 
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compounds. The extremely rare examples of such F-C-NH core-containing molecules include 
racemic 1-fluoro-pentanamine (Figure 18), polycyclic trifluorinated compound (II-2.6a),
124
 








Figure 18. Known compounds with -fluoro--amino core. 
Reports on applications of -fluoro--nitro-containing substrates are rare (all reported 
reactions are shown on Scheme 62).
128
 Fluoro--nitrobenzyls (II-2.1) were used in two 
racemic reactions – addition to aldehydes leading to nitro-Henry product (II-2.11) and 
addition to acrylates leading to adducts II-2.12. Ethyl ester of fluoronitroacetic acid was used 
in Michael addition to enones yielding enantio-enriched products (II-2.9) and heterocycles 
(II-2.10) after denitration. Allyl ester of the same fluoronitroacetic acid was demonstrated to 
undergo palladium catalyzed rearrangement/decarboxylation leading to fluoronitroalkene II-
2.13. Recently, fluoronitro(phenylsulphone)methane (FNSM) emerged as a reagent for the 
monofluoromethylation of ,-unsaturated aldehydes or ketones, leading to products like II-
2.15; however cleavage of the phenylsulfonyl moieties without breaking down the molecule 
has not been realized.  
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Scheme 62. Reported reactions with -fluoro--nitro-containing substrates. 
We were intrigued by the elusive -fluoro--amino- motif and envisioned that accessible pro-
chiral -fluoro--nitro-containing benzylic compounds (II-2.1, Figure 19) could be used in 
generating the F-C-NH core (II-2.4), as well as novel fluorinated six-member heterocyclic 
structures such as pyrimidines (II-2.5a). 
 
Figure 19. Hypothetical approach towards -fluoro--amino-containing compounds. 
The nitroalkenes were the acceptors of choice as the nitro functionalities in both reactants 
could be subsequently reduced to amine and cyclized to pyrimidines. Alternatively, the 
nitromethyl- function originating from nitroolefin could be oxidized to yield -fluoro--
amino acids (II-2.4b).   
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II-2.2. Organocatalytic Michael addition of -fluoro--nitro benzyls 
to nitroalkenes: reaction optimization 
We began our investigation on a model Michael addition of -fluoro--nitro benzyl to (E)--
nitrostyrene catalyzed by Cinchona alkaloid-derived organocatalysts (Table 3). We found that 
both pseudo-enantiomers of simple Quinidine or Quinine-derived thioureas (I-194b and I-
194a respectively) were effective in terms of yields but poorly stereoselective (entries 12). 
Replacing thiourea with sulphonamide in Quinine-derived catalyst (II-2.16) resulted in a slow 
reaction (entry 3), just as replacing Cinchona alkaloid core with DABCO did (entry 4). The 
tryptophan-derived organocatalyst (Trp1), highly enantioselective in Mannich addition of 
fluorinated ketoesters (chapter II-5), was not stereoselective here, although high yield of the 
desired product could be obtained (entry 5). 














I-194b Toluene 90 9 1:1 
2
e 
I-194a Toluene 91 19 1:1 
3
e 
II-2.16 Toluene <15 n.d. n.d. 
4
e 
II-2.17 Toluene 30 n.d. n.d. 
5
e 
Trp1 Toluene 88 18 1:1 
6
e 
II-1.11 Toluene 92 86 3:1 
7
 
II-1.11 Toluene 85 90 7:2 
8 II-2.18 Toluene 66 86 3:1 
9
 
II-1.12a Toluene 87 86 5:1 
10
 
II-1.12b Toluene 85 90 5:1 
11 II-1.11 CH2Cl2 51 88 2:1 
12 II-1.11 Et2O 20 87 2:1 
13 II-1.11 THF 90 78 3:2 
14 II-1.11 CHCl3 62 86 5:2 
15 II-1.11 Xylene 72 89 3:1 
16
f
 II-1.11 Toluene 78 86 5:1 
17
g
 II-1.11 Toluene 80 91 3:1 
18
h
 II-1.11 Toluene 86 78 5:2 
19 II-1.12b Toluene 85 90 5:1 
a
 Reaction conditions: II-2.1a (0.1 mmol), the catalyst (0.01 
mmol) in the solvent (1ml) with nitrostyrene I-189a (0.11 mmol) 
at 0 
o




 Determined by 
HPLC analysis on a chiral stationary phase. 
d
 Determined by 
1
H 
NMR analysis of the crude reaction mixture. 
e
 Reaction at rt, 
over 3 days. 
f
 Reaction in the presence of 3Ǻ molecular sieves 
(10 mg). 
g
 Reaction in the presence of 4Ǻ molecular sieves (10 
mg); 
h
 Reaction in the presence of 5Ǻ molecular sieves (10 mg).  
We then surveyed our Cinchona alkaloid-derived catalysts incorporating amino acid in-
between the tert-amine and thiourea moieties, and found to our satisfaction that dramatically 
improved enantioselectivities and high yield could be achieved with Quinine-tert-leucine 
incorporating catalyst II-1.11 (entry 6). Lowering the reaction temperature to 0
o
C did not 
affect the yield but slightly improved the ee and dr values (entry 7), therefore all the 
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subsequent reactions were conducted at 0
o
C. Unexpectedly, by replacing tert-Leucine with 
TBDPS-protected L-Threonine (II-2.18), we noticed a large drop in yield and slight decrease 
in stereocontrol (entry 8). In the following attempt to improve dr values, two Cinchonidine-
derived organocatalysts incorporating L-Threonine with (TBS, II-1.12a) or (TBDPS, II-
1.12b) protecting groups were screened. To our satisfaction, we found the yields of the 
reaction improved, while catalyst II-1.12b (with TBDPS-protected L-Threonine) led to the 
desired product with the best stereocontrol (90% ee & 5:1 dr, entry 10). We then performed 
solvent and additive screening using catalyst II-1.11, and identified toluene, followed by 
xylene (entry 15) to be the best solvents. Other common solvents were generally well 
tolerated, except for diethyl ether (low yield, entry 12) and THF (lower ee, entry 13). We 
were intrigued by the noticeable (negative) influence of molecular sieves (3Ǻ, 4Ǻ, 5Ǻ) on 
enantioselectivities (entries 1618), which is difficult to rationalize. The optimum conditions 
were found to be: 10 mol% of catalyst II-1.12b in toluene, at 0
 o
C in the absence of any 
additives, leading to the desired product II-2.3a in high yield (85%), very good ee (90%) and 
decent diastereocontrol (5:1).  
II-2.3. Preparation of substrates 
The -fluoro--nitro benzyls were prepared from the respective benzyl or alkyl bromides 
using sodium nitrite and urea in DMF at -20 
o
C over 2 - 5 hours, an adaptation of the 
previously reported procedure.
129
 The key issue was controlling the reaction temperature and 
time, as prolonged reaction time or increase in reaction temperature resulted in the generation 
of side products of similar polarity to the desired nitro compound leading to difficulties in 
isolation. Over the course of substrate preparation, one incorrect literature report was 
identified, concerning facile preparation of nitro compounds from respective alcohols, which 
led to nitrites instead.
130
 The fluorination was performed using Selectfluor
®
 in 
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 N. Kornblum , W. M. Weaver , J. Am. Chem. Soc. 1958 , 80 , 4333. 
130
 a) A. Baruah, B. Kalita, N. C. Barua, Synlett, 2000, 1064; b) the critique: M. Makosza, M. 
Barbasiewicz, K. Wojciechowski, Synlett, 2001, 1121. 
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acetonitrile/water (1/1) at rt over 12h with KOH as base, using the modified reported 
procedure.
131 
A representative range of -fluoro--nitro-containing substrates was prepared, 
some novel, in the two-step sequence (Figure 20). Para-halobenzyl bromides, 3,4-
dichlorobenzylbromide, 9-(bromomethyl)-anthracene  and phenanthrene all gave complex 
mixture of products in the nitration reaction and were not isolated. Alkyl nitro compounds 
were volatile (such as 2-methyl-1-fluoro-1-nitropropane and 3-methyl-1-fluoro-1-nitrobutane) 
and therefore difficult to isolate. 
 
Figure 20. Substrates prepared for the Michael addition. 
Nitroalkenes were prepared according to known procedures from the corresponding 
aldehydes and nitromethane. 
II-2.4 Scope of the reaction and absolute configuration 
With optimum conditions in hand, we then investigated the reaction scope with regards to 
both substrates (Table 4). Electron withdrawing group on the phenyl ring in the fluoro-
nitroaryl substrate was well tolerated and the corresponding product (II-2.3b) was obtained in 
quantitative yield with 6:1 dr and 88% ee. Furthermore, the reaction was faster and reached 
completion in 12h. High yields, diastereo- and enantio-selectivities were maintained when 
methyl substituent was installed in para- orientation or halogen in meta- position on aryl ring 
in fluorinated donor (II-2.3c and II-2.3d, respectively). The same trend was maintained with 
regards to substitution pattern on nitroalkene - halogen, electron donating or withdrawing 
substituents in para- or meta- positions on aryl ring in -nitrostyrene were all well tolerated, 
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 W. Peng, J. M. Shreeve, Tetrahedron Letters, 2005, 46, 4905. 
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leading to products in very high yields (80%  90%), good dr values (5:1 8:1) and high 
enantioselectivities (88% 91%, II-2.3eh). It was found that enantioselectivity is 
significantly lower (70% ee) when nitrostyrene with chlorine substituent in ortho- position 
was employed as an acceptor (II-2.3i). On the other hand, that negative effect can be nullified 
by the application of catalyst II-1.12a - with TBS protecting group on L-Threonine scaffold 
instead of TBDPS as in II-1.12b. Thus, the desired product of addition to ortho-fluoro-
nitrostyrene (II-2.3j) was obtained with 85% ee, 5:1 dr and high yield. Bis-substitution with 
two fluorine atoms, both in meta- orientation on nitrostyrene, was especially favored, as the 
corresponding product (II-2.3k) was obtained with excellent 96% ee in quantitative yield and 
good 8:1 dr. Heterocyclic nitroalkene was found well tolerated in the reaction system, 
affording the desired product (II-2.3l)  with high yield (91%), enantio- and 
diastereoselectivities (88% ee and 7:1 dr). Lastly, alkyl substituted nitroolefins, the more 
difficult substrates, required the use of more reactive para-cyano-substituted Michael donor 
to allow reaction completion. In fact, under these conditions, the corresponding products (II-
2.3m and II-2.3n) were obtained within one day in very high yields (90% - 95%), decent dr 
(5:1  6:1) and 82% ee, while the use of 20 mol% of catalyst was found unnecessary. The 
aliphatic 1-fluoro-1-nitroalkanes were found unreactive and only trace amount of product (II-
2.3o) was obtained regardless of increased catalyst loading or extended reaction time. The 
absolute configuration of the Michael addition products was assigned by X-ray analysis of 
single crystal of compound II-2.3e (Figure 21). 






 Reaction conditions: Michael donor (II-2.1a-1f, 0.1 mmol), the catalyst (0.01 mmol) in toluene 
(1ml) with nitroalkene (I-189a-k, 0.11 mmol) at 0 
o






H NMR analysis of the crude reaction mixture. 
d
 Determined by HPLC analysis on a 
chiral stationary phase; 
e
 reaction time: 12 h; 
f
 II-2.12a (10 mol%) was used as catalyst 
g
 20 mol% of 
catalyst used; reaction time 14 h. 
 




II-2.5. Reduction of the nitro groups and synthesis of 
tetrahydropyrimidine 
Having assessed the reaction scope, the synthetic utility of thus prepared Michael addition 
products was then investigated. Our main objective was to find an effective route to 
molecules with sought-after -fluoro--amino core, by reducing the nitro groups of the 
Michael adducts (Scheme 63).  
 
Scheme 63. Reduction of nitro group(s) leading to amines (II-2.4). 
Reductions with the robust nickel boride (Ni/NaBH4), as well as classical Fe/AcOH, led to de-
fluorinated products, while zirconium boride (ZrCl4/NaBH4) was unreactive. Standard 
palladium on carbon (Pd/C) also led to defluorination of our substrate II-2.3a at 1 atm of 
hydrogen; however the reaction seemed cleaner as compared to reduction with metal borides. 
Therefore, attention was turned towards less reactive palladium sources and it was found that 
Lindlar‟s catalyst (Pd/CaCO3, lead poisoned) could afford the desired reduction, however 
with low yield due to defluorination. On the contrary, C-F cleavage was mostly suppressed 
when palladium on barium sulphate was used as a catalyst, yet the yield remained 
unsatisfactory and only trace amount of desired product was detected under 1 atm of 
hydrogen. Eventually, by increasing the pressure of hydrogen to 15 atm, the desired 
fluorinated diamine (II-2.4, Scheme 64) could be isolated in 62% yield after 2 days. The 
novel, fluorinated tetrahydropyrrolidine (II-2.5) with fluorine and amino moieties installed on 
the same carbon, was then easily obtained in a high-yielding condensation with 
formaldehyde. It is reasonable to assume that, analogical condensation with acid chlorides or 
anhydrides could also be performed leading to deoxo-uracil-like heterocycles, while the two 
hydrocarbon substituents could be easily tuned by means of applying different Michael 
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donors/acceptors. We believe that such general methodology could be of interest with regards 
to preparation of fluorinated precursors of bioactive compounds. Notably the substitution 
pattern on the fluorinated pyrimidine (II-2.5) resembles closely to that of the non-fluorinated 
compounds of recent interest for their modulating-inhibiting properties of neurotransmitters 
reuptake (II-2.5.1).
132
 Additionally, isolation of the functionalized mono-amine (II-2.6) was 
attempted and successful in a reasonable 56% yield after 12 hours of reduction. The 
nitromethylene group of the amine could possibly be oxidized under the Nef reaction 
protocol, leading to -fluoro--amino acid; however this was not attempted due to time 




Scheme 64. Preparation of fluorinated amines and tetrahydropyrimidine. 
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 a) R. W. Lewis, J. Mabry, J. G. Polisar, K. P. Eagen, B. Ganem, G. P. Hess, Biochemistry, 2010, 49, 
4841; b) PCT Int. Appl., WO  2009/089479 A2, 2009. 
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 a) F. A. Luzzio, D. Y. Duveau, W. D. Figg, Heterocycles, 2006, 70, 321; b) for a recent review on 




In summary, Michael donors containing the-fluoro--nitro- core, some prepared for the first 
time, were successfully applied in organocatalytic addition to nitroalkenes, generating a broad 
scope of enantioenriched fluorinated di-nitro products in high yields (76% - 99%) and under 
good stereo-control (82%  91% ee with 5:1  8:1 dr). Synthetic application of this 
methodology was assessed by converting one of the Michael addition products to fluorinated 
amine, diamine and tetrahydropyrrolidine, all containing vastly unknown - -fluoro--amino 





II-3. Enantioselective preparation of functionalized fluorinated 
phosphonates via Michael addition of -fluoro--ketophosphonates 
to nitroalkenes.  
 
Undoubtedly, phosphate is one of the most important functional groups in bio-sciences and 
therefore synthesis of its analogues and isosteres is of great importance. Knowing fluorinated 
phosphonates for being excellent phosphate mimics we decided to design enantioselective 
route towards this class of compounds. This chapter describes our research efforts in the 
development of asymmetric Michael addition of prochiral -fluoro--ketophosphonates to 
nitroalkenes with subsequent application in preparation of pyrrolidines.   
II-3.1. Introduction 
Phosphates are fundamental functional groups present in bioactive molecules
134  
and as such 
they seem to be an excellent unit to incorporate into the design of pharmaceutical agents. 
However, due to numerous roles they have played in biological systems, phosphates are 
susceptible to hydrolytic cleavage by a large number of enzymes, which hampers their 
applications in medicinal chemistry. On the other hand, phosphonates were found to be good 
mimics of phosphates, while being much more stable in biological systems.
135
 Consequently, 
phosphonate substructures are incorporated in numerous important pharmaceuticals and 
antibodies.
136
 Fluorinated phosphonates (II-IV, Scheme 1) were found to match even more 
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  a) F. H. Westheimer, Science, 1987, 235, 1173; (b) M. W. Bowler,  M. J. Cliff, J. P. Walthob, G. 
M.  Blackburn, New J. Chem., 2010, 34, 784. 
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  For a  review see: a) R. Engel, Chem. Rev., 1977, 77, 349; b) D. F. Wiemer, Tetrahedron, 1997, 53, 
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example of application of phosphonates as phosphate surrogates see: F. W. Foss Jr, A. H. Snyder, M. 
D. Davis, M. Rouse, M. D. Okusa, K. R. Lynch, T. L. Macdonald, Bioorg. Med. Chem., 2007, 15, 
663. 
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  a) For a review on antibodies see: R. A. Lerner, S. J. Benkovic, P. G Schultz, Science, 1991, 252, 
659; b) D. V. Patel, K. Rielly-Gauvin, D. E. Ryono, Tetrahedron Lett., 1990, 31, 5587; c) D. V. 
Patel, K. Rielly-Gauvin, D. E. Ryono, Tetrahedron Lett., 1990, 31, 5591; d) D. L. Pompliano, E. 
Rands, M. D. Schaber, S. D. Mosser, N. J. Anthony, J. B. Gibbs, Biochemistry, 1992, 31, 3800; e) B. 
Stowasser, K. H. Budt, J. Q. Li, A. Peyman, D. Ruppert, Tetrahedron Lett., 1992, 33, 6625; f) M. N. 
Greco, B. F. Maryanoff et al, J. Am. Chem. Soc., 2002, 124, 3810; g) C. T. Behrendt, T. Kurz et al, J. 
Med. Chem., 2011, 54, 6796. 
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closely the electronic and steric characteristics of phosphates.
137
 Therefore, such fluorinated 
structures were recently recognized as excellent replacements for phosphates in bioactive 
compounds, offering similar selectivities, increased potency and greatly enhanced resistance 
to hydrolases.
138
 Interest in fluorinated phosphonates as analogs of phosphates can be 
illustrated by the development of fluoro-phosphonate analogs (VIVII) of LPA (V, 
Lysophosphatic Acid) – an important mitogenic signaling molecule  in ovarian cancer and in 
normal cell proliferations and migration.
139
  Undoubtedly, asymmetric synthesis of fluorinated 
phosphonates would be highly desirable. 
 
Figure 22. Phosphonate analogs of phosphates 
Surprisingly, stereoselective, organocatalytic synthesis of fluorinated phosphonates has not 
been achieved before. We envisioned that employment of racemic -fluoro--
ketophosphonates
140
 in the conjugate addition with nitroalkenes could yield structurally 
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  For preparation of -fluoro--ketophosphonates, see: a) P. Coutrot, C. Grison, Tetrahedron Lett., 
1988, 29, 2655-2658; b) D. Y. Kim, Y. J. Choi, Synth. Commun., 1998, 28, 1491-1498; c) R. D. 
Chambers, J. Hutchinson, J. Fluorine Chem., 1998, 92, 45-52; d) recently improved preparation of a 
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challenging -fluoro-phosphonates containing adjacent quaternary and tertiary stereogenic 
centers (Scheme 2). Moreover, the rich functionality contained in the targets offers great 
latitudes for further structural elaborations. 
 
Scheme 65. Michael addition of -fluoro--ketophosphonates to nitroolefins. 
II-3.2. Michael addition of -fluoro--ketophosphonates to 
nitroalkenes: reaction optimization 
 
Our study was initiated by assessing the catalytic activities of Cinchona alkaloid-derived 
bifunctional thioureas in the Michael addition of -fluoro--ketophosphonates to nitroolefins 
(Table 5). Cinchona alkaloid-derived thiourea catalysts (I-194a-d) were found to be effective, 
and the Michael adducts were obtained with high ee values. However, the 
diastereoselectivities were low (entries 1-4), and such low diastereoselectivity has been 
common in the literature reports.
141
 We then decided to apply amino acid-incorporating 
multifunctional thiourea catalysts developed in our laboratory.
142
 By combining Quinidine 
with either valine (II-3.4-5), iso- or tert-leucine (II-3.6-7), the diastereoselectivity could be 
improved to 6:1 (entries 5-8). Further fine-tuning was done by employing pseudo-
enantiomeric Quinine or Cinchonidine with chiral amino acids. Tertiary amine-thiourea 
catalyst II-1.11 with incorporated L-tert-leucine moiety was found to be the best, affording 
the desired Michael product with a 16:1 diastereomeric ratio and a 99% ee value (entry 10). 
Notably, this catalytic system is highly tunable; the different configurations of the Cinchona 
                                                                                                                                                                      
narrow scope of racemic compounds was reported: K. Radwan-Olszewska, F. Palacios, P. Kafarski, 
J. Org. Chem., 2011, 76, 1170-1173. 
141
  See for example: K. Hu, T. Liu, A. D. Lu, Y. Liu, Y. Wang, G. Wu, Z. Zhou, C. Tang, Eur. J. Org. 
Chem., 2011, 3507. 
142
   Q. Zhu, Y. Lu, Angew. Chem. Int. Ed., 2010, 49, 7753. 
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alkaloid structures and the chiral amino acid building blocks make the catalysts versatile with 
little synthetic efforts. 











1 I-194c 3 90 1.4:1 86 
2 I-194b 3 80 1.5:1 97 
3 I-194d 3 81 1.5:1 -84 
4 I-194a 2 65 1.5:1 -89 
5 II-3.4 4 45 3:1 53 
6 II-3.5 4 80 3.3:1 -94 
7 II-3.6 4 38 3:1 43 
8 II-3.7 4 45 6:1 99 
9 II-3.8 4 92 17:1 98 
10 II-1.11 4 93 16:1 >99 
[a] Reaction conditions: II-3.1 (0.05 mmol), I-189a (0.06 mmol), and the catalyst (0.005 mmol) in toluene (0.5 
mL) at room temperature; [b] Isolated yield; [c] Determined by 1H NMR analysis of the crude mixture; [d] 
Determined by HPLC analysis on chiral stationary phase. 
Having achieved satisfying level of stereo-control, solvent screening was not performed; in 




II-3.3. Preparation of substrates 
The -fluoro--ketophosphonates can be prepared from easily available methyl ketones and 
triethylphosphite in a 3-step sequence: bromination, Arbuzov C-P formation and fluorination 
(Scheme 66).   
 
Scheme 66. Preparation of fluorinated phosphonates. 
The first step - bromination - was performed using relatively safe, easy to handle and readily 
available N-bromosuccinimide as the bromine source, p-toluenesulphonic acid as promoter 
and acetic acid as solvent. The ketones, being generally unreactive required the use of 
microwave irradiation to undergo the bromination. 
 
Scheme 67. Bromination of ketones. 
Under these conditions, the mono-brominated products could be obtained in high yields 
within 2 - 6 h. Bis-bromination hardly occurred and could be suppressed by lowering the 
reaction temperature or shortening the reaction time. The crude intermediates were used 
without further purification in the next step. Carbon-phosphorus bond formation was achieved 
via Arbuzov reaction (pathway a, Scheme 68). The first step of this transformation is a 
nucleophilic attack of phosphorus on the halogenated carbon to form cationic intermediate 
(IIa). Following dealkylation induced by the bromide, the formation of the desired 




Scheme 68. Mechanisms of the Arbuzov and Perkov reactions. 
However, the presence of the keto group in the substrate would cause a side reaction to occur 
- Perkov reaction. In the first step, the phosphorus would not attack the halogenated carbon, 
but the similarly electrophilic carbonyl moiety leading to intermediate IIb (pathway b). 
Subsequent attack of oxygen anion on the electrophilic phosphorus would result in C-P bond 
cleavage and formation of intermediate IIb’. Lastly, bromide-induced dealkylation would 
yield the undesired vinyl phosphate (III’). Indeed, during the preparation of the -
ketophosphonates, the Perkov reaction occurred in all cases, lowering the yields of the desired 
phosphonate severely (20% - 72%) in some cases. The only strategy to counter the formation 
of side product was to increase the reaction temperature, as the Arbuzov reaction becomes 
more favorable in higher temperatures. Fortunately, the two products were easily separable by 
flash chromatography. The last step of the substrate synthesis was fluorination (Scheme 69).  
 
Scheme 69. Fluorination of -ketophosphonates. 
In many cases, the fluorination was challenging, due to partial conversion of substrate to 
product and separation difficulties, as well as a facile bis-fluorination. The aromatic -
ketophosphonates could be fluorinated in mild, neutral conditions, using Selectfluor
®
 as the 
fluorine source and acetonitrile as solvent. The time and temperature were optimized, and 5  
10 min. of microwave irradiation at 80  110 oC was found optimal. Longer reaction times or 
higher temperatures led to bis-fluorination and product decomposition. The desired aromatic 
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mono-fluorinated phosphonates (II-3.1a-I, Figure 23) could be obtained in moderate yields 
(34%  68%). The less reactive alkyl -ketophosphonates required the use of a strong base, 
and potassium tert-butoxide was found to be optimal (others, such as metal hydrides or strong 
organic bases, led to bisfluorination or product decomposition). The desired -fluoro--
ketophosphonates with alkyl chain could be prepared in moderate yields (32% - 58%, II-3.1j-
k).  
 
Figure 23. -Fluoro--ketophosphonate donors for Michael addition. 
Upon completion of the project, an alternative method for fluorination of some of the 
phosphonates was published, based on the use of Selectfluor
®
 in aqueous media, which could 
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II-3.4. Reaction scope and determination of the absolute 
configuration 
With the optimized reaction conditions in hand, the reaction scope was then investigated 
(Figure 24). The reaction was found to be broadly applicable to a range of nitroolefins and 
various fluorinated phosphonate pronucleophiles. Different nitrolefins were suitable 
substrates, high diastereoselectivities and nearly perfect enantioselectivities were attainable, 
regardless of the substitution patterns and electronic nature of the aryl moieties (II-3.2ab  II-
3.2ag). Aryl nitroolefins containing a naphthyl, furyl or thionyl moieties were also well 
tolerated (II-3.2ah, II-3.2ai and II-3.2aj respectively). The reaction scope with regard to the 
structures of fluorinated ketophosphonates was also examined. Different -aryl--
ketophosphonates with different electronic nature and substitution patterns on the aromatic 
ring could be employed, and the products were obtained in excellent yields (84%  96%), 
with high dr (6:1  >20:1) and very high ee values (98% - 99% ee, II-3.2ba - II-3.2ge). 
Moreover, bis-substituted aryls in fluorinated phosphonates or nitroolefins were all well-
tolerated in the reaction (II-3.2hl and II-3.2im, respectively). Aliphatic nitroolefins could also 
be used, however, 20 mol% of catalyst was required, and the adducts were obtained in 
moderate yield (40%  88%) and dr (3:1  5:1), and excellent enantioselectivities (96%  
98% ee, II-3.2ak and II-3.2in). Similarly, the aliphatic -fluoro--ketophosphonates were 
found to be less reactive than their aromatic counterparts, yet with the catalyst loading 
increased to 20 mol%, the reaction proceeded with acceptable yields (55%  68%) and 
diastereoselectivities (7:2  3:1) and excellent enantiomeric excesses (96%  99%, II-3.2je 
and II-3.2ke). 






[a] Reaction conditions: phosphonate II-3.1a-k (0.05 mmol), nitroalkene I-189a-n (0.06 mmol), II-1.11 (0.005 
mmol) in toluene (0.5 mL) at room temperature; [b] Isolated yield; [c] Determined by 1H NMR analysis of crude 
product; [d] Determined by HPLC analysis on chiral stationary phase, value in bracket corresponds to the minor 
diastereomer; [e] 20 mol% of 6b was used; [f] 10 mol% of II-3.8 used. When II-1.11 was used corresponding 
product was obtained in 95% yield over 3 days with dr of 7:1 and 97% ee. 
Although some of the products were solids, attempts to obtain single crystal suitable for X-ray 
analysis failed. Therefore, the carbonyl group in the Michael adduct II-3.2ae was reduced to 
yield products in solid form (Scheme 70). High diastereoselectivity of the reduction was 
observed, presumably due to the presence of two asymmetric centers, and the products were 
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obtained as single diastereomers. Moreover, under different conditions, two different 
diastereomers of -fluoro--hydroxy--nitro phosphonates were obtained (II-3.10a & II-
3.10b). Presumably, the lithium ion chelates to the keto carbonyl group as well as 
phosphonate, forming a cyclic complex, which results in the hydroxyl and phosphonate 
groups positioned on the same side of the carbon chain in the product II-3.10b, as opposed to 
reduction in absence of lithium (II-3.10a).   
 
Scheme 70. Reduction of carbonyl leading to diastereomeric -hydroxy-derivatives. 
The single crystal of II-3.10a was obtained successfully and its X-ray structure (Figure 25) 
allowed for the assignment of the absolute configurations of the Michael addition products. 
 
Figure 25. X-ray structure of the single crystal of II-3.10a. 
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II-3.5. Preparation of -fluoro-pyrrolidine 
 
The Michael adducts contain also several other functionalities than the most valuable 
fluorinated phosphonate. The keto moiety of -ketophosphonate, in addition to increasing the 
reactivity of the Michael donor could also be subsequently subjected to functional group 
transformations leading to molecules of interest. The nitro group, contributed by nitroalkene, 
is a masked amino functionality. Having both keto and amino groups in one molecule, 
cyclization is likely to occur, yielding a heterocyclic structure. Five-member, nitrogen-
containing heterocyclic ring - pyrrolidine - is featured in many bioactive and natural 
compounds (Scheme 71),
144
  such as II-3.13a&b - alkaloids from Japanese “himekouzo” tree, 
which are highly potent poisons, like Bgugaine (II-3.15) and Irniines (II-3.16a&b). Lapiotin 
A and B (II-3.17a&b) were isolated from poisonous mushrooms Chlorophyllum molybidilis 
and Macrolepiotia neomastoidea, while II-3.14 from ant‟s venom. Such compounds are of 
interest as they may be derived into pharmaceuticals. The most appealing example of 
pyrrolidine-containing pharmaceutical was carboxylic acid-featuring Atrasentan, with 2,3,4-
substitution pattern on pyrrolidine ring. It is an interesting pharmaceutical of multiple actions 
- a drug candidate against cancer,
145
 as well as endothelin-A receptor antagonist, found to 
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Figure 26. Pyrrolidine- or phosphonate-containing natural products and pharmaceuticals. 
We have envisioned that our methodology may lead to molecules containing pyrrolidine ring 
with the same substitution patterns as seen in Atrasentan, and with carboxylic acid moiety 
replaced with fluorinated phosphonic acid. Therefore, synthesis of pyrrolidine was attempted 
(Scheme 71). When the nitro group in II-3.3ae was reduced, the cyclization took place 
spontaneously to afford cyclic imine II-3.11 in excellent yield. The reduction proceeded 
smoothly under mild conditions, and it was found that addition of indium
147
 led to improved 
yield of the imine. Surprisingly, the imine II-3.11 was very stable and could not be easily 
reduced, presumably due to its intrinsic steric hindrance. By applying two different sets of 
reaction conditions, two pyrrolidines were obtained, which were revealed by extensive NMR 
studies
148 
to be the stable rotational isomers of the desired pyrrolidine II-3.3.
 
The pyrrolidines 
obtained here represent interesting fluorinated phosphonates as analogues of Atrasentan. 
 
                                                          
147
  S. Cicchi, M. Bonanni, F. Cardona, J. Revuelta, A. Goti, Org. Lett., 2003, 5, 1773. 
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 See the experimental for details. See also: M. Michalik, M. Hein, M. Frank, Carbohydrate Res., 








In conclusion, -fluoro-phosphonate pronucleophiles were prepared, some for the first time, 
and successfully applied in highly stereoselective Michael addition to nitroalkenes, catalyzed 
by accessible, amino acid-incorporating trifunctional thiourea catalysts. This is the first report 
for highly diastereoselective and enantioselective organocatalyzed synthesis of -fluoro-
phosphonates. The broad range of products with tunable alkyl/aryl substituents contain 
several functional groups for further manipulations. Synthesis of pyrrolidine-containing 
fluorinated-phosphonate analogue of experimental pharmaceutical Atrasentan, was 








II-4. Organocatalytic Michael addition of -fluoro--diketones to 
nitroalkenes: towards fluoro-isosteres of glycerine 
 
Following the successful preparation and application of several fluorinated donors - 
phosphonates, nitroacetic acid ester and nitrobenzylic compounds, the search for other 
fluorine-containing prochiral synthons continues. In this chapter, organocatalytic addition of 
fluorinated diketones to nitroalkenes in its preliminary stage is described. Such reaction 
would lead to synthesis of fluoro-isosteres of tri-substituted glycerines with additional 
primary amine functionality. 
II-4.1. Introduction 
 
Diols, triols and tert-alcohol are common motifs in the structures of marine toxins,
149
 
macrolide antibiotics (Aspicilin, II-4.1, Erythromycin, II-4.2)
150
 and polyether antibiotics
151
, 
as well as many other sugar- or glycerine-derived bioactive compounds (e.g. 1-
Hydroxybrevicomin (II-4.3) – a fatty acid metabolism product and insect pheromone),152 
some of which were found active against leukaemia and other cancers (e.g. Fostriecin, II-
4.4),
153
 inhibiting phospholipase A2 (PLA2, e.g. Cinatrin B (II-4.5a) and C (II-4.5b))
154
 or T-
cell activation genes (e.g. immunosuppressant FK5061).
155
 Tertiary alcohol moiety was also 
found crucial in recently investigated HIV protease inhibitors (e.g. II-4.6).
156
 Such motifs are 
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 a) H. Kirst, in: “Recent progress in the chemical synthesis of antibiotics”, G. Lukacs, M. Ohno, 
Eds., Springer-Verlag: Berlin, 1990, 39; b) S. C. Sinha, E. Keinan, J. Org. Chem., 1997, 62, 377. 
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 O. Yonemitsu, K. Horita, in: “Recent progress in the chemical synthesis of antibiotics”, G. Lukacs, 
M. Ohno, Eds., Springer-Verlag: Berlin, 1990, 447. 
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 a) M. Nakatsuka, J. A. Ragan, T. Sammakia, D. B. Smith, D. E. Uehling, S. L. Schreiber, J. Am. 
Chem. Soc., 1990, 112, 5583; b) R. E. Ireland, J. L. Gleason, L. D. Gegnas, T. K. Highsmith, J. Org. 
Chem., 1996, 61, 6856. 
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 X. Wu, M. Larhed, et al, J. Med. Chem., 2008, 51, 1053. 
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most commonly prepared via methodologies based on the asymmetric Sharpless 
dihydroxylation,
157
 Jacobsen‟s epoxidation158 or the use of sugar-derived synthons.   
The size, electronic configuration and properties of fluorine render it feasible for being an 
isostere of hydroxyl and oxo groups; such modifications have been applied in lead 
optimization (e.g. see the case of Camptothecin and nucleoside-derived antiviral agents in the 
Introduction chapter).  
 
Figure 27. Bioactive compounds with triol, diol and/or tert-alcohol. 
Considering the potential biological application of such alcohols as seen above,  we believe it 
worthwhile to develop a general route towards partially fluorinated analogues of di- or tri-
hydroxy compounds. Such motif (I, Figure 28) could be accessed via Michael addition of 2-
fluoro-1,3-diketone (II) to a general acceptor (III) and subsequent reduction of the carbonyl 
moieties. Such reaction has other merits as it would lead to the generation of fluorinated 
quaternary stereocenter adjacent to three tertiary stereocenters, and as such, constitutes 
significant synthetic challenge. Furthermore, even though 1,3-dicarbonyl compounds were 
                                                          
157
 Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B., Chem. Rev., 1994, 94, 2483. 
158
 a)  Jacobsen, E. N. In Catalytic Asymmetric Synthesis; Ojima, I., Ed.; VCH Publishers Inc.: New 
York, 1993; pp 159; b) E. N. Jacobsen, W. Zhang, A. R. Muci, J. R. Ecker, L. Deng, J. Am. Chem. 
Soc., 1991, 113, 7063. 
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benchmark substrates in the development of stereoselective direct fluorination (see 
Introduction chapter), enantioselective fluorination of 1,3-diketones has not been realized to 
date.  
 
Figure 28. Route towards 2-fluoro-1,3-diols via Michael addition. 
Michael additions of acetylacetone to -nitrostyrene has become a benchmark model reaction 
in testing new catalysts, as the symmetrical scaffold provides excellent H-bonding 
acceptor/donor system without devoid of distereogenic carbon centre. Therefore, it has been 
reported several times in testing thiourea-, squaramide, primary amine-containing, sugar-, 
imidazole- or Rosin-derived organocatalysts;
159
 however, reports on the use of diketones other 
than acetylacetone or 1,3-diphenylpropanedione are rare,
159a,g
 with fluorinated diketones have 
never been employed in Michael addition to date. This may also be due to lower reactivity of 
diketones as compared to aldehydes or ketoesters, in addition to difficulties in controlling the 
diastereoselectivity of the reaction with unsymmetrical diketones, as differentiation of the two 
carbonyl groups is a challenging task.   
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II-4.2. Michael addition of 2-fluoro-1,3-diketones to nitroalkenes: 
reaction optimization 
We began our investigation on a model Michael addition of 2-fluoro-1-phenyl-1,3-butadione 
(II-4.7, Table 6) to (E)--nitrostyrene (I-189a) catalyzed by Cinchona alkaloid-derived 
organocatalysts with different types of H-bonding moiety. Quinine-derived thiourea (I-194a) 
and urea (I-194e) catalysts were found superior to their guanidine analogue (I-194f), leading 
to the desired product in a clean reaction with full conversion of starting material to product  
and 90% - 91% ee for the major diastereomer obtained in a 2:1 diastereomeric ratio (entries 1 
& 2), as compared to 28% ee and 1.5:1 dr, with low conversion of 40%, in the guanidine 
catalyzed reaction (entry 3). Therefore, the screening was continued with different thiourea-
containing organocatalysts.  In an attempt to increase the dr value, the highly stereoselective 
Quinine-derived catalyst II-1.11 incorporating L-tert-leucine moiety which was utilized in 
other Michael additions was then tested. Unfortunately, disappointing results were obtained; 
even though the enantioselectivity was high (93% & 90% ee), a 1:1 mixture of diastereomers 
was obtained. Insignificant improvement of diastereoselectivity was observed when Quinine-
derived dipeptide (L)-Val-(L)-Val-featuring catalyst (II-4.9) was employed - Michael adduct 
was obtained in 3:2 diastereomeric ratio with 84% / 85% ee in 60% conversion (entry 5). 
Next, other scaffolds besides Cinchona alkaloid-derived scaffolds were tested. The 
tryptophan-derived catalyst Trp1 was found effective (100 conv.) and enantioselective (92% 
ee), however, the dr value was still low (2:1, entry 6). Similar result was obtained in reaction 
catalysed by tryptophan-thiourea catalyst II-4.10 containing additional H-bonding hydroxyl 
group, albeit enantioselectivity was slightly lower (87%, entry 7). Further drop in 
enantioselectivity to 81% was found in the reaction catalysed by cyclohexyl-tert-amine-
containing catalyst (II-4.11) derived from TBS-protected L-threonine (entry 8). Unable to 
improve diastereoselectivity with different thiourea-containing catalysts, attention was then 
turned to sulphonamide organocatalysts.  
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Table 6. Optimization of organocatalyzed Michael addition of 2-fluoro-1-phenyl-1,3-butadione (II-
4.7a) to (E)--nitrostyrene (I-189a).a 
 










I-149b CH2Cl2 rt 100 90/87 2:1 
2
 
I-149c CH2Cl2 rt 100 91/87 2:1 
3
 
I-149d CH2Cl2 rt 40 28/30 1.5:1 
4
 
II-1.11 CH2Cl2 rt 100 93/90 1:1 
5 II-4.9 CH2Cl2 rt 60 84/85 1.5:1 
6
 
Trp1 CH2Cl2 rt 100 92/87 2:1 
7
 
II-4.10 CH2Cl2 rt 100 87/85 2:1 
8
 
II-4.11 CH2Cl2 rt 100 81/79 2:1 
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9 II-2.16 CH2Cl2 rt 100 84 3:1 
10
 
II-4.12 CH2Cl2 rt 100 -18/-22 1.5:1 
11
 
II-4.13 CH2Cl2 rt 100 10/7 1.5:1 
12 II-4.14 CH2Cl2 rt 40 25/10 2:1 
13 II-4.15 CH2Cl2 rt 100 10/5 1:1 
14 II-2.16 CHCl3 rt 100 74/61 2:5 
15 II-2.16 Toluene rt 100 70/68 3:1 
16 II-2.16 Et2O rt 100 85/76 3:1 
17 II-2.16 CH3CN rt 100 76/61 3.3:1 
18 II-2.16 Et2O 0 100 88/81 3:1 
19 II-2.16 Et2O -20 100 89/81 3:1 
20 II-2.16 Et2O -70 95 92 6:1 
21
d 
II-2.16 Et2O rt 100 67/33 3:1 
22
e 
II-2.16 Et2O rt 100 81/72 3:1 
a
 Reaction conditions: II-4.7a (0.05 mmol), the catalyst (0.005 mmol) in the solvent 
(0.5ml) with nitrostyrene I-189a (0.06 mmol) at the temp. indicated; 
b
 Determined by 
1
H NMR analysis of the crude reaction mixture.
c
 Determined by HPLC analysis on a 
chiral stationary phase. 
d
 Reaction in the presence of 4Å molecular sieves (5 mg); 
e 
20 mol% of catalyst was used. 
Quinine-derived sulphonamide catalyst with bis-(trifluoromethyl)phenyl substituent (II-2.16) 
was found effective (100% conv.) and stereoselective 84% ee with highest 
diastereoselectivity of 3:1 so far. Following that finding, other sulphonamide catalysts were 
then tested. To our surprise, the pseudo-enantiomeric Quinidine-sulphonamide catalyst (II-
4.12) led to the product with dramatically decreased enantioselectivity (-18% & -22% ee, the 
opposite enantiomers were obtained) and halved diastereoselectivity (1.5:1, entry 10). Even 
lower enantioselectivities were measured in reactions catalysed by Quinine-sulphonamide 
catalysts with pentafluoro- (II-4.13) or 2,4,6-trimethylphenyl substituents (II-4.14) - 10% & 
7% and 25% & 10% ee respectively with 1.5:1 and 2:1 dr (entries 11&12), which indicated 
the importance of the sulphone aryl substituent for stereoselectivity. In the final attempt to 
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increase the diastereoselectivity of the reaction, the best Quinine-sulphonamide catalyst was 
modified by installing L-tert-leucine moiety (catalyst II-4.15); however, only low 
enantioselectivity (10% & 5%) with no diastereoselection was the end-result (entry 13). 
Therefore, the reaction with the best catalyst- Quinidine-bis(trimethyl)phenylsulphonamide 
II-2.16 was then further optimized. First, solvents were screened (entries 14 – 17) and 
enantioselectivity was found to vary in the range of 70% - 85%, with the lowest value found 
for toluene, and highest for diethyl ether. Secondly, temperature was lowered and consistent 
increase in enantioselectivity with decrease of reaction temperature was measured – 88% at 0 
o
C, 89% ee at -20 
o
C and 92% ee at -70 
o
C (entries 18 – 20), with diastereoselectivity up to 
6:1. The following experiments with additional molecular sieves or increased catalyst loading 
(entries 21 – 22) did not furnish better result. Therefore, the optimum conditions were found 
to be 10 mol% catalyst in diethyl ether at -70 
o
C, with absence of any additives. 
To rationalize the observed importance of the bis-(trifluoromethyl)phenyl- group on the 
sulphone moiety in the structure of the best catalyst (II-2.16) on stereoselectivity, a ternary 
complex was proposed (Figure 29). The diketone enolate (black) is bound in an ionic 
interaction with ammonium cation of the catalyst. The nitro moiety of the nitroalkene (blue) 
interacts with the sulphonamide hydrogen, while the aryl substituent engages in  
interactions with the phenylsulphonyl group of the catalyst. This resulting partial shielding of 
the reverse side of the nitroalkene directs the attack of the enolate from the „‟top‟‟ side of the 
nitroolefin. The vitality of trifluoromethyl substituents (see entries 9, 11, 13, Table 6) may be 
rationalized by the known effect of fluorination on the quadrupol moment of aromatic rings 
affecting  interactions.160 Additionally, trifluoromethyl substituents are sterically 
demanding. 
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Figure 29. Ternary complex in the Michael addition promoted by catalyst II-2.16 (in red). 
II-4.3. Preparation of the substrates 
 
In order to examine the reaction scope, different 2-fluoro-1,3-diketones were prepared in a 
two-step sequence (Claisen condensation and fluorination), starting from commercially 
available aryl(alkyl)-methylketones (Scheme 72). The Claisen condensation was generally 
easy to perform and a range of diketones was easily prepared in decent yields 60% - 80%. 
The trifluoromethyl- and phenol-featuring diketones were commercially available. The 
second step -fluorination - required optimization, as some diketones were less reactive, while 
others were prone to undergo bis-fluorination. The use of any base resulted in bis-
fluorination, therefore neutral conditions were employed, with microwave irradiation required 
in some cases. The cyclic diketone II-4.7m was found unstable and attempts of purification 
either by column chromatography or distillation resulted in decomposition of the presumed 
product (as judged by TLC analysis). Notably, it was found that enantioselectivities were 
generally higher (by 5% on average) with substrates purified by reduced-pressure distillation 
than column chromatography, presumably due to the presence of a trace amount of impurities 





Scheme 72. Preparation of fluorinated diketones for Michael addition. 
II-4.4. Scope of the reaction 
With substrates in hand, the reaction scope was examined (Table 7). As compared to phenyl-
methyl diketone, phenyl-iso-propyl substrate was more stereoselective and consequently the 
corresponding product (II-4.8b) was obtained with higher enantio- and diastereoselectivity 
(96% ee & 8:1 dr versus 92% ee & 6:1 dr for II-4.8a), with good yield maintained. Diketone 
with halogen in para-position on aromatic ring was found equally reactive; however the 
corresponding product (II-4.8c) was isolated with slightly decreased enantioselectivity (89%) 
and diastereoselectivity (4:1). On the other hand, excellent enantioselectivities (96% - 97%) 
were achieved with diketones containing either a larger aryl ring (anthracene - II-4.8d) or 
heterocycle (furan - II-4.9e), albeit with decreased diastereoselectivities (9:2  5:2). Electron 
withdrawing substituent on aryl ring of nitroalkene in para orientation caused a drop in 
diastereoselectivity as the corresponding product (II-4.8f) was obtained as a 2:1 mixture of 
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diastereomers, while very high enantioselectivity (94%) and good yield (82%) were 
maintained. Electron donating group in para position on nitroalkene‟s aryl ring was especially 
favored as the corresponding product (II-4.8g) was over 99% optically pure, with the 
diastereoselectivity remaining at the moderate level (9:2). Nitroalkenes with halogen 
substituent in either meta- or ortho- orientations were well tolerated in the reaction system as 
the corresponding products (II-4.8h & II-4.8i, respectively) were obtained in very high yields 
(90%  95%), enantioselectivities (95% ee) and moderate diastereoselectivities (3:1  9:2). 
On the other hand, alkyl nitroalkene was generally a difficult substrate as only a trace amount 
of product was obtained at low temperature. When reaction temperature was increased to 0 
o
C, the corresponding product (II-4.8j) was isolated in 50% yield as a 3:2 mixture of 
diastereomers. Further increase of reaction temperature to room temperature resulted in the 
increase in isolated yield to 67%, at the expense of diastereoselectivity (1:1). The 
enantioselectivity of the product could not be assessed to date, as suitable HPLC conditions 
have not been found to separate the enantiomers. Unfortunately, the phenol-containing 
diketone and trifluoromethyl-substituted diketone were both found unreactive in the reaction 
and the formation of the corresponding products (II-4.8kl) was not observed. Generally the 
reaction was found quite tolerant with respect to diketones, while aromatic nitroalkenes were 
preferable. Further investigation of the reaction scope is necessary to assess the practicality of 
our methodology. Unfortunately, to date, no single crystal suitable for X-ray analysis has 
been obtained and consequently the configuration of the products remains unknown. Work 
will also continue on this aspect.  
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 Reaction conditions: Michael donor (II-4.7a-g, 0.1 mmol), the catalyst (0.01 mmol) in diethyl ether 
(1ml) with nitroalkene (I-189a-f, 0.11 mmol) at -70 
o






H NMR analysis of the crude reaction mixture. 
d
 Determined by HPLC analysis on a 
chiral stationary phase; 
e









II-4.5. Preparation of the glycerin analogue and further 
manipulations of the product 
 
Simultaneously to the investigations of the reaction scope, work on assessing the synthetic 
utility of the Michael adducts was undertaken. The main goal of our methodology was to find 
effective routes to fluoro-isosteres of glycerine and such structures can be easily accessed 
from the Michael adducts (Scheme 73). Facile reduction of the product II-4.8b with either 
lithium or sodium borohydrides led to a separable mixture of three compounds, out of which 
the two major products (II-4.16a and II-4.16b) were isolated, characterized  and confirmed to 
be the desired products in two diastereomeric forms. Further reduction of the nitro moiety to 
yield amino-diol was found feasible; however the product has not been isolated to date.  
 
Scheme 73. Reduction of the carbonyl groups leading to glycerine fluoro-isostere. 
Efforts were put to elucidate the absolute configuration of the two diols (II-4.16) and single 
crystals for X-ray analysis were obtained. Unfortunately, in both cases the only two suitable 
crystals contained both enantiomers, which may sometimes occur, since crystallization as a 
pair of enantiomers is in general easier than crystallization of a single enantiomer. This could 
perhaps be attributed to the sterically demanding and defined character of the diols containing 
three tertiary stereocenters adjacent to a quaternary stereocenter, and the facile H-bonding 
interactions between the hydroxyl and nitro moieties. The two crystal structures obtained are 
shown below (one enantiomer of each compound II-4.16a, Figure 30, II-4.16b, Figure 31). 




Figure 30. X-ray structure of arbitrary chosen enantiomer of diol II-4.16a. 
 
Figure 31. X-ray structure of arbitrary chosen enantiomer of diol II-4.16a. 
 
In addition to carbonyl reduction, other manipulations of the Michael adduct were attempted, 




Scheme 74. Reduction of nitro substituent leading to pyrrolidines. 
Several common methods for nitro reduction were screened. The use of Zn/AcOH or nickel 
boride (NiCl2/NaBH4) led to complicated mixtures of products, while triphenylphosphine or 
iron were not effective in the reductions. On the other hand, prior experience with similar 
reductions of fluorinated 1,3-dicarbonyl compounds suggests that Pd/C would lead to 
defluorination. Therefore, less active palladium sources such as Pd/BaSO4 will be tested in 
the future. 
II-4.6. Summary and future perspective 
 
In conclusion, a highly enantioselective Michael addition of novel fluorinated 1,3-diketones 
to nitroalkenes was demonstrated with the use of simple and accessible Quinine-
sulphonamide catalyst. Michael addition to aromatic nitroolefins led to products with high to 
excellent enantioselectivities (89%  >99%), low to good diastereoselectivities (2:1  8:1) in 
good to excellent yields (70%  95%), while aliphatic nitroalkenes were found generally 
unreactive. Two diastereomeric glycerine fluoro-isosteres with four contiguous stereogenic 
centers were prepared from the model Michael adduct upon facile reduction. Future work will 
tackle expanding the substrate scope to other 2-fluoro-1,3-diketones and nitroalkenes, 




II-5. Asymmetric Mannich reaction - towards fluorinated amino 
acids, lactones and -lactams 
 
Following the successful development of enantioselective Mannich addition of -fluoro--
ketoesters we have focused on application of the Mannich adducts in preparation of 
fluorinated bioactive molecules and useful synthons. The following section details our 
synthetic efforts in preparation of -fluoro--amino esters, -fluoro--lactam and lactone. 
The methodology was extended to application of fluorinated malonates and subsequent 
tandem decarboxylation/protonation leading to linear -fluoro--amino esters. Findings on 
this challenging process are presented in the second part of this chapter. 
Background 
Mannich addition of carbonyl compounds to imines is an especially appealing C-C bond 
forming reaction, as it may lead to - or -amino esters. Several groups have reported 
successful use of organo- or metal-containing catalysts in enantioselective addition of 
ketoesters and malonates to preformed, protected imines or its three-component version, 
leading to -amino esters (Scheme 75).161  
 
Scheme 75. Mannich addition of 1,3-dicarbonyl compounds to imines leading to -amino esters. 
                                                          
161
 a) For a recent review see: S. Kobayashi,Y. Mori, J. S. Fossey, M. M. Salter, Chem. Rev., 2011, 111, 
2626; b) Y. Hamashima, N. Sasamoto, D. Hotta, H. Somei, N. Umebayashi, M. Sodeoka, Angew. 
Chem. Int. Ed., 2005, 44, 1525; c) L. Bernardi, A. S. Gothelf, R. G. Hazell, K. A. Jørgensen, J. Org. 
Chem. 2003, 68, 2583. 
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Alternatively, addition to glyoxylate- or glycine-derived imines yields -amino esters 
(Scheme 76).  
 
Scheme 76. Mannich addition leading to -amino esters. 
II.5.1. Introduction: Development of organocatalytic Mannich addition of 
-fluoro--ketoester to N-Boc aldimines 
We envisioned that similar reaction between -fluoro--ketoester would lead to potentially 
valuable compounds, -fluoro--amino acids derivatives, via a general route.  
 
Figure 32. Hypothetical route towards -fluoro-,-diaminoacids and -fluoro--lactams. 
Upon catalyst screening and optimization, the novel tryptophan-derived catalyst (Trp1, 
Scheme 77) was found to be highly effective and stereo-selective in Mannich reaction 




Scheme 77. Asymmetric Mannich reaction catalyzed by tryptophan-derived organocatalyst Trp-1. 
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 X. Han, J. Kwiatkowski, F. Xue, K.-W. Huang, Y. Lu, Angew. Chem. Int. Ed., 2009, 48, 7604; 
Angew. Chem. Int. Ed., 2011, 50, 2653. 
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Equally good results were obtained for a broad range of aromatic imines and aromatic and 
aliphatic ketoesters, as well as with very challenging substrates - aliphatic imines (I-166a-v, 
Scheme 78) with this general reaction.  
 
Scheme 78. Structures of products attainable via Trp1 catalyzed Mannich reaction. 
To understand our catalytic system better, kinetic and computational studies (density 
functional theory) were performed. The reaction was found to be first rate with regards to 
both substrates and the catalyst. Computational modelling resulted in proposing plausible pre-
transition state model for the formation of the product I-166k. The very good stereocontrol of 
the process was attributed to the formation several of H-bonding interactions (Figure 33).
163
  
After deprotonation of the ketoester, the tert-amine formed an iminium cation that in turn 
engaged into H-bonding interactions with the imine substrate. The fluorinated enolate 
substrate is bound by H-bonding interactions to the thiourea moiety, with additional 
assistance from non-classical C-H
.....
O interactions.  
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Figure 33. Proposed pre-transition state complex. 
II.5.2. Manipulation of Mannich addition product - preparation of -
fluoro--lactam and lactone 
 
Being able to prepare a broad scope of Mannich adducts with excellent optical purity, we than 
explored their synthetic utility for the preparation of fluorinated precursors of bioactive 
compounds. 
Firstly reductive amination on the model substrate to access -fluoro-,-diamino ester (II-
5.14, Scheme 79) via a one pot procedure was attempted. Benzyl or ethyl amines were used in 
combination with reducing agents such as sodium triacetoxyborohydride or sodium 
cyanoborohydride at pH = 5 in standard solvents: CH2Cl2, (CH2Cl)2 or THF. Unfortunately in 
all cases the reaction was messy, with no major product. Attempts to isolate the intermediate 
imine formed initially, evident by TLC analysis, were also unsuccessful. Presumably, the 
imine underwent facile hydrolysis during isolation, while the amine decomposed with release 




Scheme 79. Reductive amination of Mannich adduct. 
We then decided to try a different route - reduction of ketone, followed by mesylation, 
displacement with azide and reduction (Scheme 80). Alcohol (II-5.15) could be obtained 
easily by reduction with either sodium or lithium borohydride in ethanol. Further mesylation 
of the alcohol was successful as well; however problems were encountered during the 
subsequent step - nucleophilic substitution with azide. 
 
Scheme 80. Alternative route towards -fluoro-,-diamino ester. 
The reaction was sluggish at room temperature, but became messy at elevated temperatures 
(up to 80 
o
C), with no major spot. The observed reactivity was attributed to the presence of 
fluorine on the neighbouring carbon; the electron withdrawing effect could diminish the very 
good leaving ability of the mesyl group. On the other hand, the azide could attack the highly 
electron-positive fluorinated carbon atom at elevated temperatures in polar solvent (DMF). 
We then decided to reduce the keto moiety to hydroxy in order to stabilize the molecule, and 
subsequently seek the routes towards free amino acid, -lactam and -lactone, as such 
compounds belong to the families of bioactive compounds (Scheme 81).
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  For the antibacterial activity and synthesis of -lactam, see: a) J. D. Buynal, Curr. Med. Chem., 
2004, 11, 1951; b) A. Brandi, S. Cicchi, F. C. Cordero, Chem. Rev., 2008, 108, 3988; c) R. Pal, S. C. 
Ghosh, K. Chandra, A. Basak, Synlett, 2007, 2321; for an example of drug candidate with lactone, 




Scheme 81. Synthesis of a-fluoro-b-lactam and lactone; X-ray crystal structure of I-148.  
The amine Boc protecting group in alcohol (II-5.15) was easily cleaved by TFA (10% in 
CH2Cl2). Common bases were tried to initiate lactamization, such as n-BuLi or LDA, both at -
78 
o
C; however no desired product was obtained - the reactions were messy in both cases, 
with no major spot observed by TLC. Eventually, the resulting free amine was cyclised to -
lactam with the use of strong, non-nuclophilic base - freshly prepared iso-propyl-magnesium 
chloride (deprotonation of amino- moiety with its subsequent attack on the ester). The single 
crystal of the chiral -fluoro--lactam was than analyzed by X-ray crystallography and the 
structure was unambiguously resolved. The result allowed for the assessment of configuration 
of all Mannich adducts (I-166a-v), alcohol (II-5.15) and lactone (I-169). The enantiopure -
fluoro--lactam can be screened for bioactivities, used as chiral building block via the lactam-
opening methodologies or coupled with bioactive component to alter its properties, e.g. via 
ester or ether bond formed with the hydroxy moiety available on lactam‟s -position. 
In parallel to the preparation of lactam, efforts were also put to prepare lactone, as such motif 
is common in drug candidates.
164d
 Ester (II-5.15) prepared as described above, was subjected 
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to hydrolysis by sodium hydroxide at room temperature, over 2.5 hours. The solvent mixture 
THF/MeOH/water (1/0.5/1) was developed to compensate for the somewhat poor solubility of 
the ester in MeOH/water, while reaction in THF/water was sluggish. The isolated 
hydroxyacid (II-5.17) was subsequently intramolecularly esterified by DCC and DMAP in 
CH2Cl2, at room temperature, over 6 h, yielding enantio-pure -fluro--lactone (I-149), 
which is an interesting synthon that could be screened for bioactivities itself, or incorporated 
into macromolecular structure e.g. via the amino group handle installed in -position.  
Summary 
In conclusion, the Mannich addition of -fluoro--ketoesters to N-Boc imines catalyzed by 
accessible tryptophan-derived organocatalysts was proven to be a short and effective route 
towards diverse -fluoro--amino acids, -fluoro--lactams and lactones. The fluorinated 
synthons prepared in such a way, possess tuneable substituents, as well as functional group 
(OH or NHBoc) in -position for further functionalization or usage as a linker with 
macromolecules. 
II.5.3. Decarboxylation/asymmetric protonation of Mannich 
malonate addition product 
 
The development of enantioselective Mannich addition to imines, as describe in the previous 
section, provided an efficient route to -fluoro--amino acids with a branched carbon chain. 
Construction of such molecules containing two tertiary stereocenters adjacent to a quaternary 
is a considerable challenge; however one may expect the effect of fluorination on the 
functional groups (pKa, pKb) diminished by electron donation from the aromatic and aliphatic 
hydrocarbon substituents. Moreover, the steric hindrance imparted by the substituents may 
affect negatively synthetic applications of such synthons. Therefore we were interested in 
devising methodology for the preparation of linear fluorinated amino acids precursors, with 
little steric hindrance and maximized effect of fluorine on neighbouring groups. Such 
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molecules would be close fluorinated -amino-analogs of natural amino acids and precursors 
of simple -lactams and could arise from Mannich addition of fluoromalonate to imines, 
followed by mono-decarboxylation (Scheme 82). 
 
Scheme 82. Hypothetical route towards fluorinated analogs of proteinogenic amino acids and lactams.  
  It was expected that the methodology developed in the previous chapter would be general 
and applicable not only to ketoesters but malonates as well. The second step however, 
decarboxylation/asymmetric protonation, seemed rather challenging. This section will 
describe our efforts to tackle the transformation. 
Introduction 
 
Asymmetric decarboxylation/protonation is a challenging transformation, and consequently 
the reports on the reaction are scarce, with metal-assisted processes more explored than those 
conducted under metal-free conditions. One of the best catalytic decarboxylation/asymmetric 
protonation was achieved by Stoltz and co-workers (Scheme 83).
165
 The reaction is believed 
to proceed via the enolate intermediate - product of -ketoester decarboxylation, stabilized by 
palladium-oxazoline complex; subsequent protonation by formic acid leads to formation of 
the corresponding products with good to excellent yields and enantioselectivities. Notably, -
ketoesters undergo decarboxylation very easily; additionally, only cyclic ketoesters were used 
as substrates (rigid, easier to control stereoselectivity as compared to acyclic ketoesters). 
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Scheme 83. Palladium-assisted decarboxylation/asymmetric protonation by Stoltz. 
The best result based on the use of organocatalysts in the decarboxylation/protonation of 
malonate was achieved in Rouden‟s group 166a (Scheme 84): up to 93% ee was achieved using 
stoichiometric amount of base over seven days, or 69% ee using 20 mol% of the base (in 
slightly less than two weeks of reaction time). It is also worth noticing, that most reports 
concern decarboxylation/protonation of α-amino malonates,166 which may imply participation 
of the α-amino- group in the process, perhaps in stabilizing intermediate species. Up to date, 
there are no examples of the asymmetric decarboxylation/protonation of simple or α-
fluorinated malonates. 
 
Scheme 84. Asymmetric decarboxylation/protonation promoted by Cinchona alkaloid-derived base. 
Research results 
The previously developed protocol for asymmetric Mannich addition of -fluoro--ketoesters 
to N-Boc imines was found applicable to malonates as well. The addition of 
diethylfluoromalonate to model N-Boc imine (I-164a, Scheme 85) proceeded smoothly and 
the corresponding product (I-171a) was obtained with very good yield and enantioselectivity 
(98% & 93% ee), which prompted us to pursue this reaction more thoroughly. Unfortunately, 
                                                          
166  a) M. Amere, M.-C. Lasne, J. Rouden, Org. Lett., 2007, 9, 2621; b) H. Brunner, M. A. Baur, Eur. 
J. Org. Chem., 2003, 2854; c) L. M.-A. Rogers, J. Rouden, L. Lecomte, M.-C. Lasne, Tetrahedron 
Letters, 2003, 44, 3047; d) T. Seitz et al., Tetrahedron, 2006, 62, 6155. 
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during the course of our research, another group has reported the same transformation.
167
 
Nevertheless, our main goal - decarboxylation/asymmetric protonation remained 
unchallenged.  
We envisioned that if we succeed in the subsequent decarboxylation/asymmetric protonation 
of the product (I-171a), a simple and practical strategy towards unbranched and general α-
fluoro-β-amino acids (II-5.24) and α-fluoro-β-lactams (II-5-25) from inexpensive, 
commercially available diethyl fluoromalonate could be achieved. 
 
Scheme 85. Asymmetric Mannich and tandem decarboxylation/protonation reactions. 
  
We hypothesized that the key to control the stereo-selectivity of the process is to engage the 
enolate (II, Scheme 86) in hydrogen bonding and ionic interactions (and any other weak to 
medium interactions) with chiral catalyst (III), which is also a donor of the proton, to form 
chiral complex. Eventually, the proton transfer would occur within the complex - from 
quaternary amine (catalyst) to enolate – in a stereo-controlled way due to the chiral 
environment. 
 
Scheme 86. Hypothesized mechanism of decarboxylation/protonation. 
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  J. H. Lee, D. Y. Kim, Synthesis, 2010, 11, 1860. 
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Optimization of the decarboxylation/asymmetric protonation 
To validate the hypothesis,  conditions for mono-hydrolysis of the model Mannich addition 
product  (I-171a, Scheme 87) were developed and the immediate substrate for 
decarboxylation/protonation (II-5.26) was eventually obtained in very high yield, under 
simple conditions, as the only diastereomer (column purification).  
 
Scheme 87. Monohydrolysis of Mannich fluoromalonate adduct. 
With the substrate in hand, we then focused on the decarboxylation. After initial trials, it 
became obvious that the monoacid (II-5.26) is quite stable and does not undergo 
decarboxylation easily. Therefore, it was necessary to find the mildest possible conditions to 
carry out the decarboxylation before moving to catalyst screening. The major challenge was 
to find the balance between the need to increase the low reactivity of the substrate, and the 
threat of racemization of the chiral centre generated during the preceding Mannich addition, 
or even its decomposition through retro-Mannich mechanism. The landmark points of the 
optimization are summarized in Table 8. The halfester II-5.26 did not undergo 
decarboxylation under the action of triethylamine (1.5 equiv.) at room temperature, even 
when polar DMF was used as solvent (entry 1, CH3CN, acetone, and non-polar solvents did 
not result in any conversion as well; DMSO could also be used with the same result as DMF). 
However, at elevated temperature, 80% conversion to the desired product was observed (entry 
2). To our satisfaction, the same result could be obtained when 0.2 equivalents of simple 
Quinidine-derived thiourea catalyst (I-194b) was used (entry 3). We then tried to lower the 
reaction temperature, which resulted in 80% conversion but over an extended reaction time of 
a week. When the chiral halfester (II-5.26) was subjected to the reaction conditions, the 
desired product (II-5.18) was obtained with 1:1.6 dr and 30% ee (entry 4). 
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1 TEA (1.5) DMF rt 20 n.r. - - 
2 TEA (1.5) DMF 65-75 20 80 - - 
3 I-194b (0.2) DMF 55-60 24 80 1.4:1 - 
4
d 
I-194b (0.2) DMSO 40-50 7d 80 1.6:1 30 
5
d 
I-194b (0.2) DMSO 40-45 72 69 1:2.3 93 
6 I-194b (0.1) DCM rt 22 - - - 
7
d 
I-194b (0.1) Acetone 70 20 40 n.d. n.d. 
8
d 
I-194b (0.2) THF 70 72 70 1.5:1 53 
9 I-194b (0.2) DMSO 40-45 72 68 1:1 31 
a
 Reaction conditions: II-5.26 (0.05 mmol), the base in the solvent (1ml). 
b
 Determined by 
1
H NMR 
analysis of the crude reaction mixture; 
c 
Determined by HPLC analysis on a chiral stationary phase of 
purified product; 
d
 Chiral substrate was used. 
Evidently, some asymmetric protonation was achieved (dr value), however the low 30% ee 
value meant racemization of the stereogenic centre created during the preceding Mannich 
addition. Fortunately, we found that racemization can be avoided if the reaction time was 
shortened to 3 days, at the expense of reaction yield, assessed now as 69% (entry 5), with a 
higher dr value of 1:2.3. Lastly, several solvents were screened, but it was found that elevated 
temperature was necessary (entries 6-8). The reaction in the only other solvent found suitable 
- THF - required 70 
o
C to reach 70% conversion and the product was obtained with a lower dr 
value of 1.5:1 with partial racemization of the pre-installed asymmetric center (to 53% ee, 
entry 8). Therefore, we concluded that the optimum (preliminary) reaction conditions were as 
follows: DMSO, 40-45 
o
C, 0.2 equiv. of the catalyst, 72 h. To determine whether the 
protonation is an enantioselective (controlled by catalyst) or diastereoselective process 
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(controlled by the neighbouring, pre-installed in Mannich addition centre of asymmetry) the 
decarboxylation was performed using racemic halfester II-5.26 (entry 9). The corresponding 
product was obtained with no dr (therefore no retro-Mannich reaction occurred) and with 31% 
ee on the newly generated asymmetric centre. This result proves that the protonation is 
controlled by catalyst; in fact the observed dr of 2.3:1 in reaction with chiral substrate 
corresponds well to 31% ee obtained in reaction with racemic halfester (31% ee is close to 2:1 
ratio of enantiomers), which further proves that the influence of neighbouring chiral centre on 
protonation is not significant.    
Catalyst screening in the decarboxylation/asymmetric protonation 
With the preliminary conditions established, the organocatalysts were then screened using 
chiral substrate II-5.26 (Table 9). The tryptophan-derived catalyst (Trp1) used for Mannich 
addition, displayed similar reactivity to the benchmark Quinidine-derived thiourea catalyst (I-
194b), however the product was obtained as 1:1 mixture of diastereomers (entries 1 and 2). 
Next, the usually much more diastereoselective, Quinine-amino acid incorporating catalysts 
were trialed. All four catalysts were found more active, since the full conversion was 
achieved after 30 hours instead of 3 days; however, the best in the series - (L)-valine featuring 
catalyst QLV, led to formation of the desired product with only 2:1 dr ratio; and 
diastereoselectivity was found to drop with the increase of the molecular volume of amino 
acid side chain (entries 3 5). Alternative catalysts II-5.27 and II-5.27 - devoid of 
quinuclidine tert-amine were than tested. Unfortunately, in both cases, drop in the 
enantioselectivity of the centre generated in Mannich addition (C-4) was observed (65% ee 
and 54% ee, entries 6 and 7). Next, Cinchona alkaloid-derived catalysts with additional 
functional groups were screened. It was found that Quinine-derived catalyst with de-
methylated phenolic moiety was not only highly effective (reaction complete within 24 h) but 
also the most stereo-selective, with 2.6:1 dr ratio and untouched C-4 centre (93% ee, entry 7). 
Therefore, a series of catalysts with similar motif was than evaluated; 
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1 I-194b 72 69 93 2.3:1 
2 Trp1 72 65 93 1:1 
3
d 
QLV 30 >99 92 2:1 (1:1.7)
d 
4 QtL 30 >99 93 1.5:1 
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5 QLTd 30 >99 92 1.3:1 
6 II-5.27 72 >99 65 1.4:1 
7 II-5.28 72 >99 54 1.6:1 
8 QOHBn 24 >99 93 2.6:1 
9 QOHNH 22 >99 91 1.7:1 
10 βICD 22 >99 92 2:1 
11 II-5.29 72 >99 28 2:1 
12 II-5.30 72 >99 57 2:1 
13 II-5.31 72 >99 59 1.7:1 
14 QNH 30 >99 91 2.2:1 
15 QNH & (+)CSA 69 >99 90 2:1 
16 II-5.32 51 >99 91 1.9:1 
17 II-5.33 67 >99 91 1.6:1 
18 II-5.34 n.d. <10 n.d. n.d. 
a
 Reaction conditions: II-5.26 (0.05 mmol), the base in the solvent (1ml). 
b
 Determined 
by 1H NMR analysis of the crude reaction mixture; 
c 
Determined by HPLC analysis on a 
chiral stationary phase of purified product; 
d
 Reaction with catalyst incorporating (D)-
valine instead of (L)-valine. 
Quinine-derived, phenol-containing catalyst QOHNH with additional primary amine was 
equally effective, but the dr ratio was lower (1.7:1, entry 8); similar result was also obtained 
with β-iso-Cupreine (βICD, entry 9). Subsequently, it was decided to explore the other 
hydroxyl-containing catalysts in the reaction (II-5.2931, entries 1012). Unfortunately, a 
decrease in ee value at C-4 asymmetric centre was observed in all three cases, with catalyst 
II-5.29 containing benzylic hydroxyl group and flexible chain causing the most damage (only 
28% ee detected, entry 11). Attention was then turned back to primary amine-containing 
catalysts in an effort to improve the previous result with phenolic and primary amine 
containing catalyst QOHNH. The primary Quinine-derived amine, with methylated phenolic 
moiety QNH, was as effective as QOHNH with diastereoselectivity improved to 2.2:1 (entry 
14). Furthermore, addition of 1 equiv. of + CSA resulted in a slight decrease in reaction rate 
and diastereoselectivity (2:1 dr). Based on these results, it was reasoned that primary amine 
moiety may be as beneficial as phenolic OH, and subsequently two more primary amine-
126 
 
containing catalysts were prepared and tested. Catalyst II-5.32 displayed lower reactivity than 
QNH (reaction time extended to 51 h) and similar diastereoselectivity (1.9:1). The second 
catalyst - II-5.33 - with an additional phenolic OH installed on the phenyl ring, was found to 
be even less reactive (67 h) and diastereoselective (1.6:1). Lastly, the general (R)-Binol-
derived phosphoric acid was found ineffective in the reaction, yielding hardly any conversion 
of the malonate halfester.  
The results obtained indicate that decarboxylation followed by enantioselective protonation 
took place, however despite extensive catalyst screening, we were unable to achieve practical 
levels of stereocontrol. Further understanding of the process and the relationship between 
catalyst and hypothetical enolate are necessary to envision suitable catalysts. Additionally, 
computational methods to approximate the protonation step and interactions between the 
catalyst and the enolate could aid catalyst design. Lastly, the use of external proton sources 
for the protonation step should also be considered in subsequent screenings. 
II.5.4. Conclusion 
The enantioselective Mannich addition to N-Boc imines led to preparation of diverse products 
with excellent optical purity. The model adduct was than transformed efficiently into -
fluoro--amino acid in 2 simple steps, -fluoro--lactam and -fluoro--lactone, both in 3 
steps. The synthons prepared via this methodology possess two substituents easily tuneable by 
means of varying ketoesters and imines in the Mannich reaction. Furthermore, additional 
functional group present in the -position of products (OH or NHBoc) is available for further 
modifications or may serve as a point of connection of the synthon to macromolecule. 
The methodology for highly enantioselective Mannich addition was applicable to fluorinated 
malonate and the addition product to model N-Boc imine was obtained in 98% yield and with 
93% ee.  Subsequent tandem mono-decarboxylation/asymmetric protonation of the adducts 
was envisioned as an effective route towards unbranched -fluoro--amino acids and was 
investigated. A large pool of organocatalysts was tested and found suitable for the 
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transformation and the enantioselective protonation was achieved with up to 2.6:1 
diastereoselectivity ratio (or 31% ee). Further understanding of the reaction mechanism 






























Understanding the importance of fluorination as a tool for modifying the properties of 
bioactive molecules, studies in this thesis detail the efforts put toward the design and 
development of effective routes toward chiral selectively fluorinated compounds, focusing on 
nitrogen-containing species. Several new fluorinated donors were prepared and employed in 
Michael additions to representative acceptors - nitroalkenes.  
Synthesis of compounds containing -fluoro--amino core was achieved employing -
fluoro--nitro-containing prochiral donors. -Fluoro--amino esters (II-1.12, Figure 34), -
fluoroesters (II-1.14) and precursors of -fluoro-,-diamines (II-1.13) were accessed via 
ethyl fluoronitroacetate (Chapter II-1). A practical route towards -fluoro- mono- and 
diamines (II-2.4&6), as well as fluorinated heterocycles (tetrahydropyrimidines, II-1.5) was 
demonstrated with the use of 1-fluoro-1-nitro-1-arylmethanes (Chapter II-2).  
Preparation of -fluoro--amino-containing molecules was successfully carried out 
employing 2-fluoro-1,3-dicarbonyl prochiral donors. -Fluoro--amino acid (II-5.17), -
lactam and lactone (I-168&169) were prepared through functional group manipulations 
performed on representative Mannich addition product (II-5.15, Chapter II-5). Analogical 
enantioselective Mannich additions of fluorinated malonate led to -fluoro--amino malonate 
halfester (II-5.26) and the subsequent mono-decarboxylation/asymmetric protonation 
afforded linear -fluoro--amino ester (II-5.18a). The latter challenging transformation was 
proven possible, however more work is necessary to increase stereoselectivity. The 
investigation also led to establishing a direct route toward the linear -fluoro--amino esters 




 The work above demonstrates a general methodology for Michael additions, applicable to 
other fluorinated acceptors as well. Addition of 2-fluoro-1,3-diketones was demonstrated as a 
method for the rapid generation of fluoro-isosteres of glycerines containing multiple 
asymmetric centers (II-4.16a&b, Chapter II-4); however more work is necessary to elucidate 
the absolute configuration of the products. Addressing the scarcity of methodologies for the 
preparation of fluorinated phosphorus-containing species, prochiral -fluoro--
ketophosphonates were synthesized and employed in Michael additions yielding branched 
and functionalized fluorinated phosphonates and pyrrolidines (II-3.2, II-3.10 & II-3.3 
Chapter II-3).  
Overall, the research presented in this thesis contributed several practical methodologies for 
the synthesis of precursors of fluorinated bioactive molecules via enantioselective Michael 
and Mannich additions, as well as decarboxylations. The uncommon -fluoro--amino-
containing species prepared for the first time (amino acid, amines and tetrahydropyrimidines), 
as well as novel fluorinated phosphonates and -fluoro--amino-containing molecules (esters, 









III-2. Preliminary results and future perspective:  decarboxylative 




Generation of nucleophilic enolate by decarboxylation (especially malonate half-thioesters 
MAHT) is a process common in biological systems,
168
 less so in a synthetic laboratory.
169
 
Successful methodologies concern mainly decarboxylative additions of reactive acids such as 
malonate half-thioesters (III-2.1, Scheme 88),
170
 -cyanoacids (III-2.3)171 or -ketoacids.172 
However, no such reactions have been reported for malonic acid halfesters, probably due to 
low reactivity.  
 
Scheme 88. Decarboxylative additions of halfesters. 
We envisioned that fluorine substituent in the  position on malonic acid halfester would 
polarize the molecule and stabilize the resulting enolate, and as such, activate fluoromalonate 
halfester towards decarboxylation. Subsequent addition of the stabilized enolate to 
electrophiles would yield products of the formal addition of -fluoroacetic acid ester synthon; 
utilizing nitroalkenes as Michael acceptor would yield products being direct precursors of -
                                                          
168
 a) A. Hill, Nat. Prod. Rep., 2006, 23, 256; b) M. B. Austin, M. Izumikawa, M. E. Bowman, D. W. 
Udwary, J. L. Ferrer, B. S. Moore, J. P. Noel, J. Biol. Chem., 2004, 279, 45162. 
169
  For a recent review see: Z.-L. Wang, Adv. Synth. Catal., 2013, 355, 2745. 
170
 See for example: H. Y. Bae, S. Some, J. H. Lee, J. Y. Kim, M. J. Song, S. Lee, Y. J. Zhang, C. E. 
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fluoro--amino acids and lactams (Scheme 89) - biologically important molecules (analogues 
of GABA
173
) and synthons for further synthesis. 
 
Scheme 89. Hypothetical route towards -fluoro--amino acids and -fluoro--lactams. 
Preliminary results and future perspectives 
 
Investigations on the possible mechanisms of the decarboxylation of Mannich adduct (see 
chapter 5) led us to the analogical hypothetical mechanism of decarboxylative addition of 
fluoromalonate halfesters to nitroalkenes (Scheme 90). We speculated that bifunctional 
catalyst (IIIb) would hold the two reaction partners in proximity – enolate (IIIa) via 
electrostatic interactions and nitroolefin (I-189) by the means of hydrogen-bonding of the 
nitro moiety to thiourea - a well proven interaction, while the chiral environment originating 
from chiral catalyst scaffold would enforce stereo-selectivity of the addition. 
 
Scheme 90. Decarboxylative addition of malonate hemiester to nitroolefins. 
                                                          
173
 GABA - -aminobutyric acid - one of the most important neurotransmitters in mammalian central 
nervous system; compound frequently targeted in biochemical and pharmaceutical research. 
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Successful development of this methodology would be of great significance, as such simple 
general one step synthetic process from accessible fluorinated malonate hemiester and 
nitroolefins, yielding chiral fluorinated GABA analogues has not been reported to date. 
Ethyl fluoromalonate halfester was found to be easily accessible via monohydrolysis of 
commercially available diethyl fluoromalonate after optimizing the reaction conditions 
(Scheme 91).  
 
Scheme 91. Monohydrolysis of diethyl fluoromalonate. 
With the substrate in hand, we began to screen the reaction. It was found that the monoacid 
was quite stable and did not undergo decarboxylation easily under catalytic conditions; 
however 70% yield of the product was obtained at room temperature after 20 h when an 
excess of triethylamine (TEA) was used (entries 1 and 2, Table 10). Fortunately, in the 
absence of base, almost no reaction took place even at elevated temperature, therefore stereo-
selective process would not be compromised by background racemic reaction at temperatures 
as high as 70 
o
C (entry 3). We then began searching for the mildest conditions in terms of 
temperature and catalyst loading in which the reaction would proceed with acceptable yield. It 
was found that a combination of 1 equiv. of TEA and 0.2 equiv. of chiral base I-194b, led to 
50% conversion after 3 days at room temperature (entry 4). At elevated temperature, the 
reaction was found to proceed with catalytic amount of catalyst (entries 5-9); acceptable 
conversions can be achieved at 55 - 60 
o
C over 24 h (54%) or at 40 - 45 
o
C over 7 days (65%). 
In all cases, the observed diastereoselectivity was 1:1, while measurement of 




Table 10. Decarboxylative addition of nitroolefin to fluoromalonate hemiester.
a,b 
 
Entry Base (equiv.) Temp [
o





1 TEA (1.5) rt 20h 70% 1:1 





22h <10% n.d. 
3 I-194b (0.2) + TEA (1) rt 72h 50% 1:1 




20h 55% 1:1 




22h 44% 1:1 




24h 54% … 




7d 65% 1:1 
a
 Reaction conditions: III-2.6 (0.05 mmol), nitroalkene (0.06 mmol), the base in the solvent (1ml). 
b





 Determined by 
1
H NMR analysis of the crude reaction mixture. 
Upon finding the conditions to measure the ee value, more catalysts will be screened for this 
transformation. Furthermore, the methodology is general and other acceptors can be 
employed, such as vinyl sulphones (Scheme 92).  
 
Scheme 92. Decarboxylative addition of fluoromalonate hemiester to vinyl sulphone. 
Such reaction would lead to general and linear -fluoro-esters - a class of important yet 
under-investigated compounds in three steps, which would otherwise be difficult to 
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All the starting materials were obtained from commercial sources and used without further 
purification unless otherwise stated. Solvent purification system was used to dry and purify 
toluene, CH2Cl2 and diethyl ether while THF was dried and distilled from sodium 












spectrometer. Chemical shifts were reported in parts per million (ppm), and the residual 
solvent peak was used as an internal reference: proton (chloroform δ 7.26), carbon 
(chloroform δ 77.0), fluorine CFCl3 (AMX400) or TFA (ACF300). Multiplicity was indicated 
as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of 
doublets), bs (broad singlet). Coupling constants were reported in Hertz (Hz). Low resolution 
mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI mode, and a 
Finnigan/MAT 95XL- T mass spectrometer in FAB mode. All high resolution mass spectra 
were obtained on a Finnigan/MAT 95XL- T spectrometer. For thin layer chromatography 
(TLC), Merck pre- coated TLC plates (Merck 60 F254) were used, and compounds were 
visualized with a UV light at 254 nm. Further visualization was achieved by staining with 
KMnO4 aqueous solution or ninhydrine solution in ethanol, followed by heating with a heat 
gun. Flash chromatographic separations were performed on Merck 60 (0.040- 0.063 mm) 
mesh silica gel. The enantiomeric excesses of products were determined by chiral-phase 
HPLC analysis. Optical rotations were recorded on Jasco DIP-1000 Digital Polarimeter with 
10 mm cell and 589 nm sodium lamp.  
All the catalysts used in screenings were prepared according to known procedures (see the 
general Scheme 93) and their data identical with reported data. 2-fluoro-1,3-diketones were 
prepared according to known procedures (scheme shown in chapter II-4) and their NMR 
characteristics were identical with reported data.
174
 Nitroalkenes were prepared according to 
published procedures from corresponding aldehydes and nitromethane. 
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IV-1. Towards the enantioselective synthesis of functionalized -
fluoro--amino acids: organocatalytic Michael addition / 
hydrogenation of ethyl fluoro -nitroacetate 
IV-1.1. Preparation of Substrates 
Nitroalkenes were prepared from respective aldehydes and nitromethane according to 
reported procedures. Ethyl fluoronitroacetate was prepared from commercially available ethyl 
nitroacetate. As the compound is unstable and decomposes over several hours it was freshly 
prepared before each batch of reactions. It can be stored for a week at -78 
o
C, however the 
trace impurities generated over that time would affect negatively the enantioselectivities of 
Michael addition products.  
 
To a dried round bottom flask (heated under vacuum with heat gun) filled with argon was 
added freshly distilled THF (10 ml) and ethyl nitroacetate (2mmol, 266 mg). The flask was 
placed into cooling bath and 15 minutes later; NaH (60% dispersion in oil, 80 mg) was added 
in one portion, under the protection of argon. The reaction mixture was then stirred overnight 
at room temperature. After 12-16 h, TLC analysis or crude NMR indicated 40% - 50% 
conversion of ethyl nitroacetate into ethyl fluoronitroacetate. The reaction mixture was 
diluted with ethyl acetate (50 ml) and washed 3 times with 1M aqueous solution of HCl, 
followed by brine (1x). After drying over sodium sulphate, organic layer was evaporated and 
the crude product subjected to purification by column chromatography on silica get column 
eluting with Hexane/diethyl ether = 7/1. The product was obtained as a lively, pale yellow oil 
- 109 mg, 36% yield.
176
 The analytical data was identical with previously reported data for 
that compound. 
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 The quality of ethyl fluoronitroacetate affects severely the enantioselectivities obtained in the 
Michael reaction. Impurities are difficult to spot on 
1
H NMR spectrum due to overlapping peaks with 
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Ethyl fluoronitroacetate (II-1.5a) 
1H NMR (400 MHz, CDCl3): (d, J = 48.6 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.0 
Hz, 3H). 
iso-Propyl fluoronitroacetate (II-1.5b) 
1H NMR (400 MHz, CDCl3): d, J = 48.8 Hz, 1H), 5.21 (m, 1H), 1.36 (d, J = 6.3 Hz, 6H); 
13C NMR (100.62 MHz, CDCl3): 158.56 (d, J = 24.9 Hz), 102.91 (d, J = 250.1), 73.43, 21.33, 
21.29; 19F NMR (376.46 MHz, CDCl3): -150.00 (d, J = 48.9 Hz). 
 
IV-1.2. Experimental procedure and the analytical data of the Michael reaction 
products  
Michael addition of ethyl fluoronitroacetate to nitroalkenes - representative procedure:  
To a sample vial containing the fluoronitroacetate (0.1 mmol, 15 mg) in toluene (1 ml), II-
1.11b (0.01 mmol, 10 mg) was added. The vial was then capped and the reaction mixture was 
stirred for 5 minutes at 0 
o
C. Subsequently nitroalkene (0.11 mmol) was added at 0 
o
C under 
nitrogen protection, the vial was sealed and the reaction mixture was stirred at that 
temperature for one hour. Upon completion of the reaction, the mixture was passed through a 
short silica gel column to remove the catalyst (possible recovery of the catalyst), evaporated 
and analyzed by 
1
H NMR. Lastly, the crude product was subjected to column 
chromatographic separation eluting with hexane/ethyl acetate (20 : 1  10 : 1) to afford the 




                                                                                                                                                                      
the desired product but manifest themselves by colouring the ethyl fluoronitroacetate to a more intense 
yellow to orange. 
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Ethyl (2S,3S)-2-fluoro-2,4-dinitro-3-phenylbutanoate (II-1.10a) 
*α+270D = +56.1 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.34m, 3H), 7.29 
(m, 2H), 5.07(dd, J = 13.2 Hz, 4.4 Hz, 1H), 4.96 – 4.82 (m, 3H), 4.42 (m, 2H), 1.37(t, J = 7.2 
Hz, 3H); 13C NMR (100.62 Hz, CDCl3) 160.28, 160.01, 129.86, 129.34, 129.10, 113.03 (d, J = 
257.5 Hz), 74.57, 65.28, 47.09 (d, J = 18.1 Hz), 13.63; 19F NMR (376.46 Hz, CDCl3) -32.88 
(d, J = 28.5 Hz); HRMS (ESI) m/z calcd for C12H12FN2O6 [M-H]
+ = 299.0685, found = 299.0681; 
the ee value was 97%, tR (major) = 17.5 min, tR (minor) = 20.2 min (Chiralcel IB, λ = 254 nm, 
10% iPrOH/hexanes, flow rate = 1 mL/min). 
Isopropyl 3-(3-bromophenyl)-2-fluoro-2,4-dinitrobutanoate (II-1.10b) 
*α+270D = +56.7 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.51m, 1H), 7.46 
(s, 1H), 7.23 (d, J = 4.8 Hz, 2H), 5.22 (m, 1H), 5.06 (dd, J = 13.6 Hz, 5.2 Hz, 1H), 4.91 – 4.78 (m, 
2H), 1.35 (d, J = 6.4 Hz, 3H), 1.33 (d, J – 6.4 Hz, 3H); 13C NMR (100.62 Hz, CDCl3)  159.52, 
159.26, 133.14, 132.15, 130.81, 127.79, 123.28, 112.79 (d, J = 257.99 Hz), 74.65, 74.33, 
46.63 (d, J = 18.1 Hz), 21.24, 21.05; 19F NMR (376.46 Hz, CDCl3) 32.50 (d, J = 27.85 Hz); 
HRMS (ESI) m/z calcd for C13H14FN2O6 [M-H]
- = 313.0857, found = 313.0853; the ee value was 
86%, tR (major) = 15.0 min, tR (minor) = 9.2 min (Chiralcel IB, λ = 254 nm, 10% 







Ethyl 2-fluoro-3-(naphthalen-2-yl)-2,4-dinitrobutanoate (II-1.10c) 
*α+270D = +52.1 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 85 – 7.77m, 
4H), 7.52 (m, 2H), 7.38 (d, J = 8.4 Hz, 1H), 5.18 – 4.94 (m, 3H), 4.63 – 4.41 (m, 2H), 1.38 (t, J = 
7.2 Hz, 3H); 13C NMR (75.47 Hz, CDCl3)  160.17 (d, J = 26.4 Hz), 133.53, 133.03, 129.44, 
129.39, 128.18, 127.69, 127.27, 127.21, 126.87, 125.37, 113.06 (d, J = 267.7 Hz), 74.62 (d, J = 
3.5 Hz), 65.33, 47.22 (d, J = 18.3 Hz), 13.64; 19F NMR (376.46 Hz, CFCl3) -132.44 (d, J = 27.8 
Hz); HRMS (ESI) m/z calcd for C16H14FN2O6 [M-H]
- = 349.0837, found = 349.0841; the ee value 
was 82%, tR (major) = 18.1 min, tR (minor) = 14.2 min (Chiralcel IA, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 1 mL/min). 
Ethyl 2-fluoro-2,4-dinitro-3-(4-(trifluoromethyl)phenyl)butanoate (II-1.10d) 
*α+270D = +54.4 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.63d, J = 8.0 
Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.24 (dd, J = 5.2 Hz, 0.80 Hz, 2H), 5.11 (dd, J = 13.6 Hz, 4.0 Hz, 
1H), 5.98 (ddd, J = 28.0 Hz, 10.0 Hz 4.4 Hz, 1H), 4.84 (dd, J = 12.0 Hz, 9.2 Hz, 1H), 4.43 (m, 
2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (100.62 Hz, CDCl3)  159.70, 133.97, 131.99, 129.72, 
126.36, 124.82, 122.11, 112.62 (d, J = 258.14 Hz), 74.17, 65.57, 46.76 (d, J = 17.8 Hz), 13.61; 
19F NMR (376.46 Hz, CDCl3) 32.62 (d, J = 27.8 Hz); HRMS (ESI) m/z calcd for 
C13H11F4N2O6 [M]
- = 367.0559, found = 367.0541; the ee value was 96%, tR (major) = 12.9 






Ethyl 2-fluoro-2,4-dinitro-3-(p-tolyl)butanoate (II-1.10e) 
*α+270D = +75.1 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.16m, 4H), 5.07 
– 5.02 (m, 1H), 4.92 – 4.79 (m, 2H), 4.42 (m, 2H), 2.32 (s, 3H), 1.36 (t, J = 7.2 Hz, 3H); 13C NMR 
(100.62 Hz, CDCl3)  160.07, 139.91, 130.03, 128.94, 128.92, 126.74, 113.12 (d, J = 257.03 
Hz), 74.62, 65.22, 46.81 (d, J = 17.7 Hz), 21.12, 13.63; 19F NMR (376.46 Hz, CDCl3) 33.01 
(d, J = 28.6 Hz); HRMS (ESI) m/z calcd for C13H15FNaN2O6 [M+Na]
+ = 337.0806, found = 
337.0812; the ee value was 82%, tR (major) = 21.5 min, tR (minor) = 22.8 min (Chiralcel IB, λ 
= 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
Ethyl 3-(3-bromophenyl)-2-fluoro-2,4-dinitrobutanoate (II-1.10f) 
*α+270D = +49.0 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.51m, 1H), 
7.47 (s, 1H), 7.24 (dd, J = 5.2 Hz, 0.80 Hz, 2H), 5.22 (m, 1H), 5.06 (dd, J = 13.6 Hz, 4.0 Hz, 1H), 
4.92 – 4.77 (m, 2H), 4.42 (m, 2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (100.62 Hz, CDCl3)  
160.03, 133.18, 132.14, 130.83, 127.80, 127.78, 123.30, 112.67 (d, J = 257.84 Hz), 74.26, 
65.48, 74.33, 46.65 (d, J = 18.2 Hz), 13.63; 19F NMR (376.46 Hz, CDCl3) 32.61 (d, J = 27.8 
Hz); HRMS (ESI) m/z calcd for C12H11BrFN2O6 [M]
- = 376.9690, found = 376.9787; the ee value 
was >99%, tR (major) = 17.8 min, tR (minor) = 15.5 min (Chiralcel IB, λ = 254 nm, 10% 






Ethyl 2-fluoro-3-(2-fluorophenyl)-2,4-dinitrobutanoate (II-1.10g) 
major diastereomer 
*α+270D = +3.8 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 9 – 7.30m, 2H), 7.18 – 7.08 (m, 
2H), 5.34 – 5.31 (m, 1H), 5.25 (dd, J = 8.0 Hz, 4.8 Hz, 1H), 5.11 (dd, J = 14.0 Hz, 4.8 Hz, 1H), 
4.41 (qd, J = 7.2 Hz, 2.0 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (125.77 Hz, CDCl3)  159.93 
(d, J = 26.8 Hz), 131.90, 130.17, 125.04, 117.59, 116.72, 116.55, 112.68 (d, J = 258.8 Hz), 
73.64 (d, J = 3.3 Hz), 65.38, 40.90 (d, J = 18.9 Hz), 13.62; 19F NMR (376.46 Hz, CDCl3) 
-131.42 (dd, J = 27.4 Hz, 15.8 Hz); HRMS (ESI) m/z calcd for C12H12F2NaN2O6 [M]
+= 
341.0561, found = 341.0565; the ee value was 63%, tR (major) = 17.1 min, tR (minor) = 34.3 
min (Chiralcel IB+IC, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
 
minor diastereomer 
1H NMR (400 MHz, CDCl3): 42 – 7.38m, 1H), 7.37 – 7.30 (m, 1H), 7.21 – 7.11 (m, 2H), 
5.39 – 5.30 (m, 1H), 4.93 (t, J = 8.4 Hz, 2H), 4.22 (q, J = 7.2 Hz, 1H), 1.19 (t, J = 7.2 Hz, 3H); 13C 
NMR (75.47 Hz, CDCl3)  159.10 (d, J = 27.2 Hz), 131.91, 129.52, 125.10, 117.53, 116.63, 
116.32, 112.56 (d, J = 257.2 Hz), 73.16 (d, J = 4.4 Hz), 64.99, 40.12 (d, J = 19.5 Hz), 13.42; 19F 
NMR (376.46 Hz, CDCl3) 130.52 (dd, J = 22.9 Hz, 11.3 Hz); HRMS (ESI) m/z calcd 
for C12H12F2NaN2O6 [M]
+= 341.0561, found = 341.0567; the ee value was 26%, tR (major) = 
18.8 min, tR (minor) = 30.8 min (Chiralcel IB+IC, λ = 254 nm, 10% iPrOH/hexanes, flow rate 




Ethyl 3-(3,4-dichlorophenyl)-2-fluoro-2,4-dinitrobutanoate (II-1.10h) 
 
major diastereomer 
*α+270D = +59.8 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.44 (d, J = 8.4 Hz, 1H), 7.40 (s, 1H), 
7.16 (d, J = 8.6 Hz, 1H), 5.06 (dd, J = 13.6 Hz, 4.0 Hz, 1H), 4.92 – 4.74 (m, 2H), 4.46 – 4.40 (m, 
2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (125.77 Hz, CDCl3)  159.70 (d, J = 26.5 Hz), 134.72, 
133.74, 131.36, 131.10, 129.97, 128.33, 112.48 (d, J = 257.9 Hz), 74.08 (d, J = 3.6 Hz), 65.60, 
46.20 (d, J = 18.1 Hz), 13.62; 19F NMR (376.46 Hz, CDCl3) -132.65 (d, J = 27.4 Hz); HRMS 
(ESI) m/z calcd for C12H10Cl2FN2O6 [M]
- = 366.9905, found = 366.9922; the ee value was 83%, 
tR (major) = 25.4 min, tR (minor) = 31.7 min (Chiralcel IB, λ = 254 nm, 20% iPrOH/hexanes, 
flow rate = 1 mL/min). 
 
minor diastereomer 
1H NMR (400 MHz, CDCl3): 7.47 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H), 4.95 
– 4.77 (m, 3H), 4.27 (qd, J = 7.2 Hz, 1.6 Hz, 2H), 1.20 (t, J = 7.2 Hz, 3H); 13C NMR (125.77 Hz, 
CDCl3)  158.81 (d, J = 26.3 Hz), 134.70, 134.74, 131.37, 130.03, 128.35, 112.82 (d, J = 254.8 
Hz), 73.59 (d, J = 5.3 Hz), 65.19, 46.27 (d, J = 18.4 Hz), 13.57; 19F NMR (376.46 Hz, CDCl3) -
131.95 (d, J = 24.0 Hz); HRMS (ESI) m/z calcd for C12H10Cl2FN2O6 [M]
- = 366.9905, found = 
366.9922; the ee value was 17%, tR (major) = 29.6 min, tR (minor) = 36.4 min (Chiralcel IB, λ 
= 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
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(2S,3S)-ethyl 3-(3,4-dimethoxyphenyl)-2-fluoro-2,4-dinitrobutanoate (II-1.10i) 
*α+270D = +37.4 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3) (diastereomeric 
mixture 2:1): 6.87 - 6.72 (m, 6H), 5.05 – 5.02 (m, 1H), 4.89 – 4.77 (m, 5H), 4,41 (m, 2H, 
major dr), 4.19 (q, J = 7.0 Hz, 2H, minor dr), 3.86 (m, 12H), 1.36 (t, J = 7.0 Hz, 3H, major dr), 
1.16 (t, J = 7.0 Hz, 3H, minor dr); 13C NMR (100.62 Hz, CDCl3)   159.97, 150.12 (d, J = 
3.6 Hz), 149.32 (d, J = 3.8 Hz),112.15 (d, J = 20.3 Hz), d, J = 19.6 Hz), 
111.45, 74.68 (d, J = 7.8 Hz), 74.24 (d, J = 8.6 Hz), 65.25, 64.75, 56.01, 55.82, 46.97 (d, J = 3.8 
Hz), 46.73 (d, J = 3.5 Hz), 29.69, 29.35, 14.11, 13.65; 19F NMR (376.46 Hz, CDCl3) -56.652 (d, 
J = 33.8 Hz), -57.01 (d, J = 39.1 Hz); HRMS (ESI) m/z calcd for C14H16FN2O8 [M]
- = 359.0891, 
found = 359.0894; the ee value was 85%, tR (major) = 32.9 min, tR (minor) = 36.4 min 
(Chiralcel IB, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1.2 mL/min). 
Ethyl 3-(3,5-difluorophenyl)-2-fluoro-2,4-dinitrobutanoate (II-1.10j) 
*α+270D = +54.8 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 6.87 – 6.83m, 
3H), 5.08 (dd, J = 14.0 Hz, 4.4 Hz, 1H), 4.87 (ddd, J = 27.6 Hz, 9.6 Hz, 6.4 Hz, 1H), 4.78 (dd, J = 
13.6 Hz, 10.0 Hz, 1H), 4.46 – 4.41 (m, 2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (75.47 Hz, CDCl3)  
164.75 (d, J = 12.8 Hz), 161.45 (d, J = 12.4 Hz), 159.71 (d, J = 26.3 Hz), 133.30, 112.77, 112.39, 
112.35 (d, J = 256.5 Hz), 74.05 (d, J = 3.6 Hz), 65.64, 46.52 (d, J = 17.6 Hz), 13.62; 19F NMR 
(376.46 Hz, CDCl3) tJ = 7.1 Hz), -132.68 (d, J = 27.4 Hz); HRMS (ESI) m/z calcd for 
C12H10F3N2O6 [M]
-= 335.0491, found = 335.0498; the ee value was 77%, tR (major) = 6.5 min, 




Ethyl 2-fluoro-3-(furan-2-yl)-2,4-dinitrobutanoate (II-1.10k) 
*α+270D = +36.9 (c 1, CHCl3);  
1H NMR (300 MHz, CDCl3) (diastereomeric 
mixture): 47.42 (m, 2H), 6.45 (dd, J = 3.3 Hz, 0.3 Hz, 1H), 6,41 – 6.36 (m, 3H), 517 – 
5.04 (m, 2H), 5.01 – 4.93 (m, 3H), 4.85 – 4.80 (m, 1H), 4.42 (q, J = 7.0 Hz, 2H, minor dr), 4.32 
(q, J = 7.2 Hz, 2H, major dr), 1.37 (t, J = 7.0 Hz, 3H, minor dr), 1.28 (t, J = 7.2 Hz, 3H, major 
dr); 13C NMR (75 Hz, CDCl3)  159.94, 159.59, 144.53, 144.46, 143.11, 143.03, 112.07, 112.00 
(d, J = 255.5 Hz), 111.99, 111.76 (d, J = 254.3 Hz), 111.11, 111.07, 72.12, 72.09, 65.34, 65.09, 
41.73, 41.46, 13.63; 19F NMR (376.46 Hz, CDCl3) -129.78 (d, J = 24.8 Hz)32.04 (d, J = 
28.2 Hz); HRMS (ESI) m/z calcd for C10H11FNaN2O7 [M+Na]
+ = 313.0443, found = 313.0450; the 
ee value was 81% for major diastereomer, tR (major) = 13.3 min, tR (minor) = 17.2 min 
(Chiralcel IA, λ = 254 nm, 2% iPrOH/hexanes, flow rate = 1 mL/min); the ee value was 27% 
for the minor diastereomer, tR (major) = 11.9 min, tR (minor) = 15.5 min (Chiralcel IA, λ = 
254 nm, 2% iPrOH/hexanes, flow rate = 1 mL/min). 
Ethyl 2-fluoro-2-nitro-3-(nitromethyl)-5-phenylpentanoate (II-1.10l) 
 
major diastereomer 
*α+270D = +11.7 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3): 7.31 (t, J = 6.8 Hz, 2H), 7.24 (d, J = 
7.2 Hz, 1H), 7.14 (d, J = 8.4 Hz, 2H),4.73 (dd, J = 14.8 Hz, 5.6 Hz, 1H), 4.49 (dd, J = 14.4 Hz, 5.2 
Hz, 1H), 4.36 (qd, J = 7.2 Hz, 2.0 Hz, 2H), 3.73 – 3.64 (m, 1H), 2.82 – 2.64 (m, 2H), 1.91 – 1.85 
(m, 1H), 1.81 – 1.76 (m, 1H), 1.34 (t, J = 7.2 Hz, 3H); 13C NMR (125.77 Hz, CDCl3)  160.05 (d, J 
= 26.8 Hz), 139.13, 128.81, 128.24, 126.79, 114.05 (d, J = 254.1 Hz), 73.19 (d, J = 2.9 Hz), 
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65.03, 40.83 (d, J = 19.9 Hz), 32.65, 28.89, 13.58; 19F NMR (376.46 Hz, CDCl3) -131.08 (d, J = 
22.3 Hz); HRMS (ESI) m/z calcd for C14H16FN2O6 [M-H]
- = 327.0998, found = 327.0985; the ee 
value was 81%, tR (major) = 19.9 min, tR (minor) = 17.9 min (Chiralcel IB, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 1 mL/min). 
 
minor diastereomer 
1H NMR (400 MHz, CDCl3): 7.31 (t, J = 6.8 Hz, 2H), 7.24 (t, J = 7.2 Hz, 1H), 7.14 (d, J = 7.2 
Hz, 2H),4.78 (dd, J = 14.4 Hz, 4.8 Hz, 1H), 4.45 (dd, J = 14.8 Hz, 6.0 Hz, 1H), 4.38 (qd, J = 7.2 
Hz, 2.0 Hz, 2H), 3.65 – 3.59 (m, 1H), 2.82 – 2.66 (m, 2H), 2.07 – 1.98 (m, 1H), 1.84 – 1.74 (m, 
1H), 1.34 (t, J = 7.2 Hz, 3H); 13C NMR (75.47 Hz, CDCl3)  159.90 (d, J = 26.9 Hz), 139.25, 
128.79, 128.24, 126.77, 114.03 (d, J = 276.5 Hz), 73.64 (d, J = 4.5 Hz), 65.04, 40.82 (d, J = 20.7 
Hz), 32.68, 29.62, 13.66; 19F NMR (376.46 Hz, CDCl3) -127.88 (d, J = 18.4 Hz); HRMS (ESI) 
m/z calcd for C14H16FN2O6 [M-H]
- = 327.0998, found = 327.0985; the ee value was 14%, tR 
(major) = 14.7 min, tR (minor) = 15.9 min (Chiralcel IB, λ = 254 nm, 5% iPrOH/hexanes, 
flow rate = 1 mL/min). 
Ethyl 2-fluoro-4-methyl-2-nitro-3-(nitromethyl)pentanoate (II-1.10m) 
*α+270D = +21.4 (c 1, CHCl3);  
1H NMR (400 MHz, CDCl3) (diastereomeric mixture): 
4.61 (td, J = 15.2 Hz, 6.0 Hz, 2H), 4.50 (ddd, J = 15.2 Hz, 4.0 Hz, 2.0 Hz, 2H), 4.42 (q, J = 7.2 
Hz, 2H), 4.35 (q, J = 7.2 Hz, 2H), 3.82 – 3.79 (m, 1H), 3.78 – 3.73 (m, 1H), 2.20 – 2.16 (m, 1H, 
minor dr), 2.01 – 1.97 (m, 1H, major dr), 1.37 (m, 6H), 1.09 (dd, J = 6.8 Hz, 5.2 Hz, 6H), 0.96 
(m, 6H); 13C NMR (100.62 Hz, CDCl3)  160.30 (d, J = 34.3 Hz), 160.15 (d, J = 33.6 Hz), 115.13 
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(d, J = 255.2 Hz), 114.89 (d, J = 255.9 Hz), 70.33, 70.30, 65.04, 64.93, 45.45 (d, J = 17.9 Hz), 
45.26 (d, J = 17.8 Hz), 27.72, 27.41, 21.40, 21.36, 17.41, 17.35, 13.69, 13.51; 19F NMR (376.46 
Hz, CDCl3) -129.75 (d, J = 24.5 Hz)32.00 (d, J = 28.2 Hz); HRMS (ESI) m/z calcd for 
C9H14FN2O6 [M-H]
- = 265.0841, found = 265.0833; the ee value for the major diastereomer was 
78%, tR (major) = 6.9 min, tR (minor) = 8.3 min (Chiralcel ID, λ = 254 nm, 5% 
iPrOH/hexanes, flow rate = 1 mL/min). 
 




Michael adduct (II-1.10a, 0.2 mmol, 60 mg) was dissolved in MeOH (2 ml). Boc anhydride 
was then added (1.5 equiv. 65.5 mg), followed by 2 drops of glacial acetic acid, Pd/BaSO4 (3 
mol% Pd, 0.006 mmol, 12.8 mg of 5 wt% Pd/BaSO4). The reaction mixture was placed in 
autoclave and stirred for 12 h at 6 atm H2 with stirring at room temperature. After that time, 





 The crude reaction mixture was purified on silica gel column eluting with 
hexane/ethyl acetate (20/1  10/1). The pure product was obtained as a white solid (15 mg, 
20%). 
*α+270D = -15.0 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 7.39 - 7.33 (m, 5H),5.39 – 5.31 (m, 
2H), 4.99 (dd, J = 12.0 Hz, 7.2 Hz, 1H), 4.33 (q, J = 7.2 Hz, 2H), 3.98 (s, 1H), 1.56 (s, 9H), 1.32 
                                                          
177
 Heating should be avoided and it is recommended to remove acetic acid together with solvent to 
avoid defluorination - thus the use of vaccum; other work-up procedures resulted in lower isolated 
yield of product. 
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(t, J = 7.2 Hz, 3H); 13C NMR (125 Hz, CDCl3)  162.34, 154.24, 133.45, 129.22, 128.40, 118.22, 
85.43, 75.12, 62.99, 41.8, 27.63, 13.90; 19F NMR (376.46 Hz, CDCl3) -132.82 (d, J = 28.2 Hz); 
HRMS (ESI) m/z calcd for C17H26FN2O7 [M+H3O]
+ = 389.1336, found = 389.1348. 




The Michael addition reaction mixture was filtered through a short column of silica gel to 
remove the catalyst and concentrated. The crude residue (approx. 0.1 mmol of product) was 
dissolved in dry THF (1.5 ml) and Pd/C was added (10 mol%, 0.01 mmol, 10.6 mg of 10 w% 
Pd/C). The reaction mixture was capped, placed in 0 
o
C cooling bath and stirred for 10 mins. 
Then, 1.5 equiv. of sodium borohydride was added in one portion (6 mg, 0.15 mmol) and the 
reaction mixture was stirred at 0 
o
C for additional 30 mins. Upon completion (TLC analysis), 
the reaction was quenched with satd. aqueous ammonium chloride (2 ml) and extracted with 
CH2Cl2 (3 x 5 ml). The organic phases were combined, dried over sodium sulphate and 
evaporated. The residue was purified on silica gel column eluting with hexane/ethyl acetate 
(20/1 - 10/1) and both diastereomers were separated and collected as pure products - pale 







((2S)-1-fluoro-1,3-dinitropropan-2-yl)benzene, major (II-1.13a) 
*α+270D = +19.0 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 7.34 - 7.36 (m, 3H), 
7.21 (m, 2H), 6.22 (dd, J = 50.5 Hz, 3.0 Hz, 1H), 4.98 (dd, J = 14.5 Hz, 5.5 Hz, 1H), 4.79 (dd, J = 
14.5 Hz, 6.6 Hz, 1H), 4.51 – 4.42 (m, 1H), ; 13C NMR (125 Hz, CDCl3)  129.89, 129.53, 128.69, 
108.90 (d, J = 242.9 Hz), 73.84, 46.13; 19F NMR (376.46 Hz, CDCl3) -155.50 (dd, J = 50.4 Hz, 
27.8 Hz); HRMS (ESI) m/z calcd for C9H8FN2O4 [M-H]
- = 227.0474, found = 227.0474. 
((2S)-1-fluoro-1,3-dinitropropan-2-yl)benzene, minor (II-1.13b) 
*α+270D = -13.7 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 7.42 - 7.41 (m, 
3H),7.28 (m, 2H), 6.07 (dd, J = 49.5 Hz, 4.5 Hz, 1H), 4.89 (d, J = 9.0 Hz, 2H), 4.44 – 4.34 (m, 
1H); 13C NMR (125 Hz, CDCl3)  130.97, 129.83, 129.72, 128.17, 110.33 (d, J = 242.9 Hz), 
73.33, 46.30; 19F NMR (376.46 Hz, CDCl3) -133.34 (dd, J = 49.3 Hz, 20.6 Hz); HRMS (ESI) m/z 
calcd for C9H8FN2O4 [M-H]
- = 227.0474, found = 227.0467. 
IV-1.5. Denitration and analytical data of -fluoroesters 
 
Experimental procedure: 
The Michael addition reaction mixture was filtered through a short column of silica gel to 
remove the catalyst and concentrated. The crude residue (approx. 0.1 mmol of product) was 
dissolved in dry benzene (1.5 ml) and (n-Bu)3SnH was added (1.5 equiv., 0.15 mmol, 43.6 
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mg), followed by 0.5 equiv. of ACHN (1,1‟-Azobis(cyclohexanecarbonitrile) (0.05 mmol, 12 
mg). The reaction mixture was flushed with argon, and refluxed under argon for 4 h. After 
this time only trace amount of starting material was detected (TLC analysis) and the reaction 
was cooled to room temperature. After removing benzene in vacuo, the residue was purified 
on silica gel column eluting with hexane/ethyl acetate (20/1 - 10/1) and both diastereomers 
were separated and collected as pure products - white solids in 2:1 ratio. Total yield was 78% 
(20 mg). 
((2S)-1-fluoro-1,3-dinitropropan-2-yl)benzene, major (II-1.14a) 
*α+270D = +5.0 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 7.34 - 7.33 (m, 3H), 
7.27 (m, 2H), 5.28 (dd, J = 48.5 Hz, 3.0 Hz, 1H), 4.95 (dd, J = 14.0 Hz, 8.5 Hz, 1H), 4.75 (dd, J = 
13.5 Hz, 7.0 Hz, 1H), 4.17 – 4.05 (m, 3H), 1.08 (t, J = 7.0 Hz, 3H); 13C NMR (125 Hz, CDCl3)  
166.93 (d, J = 22.5), 133.08, 129.03, 128.76,  88.33 (d, J = 191.5 Hz), 75.48, 61.88, 45.76 (d, J 
= 18.3 Hz), 13.91; 19F NMR (376.46 Hz, CDCl3) -200.30 (dd, J = 48.9 Hz, 31.2 Hz); HRMS (ESI) 
m/z calcd for C12H13FNO4 [M-H]
- = 254.0834, found = 254.0833. 
((2S)-1-fluoro-1,3-dinitropropan-2-yl)benzene, minor (II-1.14b) 
  *α+270D = -0.6 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 7.38 - 7.34 (m, 
3H),7.30 – 7.26 (m, 2H), 5.10 (dd, J = 48.0 Hz, 5.0 Hz, 1H), 4.89 (dd, J = 19.5 Hz, 5.5 Hz, 1H), 
4.80 (dd, J = 13.5 Hz, 9.0 Hz, 1H), 4.20 (q, J = 7.0 Hz, 2H), 4.17 – 4.09 (m, 1H), 1.22 (t, J = 7.0 
Hz, 3H); 13C NMR (125 Hz, CDCl3)  167.39 (d, J = 23.6 Hz), 133.74, 133.23, 129.21, 128.78, 
128.18, 128.11, 89.76 (d, J = 190.4 Hz), 75.04, 62.21, 46.06, 13.90; 19F NMR (376.46 Hz, 
CDCl3) -194.49 (dd, J = 48.1 Hz, 22.3 Hz); HRMS (ESI) m/z calcd for C12H13FNO4 [M-H]
- = 
254.0834, found = 254.0832. 
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IV-1.6. X-ray crystallographic analysis and determination of configurations of 
Products 
Absolute configuration of all Michael addition product was assigned is analogy to 
configuration of II-1.10a found from X-ray analysis of a single crystal.   
 
 
Table 1.  Crystal data and structure refinement for D610. 
Identification code  D610 
Empirical formula  C12 H13 F N2 O6 
Formula weight  300.24 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 5.5351(6) Å = 90°. 
 b = 11.2034(12) Å = 90°. 
 c = 21.678(2) Å  = 90°. 
Volume 1344.3(3) Å3 
Z 4 
Density (calculated) 1.483 Mg/m3 




Crystal size 0.280 x 0.150 x 0.130 mm3 
Theta range for data collection 4.078 to 72.323°. 
Index ranges -6<=h<=6, -13<=k<=13, -26<=l<=26 
Reflections collected 22572 
Independent reflections 2637 [R(int) = 0.0240] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.753 and 0.6796 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2637 / 0 / 191 
Goodness-of-fit on F2 1.094 
Final R indices [I>2sigma(I)] R1 = 0.0250, wR2 = 0.0655 
R indices (all data) R1 = 0.0253, wR2 = 0.0658 
Absolute structure parameter 0.05(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.167 and -0.248 e.Å-3 
 




IV-2. Organocatalytic Michael addition of -fluoro--nitro benzyls to 
nitroalkenes: facile preparation of fluorinated amines and 
pyrimidines 
 
IV-2.1. Preparation of Substrates   and analytical data of new -fluoro--
nitrobenzyls  
Nitroalkenes were prepared from respective aldehydes and nitromethane according to 
reported procedures.  
The -fluoro--nitro benzyls were prepared form respective benzyl bromides in reaction with 
sodium nitrite and urea in DMF at -20
o
C, according to previously reported procedure.
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 The 
fluorination was performed using selectfluor in acetonitrile/water (1/1) at rt over 12h and 





1H NMR (400 MHz, CDCl3): (d, J = 7.6 Hz, 1H), 7.76 (d, J = 4.8 Hz, 1H), 7.71 – 7.68 (m, 
2H), 6.95 (d, J = 47.6 Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 133.62, 133.52, 132.68, 132.41, 
132.40, 126.72,115.49, 112.69, 106.65 (d, J = 241.3 Hz); 19F NMR (376.46 Hz, CDCl3) -140.26 
(d, J = 47.4 Hz); HRMS (ESI) m/z calcd for C8H5FN2O2 [M]
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1H NMR (400 MHz, CDCl3): 7.52dJ7.6 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 6.59 (d, J = 48.8 
Hz, 1H), 2.43(s, 3H); 13C NMR (100.62 Hz, CDCl3) 142.47, 129.75, 127.54, 127.33, 126.51, 
126.45, 111.38, 109.00, 21.41; 19F NMR (376.46 Hz, CDCl3) (d, J = 48.5 Hz); HRMS 
(ESI) m/z calcd for C8H8FNO2 [M]
+= 168.0461, found = 168.0458. 
1-Chloro-3-(fluoro(nitro)methyl)benzene (II-2.1d) 
 
1H NMR (400 MHz, CDCl3): 7.63s1H), 7.52 (d, J = 9.6 Hz, 2H), 7.43 (m, 1H), 6.58 (d, J = 
48.4 Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 135.31, 132.19, 130.48, 126.72, 126.65, 124.69, 
124.63; 19F NMR (376.46 Hz, CDCl3) 41.29 (d, J = 48.1 Hz); HRMS (ESI) m/z calcd for 
C13H14FN3O4 [M]
=187.9915, found = 187.9899. 
2-(Fluoro(nitro)methyl)naphthalene (II-2.1e) 
 
1H NMR (400 MHz, CDCl3): (s, 1H), (m, 3H), 7.65 (dd, J = 8.8 Hz, 2.0 Hz, 1H), 
7.62 – 7.58 (m, 2H), 6.77 (d, J = 48.8 Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 
; 19F NMR (376.46 
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Hz, CDCl3) -139.08 (d, J = 48.6 Hz); HRMS (ESI) m/z calcd for C11H8FNO2 [M]
= 204.0461, 
found = 204.0532. 
IV-2.2. General procedure and analytical data of the Michael 
reaction products 
Michael addition of ethyl fluoronitroacetate to nitroalkenes - representative procedure: 
to a sample vial containing the -fluoro--nitro substrate (0.1 mmol, II-2.1af) in toluene (1 
ml), the catalyst II-1.12b (0.01 mmol, 10 mg) was added. The vial was then capped and the 
reaction mixture was stirred for 5 minutes at 0 
o
C. Subsequently nitroalkene (0.11 mmol) was 
added in one portion, under nitrogen protection, the vial was sealed and the reaction mixture 
was stirred at 0 
o
C for the time indicated. Upon completion of the reaction, the mixture was 
passed through a short silica gel column to remove the catalyst (possible recovery of the 
catalyst), evaporated and analyzed by 
1
H NMR. The crude product was then subjected to 
column chromatographic separation eluting with hexane/ethyl acetate (20:1  10:1) to afford 
the pure Michael product (II-2.3an). 
((1S,2S)-1-fluoro-1,3-dinitropropane-1,2-diyl)dibenzene (II-2.3a) 
 
*α+270D = +51.6 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.89 – 7.87 (m, 2H), 7.58 – 7.54 (m, 
3H), 7.44 – 7.42 (m, 2H), 7.39 – 7.37 (m, 3H), 5.10 (ddd, J = 38.4 Hz, 10.8 Hz, 4.0 Hz, 1H), 4.77 
(dd, J = 13.6 Hz, 10.8 Hz, 1H), 4.49 (dd, J = 13.2 Hz, 3.6 Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 

dJ244.1 Hz), 75.33 (d, J = 2.1 Hz), 50.14 (d, J = 18.3 Hz); 19F NMR (376.46 Hz, 
CDCl3) dJHz HRMS (ESI) m/z calcd for C15H12FN2O4 [M-H]
- = 303.8787, 
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found = 383.8789; the ee value was 90%, tR (major) = 12.1 min, tR (minor) = 10.6 min 
(Chiralcel IB, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
4-((1S,2S)-1-Fluoro-1,3-dinitro-2-phenylpropyl)benzonitrile (II-2.3b) 
 
*α+270D = +68.2 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (d, J = 8.8 Hz, 2H), (d, J = 
8.4 Hz, 2H), 7.40 (s, 5H), 5.05 (ddd, J = 31.6 Hz, 10.4 Hz, 4.4 Hz, 1H), 4.75 (dd, J = 13.6 Hz, 
10.0 Hz, 1H); 4.44 (dd, J = 13.6 Hz, 4.4 Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 135.19, 134.95, 
133.21, 133.19, 130.07, 129.95, 129.37, 129.34, 126.55, 126.44 117.94 (d, J = 245.9 Hz), 
117.09, 116.22, 74.89, 50.14 (d, J = 18.4 Hz) ; 19F NMR (376.46 Hz, CDCl3) -136.70 (d, J = 
31.2 Hz); HRMS (ESI) m/z calcd for C32H22F2NaN6O8 [2M-2H+Na]
- = 679.1370, found = 
679.1342; the ee value was 88%, tR (major) = 17.3 min, tR (minor) = 16.4 min (Chiralcel 
IB+ID, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
1-((1S,2S)-1-fluoro-1,3-dinitro-2-phenylpropyl)-4-methylbenzene (II-2.3c) 
 
*α+270D = +95.1 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.42 
(m, 2H), 7.38 – 7.34 (m, 5H), 5.08 (ddd, J = 31.2 Hz, 10.8 Hz, 3.6 Hz, 1H), 4.75 (dd, J = 13.6 Hz, 
10.8 Hz, 1H); 4.50 (dd, J = 13.2 Hz, 3.6 Hz, 1H), 2.42 (s, 3H); 13C NMR (100.62 Hz, CDCl3) 

dJHzdJHz; 19F NMR (376.46 Hz, 




657.1778, found = 657.1794; the ee value was 90%, tR (major) = 30.6 min, tR (minor) = 20.6 
min (Chiralcel IB, λ = 254 nm, 2% iPrOH/hexanes, flow rate = 1 mL/min). 
1-Chloro-3-((1S,2S)-1-fluoro-1,3-dinitro-2-phenylpropyl)benzene (II-2.3.d) 
 
*α+270D = +81.3 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.86m, 1H), 7.79 (d, J = 7.6 Hz, 1H), 
7.56 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 2Hz, 1H), 7.40 – 7.26 (m, 5H), 5.03 (ddd, J = 31.2 Hz, 10.8 
Hz, 4.0 Hz, 1H), 4.78(dd, J = 13.6 Hz, 10.8 Hz, 1H), 4.48(dd, J = 13.6 Hz, 4.0 Hz, 1H); 13C NMR 
(100.62 Hz, CDCl3) 135.95, 132.76, 132.53, 132.22, 130.94, 130.93, 130.35, 129.78, 129.46, 
129.44, 129.27, 125.80, 123.70, 118.07 (d, J = 245.36 Hz), 75.10, 50.19 (d, J = 18.40 Hz); 19F 
NMR (376.46 Hz, CDCl3) 6.29 (d, J = 31.2 Hz); HRMS (ESI) m/z calcd for C15H11ClFN2O4 
[M-H]- = 337.0397, found = 337.0392; the ee value was 87%, tR (major) = 15.8 min, tR (minor) 
= 11.4 min (Chiralcel IB, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
1-Bromo-4-((1S,2S)-1-fluoro-1,3-dinitro-1-phenylpropan-2-yl)benzene (II-2.3e) 
 
*α+270D = +22.2 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (dd, J = 7.6 Hz, 1.2 Hz, 2H), 7.58 
– 7.51 (m, 5H), 7.31 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 5.07 (ddd, J = 30.8 Hz, 10.8 Hz, 3.6 Hz, 1H), 
4.72 (dd, J = 13.2 Hz, 10.8 Hz, 1H); 4.47 (dd, J = 13.6 Hz, 3.6 Hz, 1H); 13C NMR (100.62 Hz, 
CDCl3)  132.48, 132.07, 131.14, 131.1, 130.07, 130.42, 129.70, 129.68, 125.31, 125.21, 
124.16, 118.64 (d, J = 244.2 Hz), 75.08, 49.65 (d, J = 18.5 Hz); 19F NMR (376.46 Hz, CDCl3) -
136.77 (d, J = 30.9 Hz); HRMS (ESI) m/z calcd for C15H11BrFN2O4 [M-H]
- = 380.9892, found = 
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380.9880; the ee value was 90%, tR (major) = 22.6 min, tR (minor) = 18.4 min (Chiralcel AD-H, 
λ = 254 nm, 2% iPrOH/hexanes, flow rate = 1 mL/min). 
1-((1S,2S)-1-fluoro-1,3-dinitro-1-phenylpropan-2-yl)-4-methylbenzene (II-2.3f) 
 
*α+270D = +65.4 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.55 
(m, 3H), 7.30 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 5.06 (ddd, J = 31.6 Hz, 10.8 
Hz, 4.0 Hz, 1H), 4.75 (dd, J = 11.2 Hz, 10.8 Hz, 1H); 4.47 (dd, J = 13.2 Hz, 3.6 Hz, 1H), 2.33 (s, 
3H); 13C NMR (100.62 Hz, CDCl3) 131.85, 131.09, 130.86, 129.89, 129.57, 129.55, 129.35, 
128.71, 127.55, 125.42, 118.98 (d, J = 244.2 Hz), 75.40, 49.85 (d, J = 18.5 Hz), 21.13 ; 19F NMR 
(376.46 Hz, CDCl3) -136.70 (d, J = 31.5 Hz); HRMS (ESI) m/z calcd for C16H15FN2O4 [M-H]
- = 
317.0943, found = 317.0949; the ee value was 88%, tR (major) = 25.7 min, tR (minor) = 20.8 
min (Chiralcel IA, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
1-((1S,2S)-1-Fluoro-1,3-dinitro-1-phenylpropan-2-yl)-4-(trifluoromethyl)benzene (II-2.3g) 
 
*α+270D = +61.9 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (dd, J = 7.6 Hz, 1.6 Hz, 2H), 
(d, J = 8.4 Hz, 2H), 7.59 (m, 5H), 5.19 (ddd, J = 31.2 Hz, 11.2 Hz, 3.6 Hz, 1H), 4.77 (dd, J = 
13.6 Hz, 10.8 Hz, 1H); 4.51 (dd, J = 13.6 Hz, 3.8 Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 134.83, 
132.18, 131.73, 130.51, 130.28, 130.07, 129.77, 126.21, 126.17, 125.29, 125.19, 124.93, new 
118.62 (d, J = 244.7 Hz), 75.00, 49.85 (d, J = 18.6 Hz) ; 19F NMR (376.46 Hz, CDCl3) 63.02-
136.54 (d, J = 30.8 Hz); HRMS (ESI) m/z calcd for C16H13F4N2O5 [M-H]
- = 371.0660, found = 
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371.0650; the ee value was 91%, tR (major) = 15.1 min, tR (minor) = 10.9 min (Chiralcel IB, λ = 
254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
1-bromo-3-((1S,2S)-1-fluoro-1,3-dinitro-1-phenylpropan-2-yl)benzene (II-2.3h) 
 
*α+270D = +53.1 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (dd, J = 7.6 Hz, 1.6 Hz, 2H), 7.61 
– 7.53 (m, 5H), 7.39 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 5.08 (ddd, J = 30.8 Hz, 
10.8 Hz, 3.6 Hz, 1H), 4.74 (dd, J = 13.6 Hz, 10.8 Hz, 1H); 4.49 (dd, J = 14.0 Hz, 4.0 Hz, 1H); 13C 
NMR (100.62 Hz, CDCl3)  132.92, 132.51, 132.08, 130.68, 130.41, 128.27, 128.25, 125.30, 
125.20, 123.17, 118.64 (d, J = 244.3 Hz), 75.09, 49.65 (d, J = 18.4 Hz); 19F NMR (376.46 Hz, 
CDCl3) -136.55 (d, J = 30.8 Hz); HRMS (ESI) m/z calcd for C15H11BrFN2O4 [M-H]
- = 380.0892, 
found = 380.9873; the ee value was 90%, tR (major) = 16.0 min, tR (minor) = 11.5 min 
(Chiralcel IB, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
2-((1S,2S)-2-(2-Chlorophenyl)-1-fluoro-1,3-dinitropropyl)naphthalene (II-2.3i) 
 
*α+270D = +77.1 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (d, J = 2.0 Hz, 1H), (d, J = 
8.8 Hz, 2H), 7.96 (dd, J = 6.8, 2.4 Hz, 1H), 7.91 (dd, J = 9.2 Hz, 2.4 Hz, 1H), 7.85 (dd, J = 8.8 Hz, 
2.0 Hz, 1H), 7.65 -7.62 (m, 2H), 7.46 (d, J = 1.6 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H), 6.39 (d, J = 2.0 
Hz, 1H), 5.49 (ddd, J = 29.6 Hz, 10.4 Hz, 3.2 Hz, 1H), 4.90 (dd, J = 13.6 Hz, 10.4 Hz, 1H); 4.43 
(dd, J = 13.6 Hz, 3.6 Hz, 1H); 19F NMR (376.46 Hz, CDCl3) -134.94 (d, J = 29.7 Hz); HRMS (ESI) 
m/z calcd for C19H13ClFN2O4 [M-H]
- = 387.0553, found = 387.0548; the ee value was 70%, tR 
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(major) = 16.0 min, tR (minor) = 11.5 min (Chiralcel IB, λ = 254 nm, 10% iPrOH/hexanes, 
flow rate = 1 mL/min). 
1-Fluoro-2-((1S,2S)-1-fluoro-1,3-dinitro-1-phenylpropan-2-yl)benzene (II-2.3j) 
 
*α+270D = +45.0 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (dd, J = 7.6 Hz, 1.6 Hz, 2H), 
(m, 3H), 7.48 – 7.40 (m, 1H), 7.39 – 7.34 (m, 1H), 7.21 – 7.10 (m, 2H), 5.53 (ddd, J 
= 30.0 Hz, 10.0 Hz, 3.6 Hz, 1H), 4.80 (dd, J = 13.6 Hz, 10.4 Hz, 1H); 4.52 (dd, J = 14.0 Hz, 4.0 
Hz, 1H); 13C NMR (100.62 Hz, CDCl3) 162.39, 132.02, 131.60, 131.51, 129.84, 129.59, 
128.04, 125.44, 125.34, 124.93, 118.75 (d, J = 245.7 Hz), 116.67, 116.44, 74.52 (d, 2.0 Hz), 
43.43 (d, J = 18.8 Hz); 19F NMR (376.46 Hz, CDCl3) -135.93 (dd, J = 31.2 Hz, 14.7 
Hz); HRMS (ESI) m/z calcd for C15H11F2N2O4 [M-H]
- = 321.0692, found = 321.0687; the ee value 
was 85%, tR (major) = 18.8 min, tR (minor) = 17.7 min (Chiralcel IB, λ = 254 nm, 2% 
iPrOH/hexanes, flow rate = 1 mL/min). 
2-((1S,2S)-2-(3,5-Difluorophenyl)-1-fluoro-1,3-dinitropropyl)naphthalene (II-2.3k) 
 
*α+270D = +58.1 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): dJ2.0 Hz, 1H), 8.04 (d, J = 
8.8 Hz, 1H), dd, J = 6.8 Hz, 3.6 Hz, 2H), (dd, J = 8.8 Hz, 2.0 Hz, 1H), 7.65 (m, 2H), 
7.04 (dd, J = 5.6 Hz, 1.2 Hz, 2H), 6.90 – 6.84 (m, 1H), 5.23 (ddd, J = 30.0 Hz, 10.8 Hz, 3.6 Hz, 
1H), 4.73 (dd, J = 14.0 Hz, 11.2 Hz, 1H); 4.50 (dd, J = 13.6 Hz, 3.6 Hz, 1H); 13C NMR (100.62 Hz, 
CDCl3) 164.35 (d, J = 12.6 Hz), 161.85 (d, J = 12.5 Hz), 134.48, 134.33, 132.51, 130.22, 
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128.92, 128.76, 127.87, 127.38, 127.15, 126.17, 126.06, 118.67 (d, J = 244.9 Hz), 113.14, 
112.85, 105.56, 75.00, 49.65 (d, J = 18.5 Hz); 19F NMR (376.46 Hz, CDCl3) 107.20-135.87 
(d, J = 30.1 Hz); HRMS (ESI) m/z calcd for C19H12F3N2O4 [M-H]
- = 389.0755, found = 389.0757; 
the ee value was 96%, tR (major) = 7.7 min, tR (minor) = 9.1 min (Chiralcel AD-H, λ = 254 
nm, 5% iPrOH/hexanes, flow rate = 1 mL/min). 
2-((1S,2R)-1-Fluoro-1-(naphthalen-2-yl)-1,3-dinitropropan-2-yl)furan (II-2.3l) 
 
*α+270D = +40.1 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (d, J = 1.6 Hz, 1H), 
m7.67 – 7.61 (m, 3H), 7.48 (dd, J = 6.8 Hz, 1.6 Hz, 1H), 7.36 – 7.32 (m, 
2H), 6.12 – 6.01 (m, 1H), 4.83 – 4.71 (m, 1H), 4.59 (dd, J = 13.2 Hz, 4.0 Hz, 1H); 13C NMR 
(100.62 
Hz,CDCl3)
127.62, 118.67 (d, J = 245.6 Hz)dJHz; 19F NMR 
(376.46 Hz, CDCl3) -134.92 (d, J = 30.8 Hz); HRMS (ESI) m/z calcd for C17H12FN2O5 [M-H]
- = 
343.0736, found = 343.0738; the ee value was 88%, tR (major) = 15.4 min, tR (minor) = 34.5 
min (Chiralcel IB, λ = 254 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min). 
4-((1S,2S)-1-fluoro-1-nitro-2-(nitromethyl)hexyl)benzonitrile (II-2.3m) 
 
*α+270D = +72.0 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.89 – 7.70 (m, 4H), 4.33 – 4.20 (m, 
2H), 3.94 (dd, J = 30.4 Hz, 5.2 Hz, 1H), 1.62 – 1.34 (m, 7H), 0.91 (m, 2H); 13C NMR (100.62 Hz, 
CDCl3) 135.22, 132.95, 126.50, 119.36 (d, J = 244.5 Hz), 117.17, 115.99, 74.03 (d, J = 4.2 
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Hz), 43.90 (d, J = 20.6 Hz), 28.32, 26.99, 22.32, 13.60; 19F NMR (376.46 Hz, CDCl3) 
dJHz; HRMS (ESI) m/z calcd for C14H15FN3O4 [M-H]
- = 308.1052, found = 
308.1053; the ee value was 82%, tR (major) = 12.5 min, tR (minor) = 11.4 min (Chiralcel ID, λ 
= 254 nm, 5% iPrOH/hexanes, flow rate = 1 mL/min). 
4-((1S,2S)-1-fluoro-3-methyl-1-nitro-2-(nitromethyl)butyl)benzonitrile (II-2.3n) 
 
*α+270D = +45.5 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.86dJ7.8 Hz, 2H), 7.77 (t, J = 
7.6 Hz, 2H), 4.43(dd, J = 14.4 Hz, 4.8 Hz, 1H), 4.16(dd, J = 14.4 Hz, 5.6 Hz, 1H), 3.99 (dtd, J = 
34.0 Hz, 5.2 Hz, 2.4 Hz, 1H), 2.06(m, 1H), 1.10 (d, J = 6.8 Hz, 3H), 1.05 (dd, J = 6.8 Hz, 2.0 Hz, 
3H); 13C NMR (100.62 Hz, CDCl3) 135.42, 132.83, 127.21, 126.60, 126.49, 120.29 (d, J = 
247.98 Hz), 117.20, 115.96, 70.76, 48.20 (d, J = 19.1 Hz), 27.86, 21.88, 17.56; 19F NMR 
(376.46 Hz, CDCl3) 7.87 (d, J = 33.8 Hz); HRMS (ESI) m/z calcd for C13H13FN3O4 [M-H]
- = 
294.0896, found = 294.0893; the ee value was 82%, tR (major) = 17.1 min, tR (minor) = 19.8 
min (Chiralcel AD-H, λ = 254 nm, 5% iPrOH/hexanes, flow rate = 1 mL/min). 
IV-2.3. Catalytic hydrogenation and analytical data of fluoroamines  
 
Experimental procedure for catalytic hydrogenation leading to bis-amine:  
Michael adduct (II-2.3a, 0.2 mmol, 61 mg) was dissolved in MeOH (2 ml). Boc anhydride 
was then added (2.5 equiv. 109 mg), followed by 2-3 drops of glacial acetic acid, Pd/BaSO4 
(5 mol% Pd, 0.01 mmol, 21.3 mg of 5 wt% Pd/BaSO4) and freshly activated MS 4Å (~20 
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mg). The reaction mixture was placed in autoclave and stirred for 48 h at 15 atm H2 with 
stirring at room temperature. After that time, the reaction mixture was filtered through cellite 




 The crude reaction mixture was 
purified on silica gel column eluting with hexane/chloroform (10/1). The pure product was 
obtained as a pale yellow oil (55 mg, 62%).                        
di-tert-butyl ((1R,2S)-1-fluoro-1,2-diphenylpropane-1,3-diyl)dicarbamate;  
 *α+270D = -52.0 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.86 (m, 2H), 
7.49 (m, 3H),7.42 (m, 2H), 7.36 - 7.30 (m, 3H), 4.59 (ddd, J = 32.8 Hz, 10.4 Hz, 3.6 Hz, 1H), 
4.13 (m, 1H), 3.73 (m, 1H), 1.44 (s, 9H), 1.26 (s, 9H); 13C NMR (125 Hz, CDCl3) 151.72, 
151.70, 133.27, 132.30, 132.11, 131.12, 129.98, 120.06, 128.60, 128.55, 125.59, 125.51, 
120.24, (d, J = 246.2 Hz)85.17, 82.62, 50.52, 49.76 (d J = 18.1 Hz), 27.83, 27.54; 19F NMR 
(376.46 Hz, CDCl3) -137.84 dJHz; HRMS (ESI) m/z calcd for C25H34FN2O4 [M+H]
+ = 
445.2503, found = 445.2504. 
Experimental procedure for catalytic hydrogenation leading to mono-amine:  
The experimental procedure is the same as the above procedure for bis-reduction, except that 
2 equiv. of Boc2O were used (87 mg) and the reaction was stopped after 12h. The pure 
product was obtained after chromatography on silica gel column eluting with hexane/ethyl 
acetate (10/1 - 5:1) as a pale yellow oil (42 mg, 56%).  
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 Heating should be avoided and it is recommended to remove acetic acid together with solvent to 
avoid defluorination - thus the use of vaccum; other work-up procedures resulted in lower isolated 




 *α+270D = +98.0 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.88 (m, 2H), 7.51 
(m, 3H), 7.43 (m, 2H), 7.32 (m, 3H), 5.98 (bs, 1H), 4.72 (ddd, J = 33.2 Hz, 10.4 Hz, 4.4 Hz, 1H), 
4.06 (dd, J = 14.4 Hz, 10.4 Hz, 1H), 3.57 (dd, J = 14.4 Hz, 4.4 Hz, 1H), 1.24 (s, 9H); 13C NMR 
(125 Hz, CDCl3) 155.37, 133.36, 132.34, 132.15, 131.15, 129.96, 129.94, 129.08, 129.07, 
128.66, 125.55, 125.47, 120.29 (d, J = 242.6 Hz), 82.31, 49.88 (d, J = 3.1 Hz), 48.96 (d, J = 18.5 
Hz), 27.95; 19F NMR (376.46 Hz, CDCl3) -137.32 dJHz; HRMS (ESI) m/z calcd for 
C20H22FN2O4 [M-H]
- = 373.1569, found = 373.1664. 
IV-2.4. Preparation of tetrahydropyrimidine and analytical data  
 
Experimental procedure:  
The bis-amine (II-2.4, 0.1 mmol, 44 mg) was dissolved in CH2Cl2 (2ml) and 0.2 ml of TFA 
was added dropwise while stirring at room temperature. Even though deprotection seemed to 
proceed fast, the reaction was stirred for additional 2 h to ensure complete deprotection of 
both amino functionalities. After that time, the reaction was quenched by addition of water 
(2ml), diluted with CH2Cl2 and brought to pH 10 by a dropwise addition of satd. aqueous 
NaHCO3. Then, the crude product was extracted with CH2Cl2 (3x 10 ml) and the organic 
phase was dried over sodium sulphate and evaporated. The crude free diamine was then 
dissolved in THF (1 ml) and 37 wt% aqueous formaldehyde was added dropwise at room 
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temperature (1 equiv., 8 mg). The reaction was then stirred at room temperature for 12 h to 
ensure full conversion and heterocyclic ring formation.
181
 Upon completion, the reaction 
mixture was diluted with CH2Cl2 (2ml), dried over sodium sulphate and concentrated. The 
pure product was obtained after column chromatography on silica gel eluting with 
toluene/chloroform (10/1 - 5/1) as a pale yellow oil (23.5 mg, 92%).                                                 
(4R,5S)-4-fluoro-4,5-diphenylhexahydropyrimidine 
 *α+270D = +65.6 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 7.92 (m, 2H), 7.53 (dd, J = 
5.5 Hz, 2.0 Hz, 3H), 7.48 – 7.45 (m, 2H), 7.38 – 7.34 (m, 3H), 6.10 (d, J = 7.2 Hz, 1H), 5.82 (d, J 
= 7.2 Hz, 1H), 5.22 (ddd, J = 33.5 Hz, 10.5 Hz, 3.7 Hz, 1H), 4.08 (dd, J = 11.8 Hz, 10.7 Hz, 1H), 
3.97 (dd, J = 12.0 Hz, 3.7 Hz, 1H), ; 13C NMR (125 Hz, CDCl3) 132.22, 131.52, 131.39, 129.53, 
129.51, 129.32, 129.08, 129.03, 128.20, 125.72, 125.64, 124.94, 119.98 (d, J = 243.6 Hz), 
65.75, 49.06, 48.92; 19F NMR (376.46 Hz, CDCl3) -59.15 dJHz; HRMS (ESI) m/z 
calcd for C16H16FN2 [M-H]
- = 255.2330, found = 255.2336. 
IV-2.5. X-Ray Crystallographic analysis and determination of 
configurations of products 
Configuration of all Michael addition products was assigned as analogical to configuration of 
product II-2.3e.  
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 The change of ninhydrine stain color on TLC suggested that the reaction proceeded fast - within 0.5 
h; however it is difficult to distinguish product and starting material spot on TLC and therefore the 





Table 1.  Crystal data and structure refinement for D345. 
Identification code  d345 
Empirical formula  C15 H12 Br F N2 O4 
Formula weight  383.18 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.6907(11) Å = 108.137(3)°. 
 b = 7.4227(14) Å = 100.781(3)°. 
 c = 9.3653(18) Å  = 90.415(3)°. 
Volume 368.39(12) Å3 
Z 1 
Density (calculated) 1.727 Mg/m3 
Absorption coefficient 2.823 mm-1 
F(000) 192 
Crystal size 0.52 x 0.50 x 0.20 mm3 
Theta range for data collection 2.34 to 27.50°. 
Index ranges -7<=h<=7, -9<=k<=9, -12<=l<=12 
Reflections collected 4816 
Independent reflections 3338 [R(int) = 0.0145] 
Completeness to theta = 27.50° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8372 and 0.5831 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3338 / 3 / 208 
173 
 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0379, wR2 = 0.0946 
R indices (all data) R1 = 0.0379, wR2 = 0.0947 
Absolute structure parameter 0.000(6) 
Largest diff. peak and hole 0.455 and -0.338 e.Å-3 
_____________  
 




IV-3. Enantioselective synthesis of functionalized fluorinated 
phosphonates via Michael addition of -fluoro--ketophosphonates 
to nitroalkenes 
IV-3. 1. Preparation of the substrates and analytical data  
 
Bromination 
Commercially available bromides were purchased, while others were synthesized with the use 
of microwave initiator. 
            
General procedure:  
To a microwave vial containing ketone (3 mmol), 10 ml of glacial acetic acid was added 
followed by p-toluenesulphonic acid monohydrate (p-TsOH x H2O,  3 mmol, 570 mg) and N-
bromo succinimide (NBS, 3 mmol, 534 mg). The vial was than capped and placed in the 
microwave initiator (40 minutes at 120
o
C). In certain cases, ketones were difficult to 
brominate (TLC control) and therefore, the reaction was repeated up to 2 more times (to the 
reaction mixture from previous step was added: NBS (3 mmol) and p-TsOH (3 mmol) and the 
reaction mixture was subjected to microwave irradiation for additional 40 minutes at 120
o
C). 
Upon completion of the reaction (TLC) the reaction mixture was evaporated, dissolved in 
Ethyl Acetate (50 ml) and washed carefully with aqueous NaHCO3 saturated solution (3- 
times), followed by brine. The Organic layer was than dried over sodium sulfate and 







Phosphonates were synthesized according to method A or B. In all cases starting materials 
(bromides) were fully consumed, while the low yields of desired phosphonates are the result 
of the generation of side products: Perkov products (in all cases) and bis-phosphonates (in the 
reactions of acetophenone-derived bromides with halogen or electron-withdrawing group at 
the para- position in the phenyl ring). 
 
Method A:  
To triethyl phosphite (3 mmol, 498 mg) stirred at 90
o
C under argon, was carefully added the 
crude bromide (dropwise, dissolved in minimum amount of CH2Cl2) and the reaction was 
stirred for 15-30 minutes (TLC control, CH2Cl2 was allowed to evaporate through needle). 
Upon consumption of the bromide, the excess of triethyl phosphite was removed over vacuum 
equipped with cold trap. The crude product was than purified by flash chromatography on 
silica gel using hexane/ethyl acetate as eluent (solvent ratio: 6/1 to 2/1).  
Method B:  
To a solution of crude bromide (~2.7 mmol) in CH3CN (15 ml) was added KI (3 mmol, 498 
mg) in one portion. The reaction was then stirred for 10 minutes at room temperature. Next, to 
the reaction mixture P(OEt)3 was added (4.5 mmol, 747 mg) in one portion and the reaction 
mixture was then brought to reflux and stirred for 0.5 – 2h. Upon consumption of the bromide 
(TLC), the reaction mixture was evaporated, dissolved in ethyl acetate (50 ml) and washed 
with water (2x) and brine (1x). The organic layer was then dried over sodium sulfate and 
evaporated.  The crude product was than purified by flash chromatography on silica gel using 






 was performed according to method A or B. In all cases, bis-fluorination was 




Method A:  
To the solution of -ketophosphonate (1 mmol) in CH3CN (5 ml, microwave vial) was added 
Selectfluor (1 mmol, 354 mg). The capped vial was subjected to microwave irradiation for 5-
10 minutes at 80 to 110
o
C. The reaction has to be stopped when optimum ratio of product to 
smarting material to byproduct is achieved (TLC analysis). Longer reaction times lead to 
increased amount of bis-fluorinated by-product whereas higher temperatures resulted in 
decomposition of the desired mono-fluorinated product. The reaction mixture was than 
evaporated and dissolved in ethyl acetate (20 ml). The organic layer was washed with 
aqueous NaHCO3 saturated solution (2- times), followed by brine. The Organic layer was 
than dried over sodium sulfate and evaporated. The desired product was then isolated using 
column chromatography on silica gel, using hexane/ethyl acetate as eluent (solvent ratio: 5/1 
to 2/1). 
 
                                                          
[
182
] During preparation of this manuscript an alternative preparation of a narrow scope of racemic 
mono-fluorinated ketophosphonates was reported: K. Radwan-Olszewska, F. Palacios, P. Kafarski, 




Method B:  
To the solution of -ketophosphonate (1 mmol) in CH3CN (15 ml) was added potassium tert-
butoxide (1.1 mmol, 123 mg) in one portion at 0
o
C. The reaction mixture was then brought to 
reflux over 30 minutes and then cooled down again to about 10
o
C. Next, N-
Fluorobenzenesulfonmide (NFSI, 1 mmol, 315 mg) was added in one portion. The reaction 
was stirred for 10 minutes at 10
o
C. Upon consumption of the starting material (TLC) the 
reaction mixture was evaporated, dissolved in ethyl acetate (20 ml). The organic layer was 
then washed with aqueous HCl (1M), 2 times), followed by brine, dried over sodium sulfate 
and evaporated. The desired product was then isolated from byproducts (bis-fluorination and 
condensations) using column chromatography on silica gel, using hexane/ethyl acetate as 
eluent (solvent ratio: 5/1 to 2/1). 




A pale yellow oil; 1H NMR (300.13 MHz, CDCl3): 1.24-1.29 (t, J = 14.0 
Hz, 6H), 3.66 (s, 1H), 3.73 (s, 1H), 4.10-4.27 (m, 4H), 7.29-7.41 (m, 2H), 
7.53-7.68 (m, 2H); 13C NMR (75.48 Hz, CDCl3)  16.19 (d, J = 6.6 Hz), 41.05, 42.75, 62.66 (d, J 
= 6.0 Hz), 118.94, 127.41, 129.75, 132.13, 133.65, 140.74, 195.01; 31P NMR (121.49 Hz, 
CDCl3) 19.59; HRMS (ESI) m/z calcd for C12H16BrO4P [M+H]
+ = 333.9970 (279.0762 – Br), 
found = 279.0759. 
 
                                                          
[
183
] NMR analysis of other phosphonates was identical with the published data; for details see: a) R‟ = 
p-OMe-C6H4-: Luke, G. P.; Seekamp, C. K.; Wang, Z.-Q.; Chenard, B. L. J.Org. Chem. 2008, 73, 
6397; Kim, D. Y.; Choi, Y. J. Synth. Comm. 1998, 28, 1491; b) R‟ = p-Br-C6H4-: Moorhoff, C. M. 
Synth. Comm. 2003, 33, 2069; c) R‟ = Et : Loreto, M. A.; et al., J. Org. Chem. 2006, 71, 2163; 
Coutrot, P.; Grison, C. Tetrahedron: lett. 1988, 29, 2655; d) R‟ = t-Bu : Sampson, P.;  Hammond, 
G. B.; Wiemer, D. F.  J.Org. Chem. 1986, 51, 4342; e) R‟ = C6H5-: Radwan-Olszewska, K.; 
Palacios, F.; Kafarski, P. J. Org. Chem. 2011, 76, 1170; f) R‟ = p-F-C6H4-: Yuen, C.; Xie, R. 
Phosphorus, Sulfur and Silicon and the Related Elements 1994, 1-4, 47-51.   
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 Diethyl (2-(2-bromophenyl)-1-fluoro-2-oxoethyl)phosphonate;  
A pale yellow oil; 1H NMR (300.13 MHz, CDCl3): 1.23-1.27 (t, J = 7.0 
Hz, 3H), 1,31-1.36 (t, J = 7.0 Hz, 3H), 4.10-4.27 (m, 4H), 5.89-5.6.09 (dd, 
J = 13.3 Hz, 47.4 Hz, 1H), 7.46 (t, J = 15.3 Hz, 2H), 7.59-7.64 (d, J = 7.6 Hz, 1H), 8.01-8.04 (d, J 
= 7.6 Hz, 2H); 13C NMR (75.48 Hz, CDCl3)  16.15 (d, J = 6.0 Hz), 16.25 (d, J = 6.0 Hz), 64.25 (d, 
J = 7.1 Hz), 87.93, 90.24 (d, J = 43.9 Hz), 92.56, 128.57, 129.27, 129.31, 134.24, 191.18 (d, J = 
16.5 Hz); 31P NMR (121.49 Hz, CDCl3) 10.66 (d, J = 71.1 Hz); 
19F NMR (282.38 Hz, CDCl3) 
131.86 (d, J = 47.3 Hz), -131.61 (d, J = 47.3 Hz); HRMS (ESI) m/z calcd for C12H15BrFNaO4P 
[M+Na]+ = 374.9773, found = 374.9764. 
Diethyl (2-(4-bromophenyl)-2-oxoethyl)phosphonate 
A pale yellow oil; 1H NMR (300.13 MHz, CDCl3): 1.19-1.24 (t, J = 7.0 
Hz, 6H), 3.50 (s, 1H), 3.58 (s, 1H), 4.04-4.09 (m, 4H), 7.53-7.56 (d, J = 
8.6 Hz, 2H), 7.80-7.83 (d, J = 8.6 Hz, 2H); 13C NMR (75.48 Hz, CDCl3)  16.05 (d, J = 6.0 Hz), 
37.51, 39.23, 62.62 (d, J = 6.0 Hz), 128.85, 130.41, 131.73, 135.04, 135.06, 190.74 (d, J = 6.6 
Hz); 31P NMR (121.49 Hz, CDCl3) 20.11. 
Diethyl (2-(4-bromophenyl)-1-fluoro-2-oxoethyl)phosphonate;  
A pale yellow oil; 1H NMR (300.13 MHz, CDCl3): 1.33 (t, J = 7.7 Hz, 
3H), 1.39 (t, J = 7.1 Hz, 3H), 4.19-4.31 (m, 4H), 5.93 (dd, J = 13.5 Hz, 
47.4 Hz, 1H), 7.68 (d, J = 8.7 Hz, 2H), 7.96 (d, J = 8.0 Hz, 2H); 13C NMR (75.48Hz) : 16.26 (t, J 
= 5.5 Hz), 64.34, 64.43, 91.18 (dd, J = 152.1 Hz, 197.1 Hz), 129.76, 130.84, 130.89, 131.97, 
132.89, 190.46 (d, J = 17.0 Hz); 31P NMR (121.49 Hz, CDCl3) 10.42 (d, J = 71.1 Hz); 
19F NMR 
(282.38 Hz, CDCl3) 131.05 (dd, J = 47.4 Hz, 71.1 Hz); HRMS (ESI) m/z calcd for 
C12H15BrFNaO4P [M+Na]




A pale yellow oil; 1H NMR (300.13 MHz, CDCl3): 1.24 (t, J = 7.4 Hz, 
3H), 1.30 (t, J = 7.1 Hz, 3H), 4.11-4.21 (m, 4H), 5.90, (dd, J = 13.5 Hz, 
47.4 Hz, 1H), 7.12 (t, J = 8.85 Hz, 2H), 8.03-8.08 (m, 2 H); 13C NMR 
(75.48 Hz, CDCl3)  16.11 (t, J = 5.5 Hz), 64.16 (d, J = 2.2 Hz), 64.25 (d, J = 2.7 Hz), 90.35 (dd, J 
= 152.1 Hz, 197.1 Hz), 115.72 (d, J = 22.0 Hz), 130.54, 132.11 (d, J = 3.3 Hz), 132.24 (d, J = 3.8 
Hz), 164.54, 167.95, 189.62 (d, J = 17.0 Hz); 31P NMR (121.49 Hz, CDCl3) 10.56 (d, J = 72.6 
Hz) ; 19F NMR (282.38 Hz, CDCl3) 26.71-(-26.68)(m), -130.98 (dd, J = 47.4 Hz, 72.2 Hz); 
HRMS (ESI) m/z calcd for C12H16F2O4P [M+H]
+ = 293.0676, found = 293.0741. 
Diethyl (2-(4-cyanophenyl)-2-oxoethyl)phosphonate; 
A pale-yellow oil; 1H NMR (300 MHz, CDCl3): 1.24 (t, J = 7.0 Hz, 
6H), 3.60 (d, J = 22.8 Hz), 4.06-4.11 (m, 4H), 7.74 (d, J = 8.4 Hz, 2H), 
8.08 (d, J = 8.4 Hz, 2H); 13C NMR (75.48 Hz, CDCl3 16.08 (d, J = 6.0 Hz), 37.98, 39.69, 62.76 
(d, J = 6.6 Hz), 116.66, 117.65, 129.33, 132.29, 139.23, 190.65 (d, J = 6.6 Hz); 31P NMR 
(121.49 Hz, CDCl3) 19.24; HRMS (ESI) m/z calcd for C13H17NO4P [M+H]
+ = 282.0817, found = 
282.0878. 
Diethyl (2-(4-cyanophenyl)-1-fluoro-2-oxoethyl)phosphonate;  
A pale-yellow oil; 1H NMR (300 MHz, CDCl3): 1.25-1.38 (m, 6H), 
4.18-4.25 (m, 4H), 5.87 (dd, J = 14.0 Hz, 47.5 Hz, 1H), 7.79 (d, J = 
8.7 Hz, 2H), 8.15 (d, J = 8.04, 2H); 13C NMR (75.48Hz)  16.20 (d, J 
= 3.3 Hz), 16.28 (d, J = 3.3 Hz), 64.49 (d, J = 2.7 Hz), 64.59 (d, J = 3.3 Hz), 90.93 (dd, J = 152.1 
Hz, 198.2 Hz), 117.29, 117.64, 129.82, 129.87, 132.30, 137.17 (d, J = 1.6 Hz), 190.76 (d, J = 
18.1 Hz); 31P NMR (121.49 Hz, CDCl3) 9.92 (d, J = 71.1 Hz); 
19F NMR (282.38 Hz, CDCl3) -
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131.04 (dd, J = 47.4 Hz, 71.1 Hz); HRMS (ESI) m/z calcd for C13H16FNO4P [M+H]
+ = 300.0723, 
found = 300.0783. 
Diethyl (2-(3,4-dichlorophenyl)-2-oxoethyl)phosphonate 
A colourless oil; 1H NMR (300 MHz, CDCl3): 1.28 (t, J = 7.0 Hz, 6H), 
3.57 (d, J = 23.0 Hz, 1H), 4.08-4.18 (m, 4H), 7.55 (d, J = 8.4 Hz, 1H), 
7.84 (dd, J = 2.0 Hz, 8.4 Hz, 1H), 8.09 (s, 1H); 13C NMR (125.77 Hz, CDCl3)  15.97 (d, J = 6.4 
Hz), 37.95, 38.94, 62.53, 127.95, 130.42, 130.69, 132.97, 135.69, 137.93, 137.98, 189.52 (d, J 
= 7.3 Hz); 31P NMR (121.49 Hz, CDCl3) 19.46; HRMS (ESI) m/z calcd for C12H16Cl2O4P [M+H]
+ 
= 325.0085, found = 325.0158. 
Diethyl (2-(3,4-dichlorophenyl)-1-fluoro-2-oxoethyl)phosphonate 
A White solid; 1H NMR (300 MHz, CDCl3): 1.26-1.31 (t, J = 7.2 Hz, 
3H), 1.31-1.36 (t, J = 7.1 Hz, 3H), 4.13-4.28 (m, 4H), 5.75-5.95 (dd, J 
= 13.7 Hz, 47.4 Hz, 1H), 7.54-7.56 (d, J = 8.4 Hz, 1H), 7.86-7.89 (dd, J = 2.0 Hz, 8.4 Hz, 1H), 
8.11 (d, J = 1.7, 1H); 13C NMR (75.48 Hz, CDCl3)  16.16 (d, J = 3.8), 16.24 (d, J = 3.3 Hz), 64.36 
(d, J = 3.3 Hz), 64.45 (d, J = 2.7 Hz), 88.28, 90.60 (d, J = 45.0 Hz), 92.92, 128.47 (d, 3.8 Hz), 
130.65, 131.18, 131.23, 133.30, 133.52, 138.92, 189.43 (d, J = 17.6 Hz); 31P NMR (121.49 Hz, 
CDCl3) 10.09 (d, J = 71.0 Hz); 
19F NMR (282.38 Hz, CDCl3) 131.08 (dd, J = 47.3 Hz, 71.7 
Hz); HRMS (ESI) m/z calcd for C12H15Cl2FO4P  [M+H]
+ = 342.9991, found = 343.0051. 
Diethyl (2-oxo-2-(phenanthren-2-yl)ethyl)phosphonate; 
An orange oil; 1H NMR (300 MHz) : 1.23 (t, J = 6.9 Hz, 6H), 3.76 (d, J 
= 22.7 Hz, 2H), 4.08-4.17 (m, 4H), 7.56-7.82 (m, 6H), 8.08 (d, J = 8.2 
Hz, 1H), 8.68 (d, J = 6.2 Hz, 1H), 9.29 (s, 1H); 13C NMR (75.48Hz)  
16.00, 16.08, 37.76, 39.48, 62.49, 62.57, 122.50, 124.86, 125.43, 125.87, 127.00, 127.16, 
127.75, 128.54, 128.57, 129.84, 130.35, 131.84, 133.76, 134.97, 191.63 (d, J = 6.6 Hz); 31P 
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NMR (121.49 Hz) : 20.94; HRMS (ESI) m/z calcd for C20H22O4P [M+H]
+ = 357.1177, found = 
357.1246. 
Diethyl (1-fluoro-2-oxo-2-(phenanthren-2-yl)ethyl)phosphonate;  
A white solid; 1H NMR (500 MHz, CDCl3): 1.24-1.27 (t, J = 7.5 Hz, 
3H), 1.34-1.37 (t, J = 7.0, 3H), 4.16-4.28 (m, 2H), 4.29-4.31 (m, 2H), 
6.12-6.24 (dd, J = 13.2 Hz, 47.3 Hz, 1H), 7.65-7.68 (m, 1H), 7.74-7.76 (m, 2H), 7.87-7.96 (m, 
3H), 8.19-8.20 (d, J = 8.2 Hz, 1H), 8.78-8.80 (d, J = 8.2 Hz, 1H), 9.48 (s, 1H); 13C NMR (125.77 
Hz, CDCl3)  16.24 (d, J = 5.5 Hz), 16.34 (d, J = 6.4 Hz), 64.33 (d, J = 6.4 Hz), 64.41 (d, J = 6.4 
Hz), 89.40, 90.78 (d, J = 44.0 Hz), 92.17, 122.89, 125.71, 126.16, 127.39, 127.61, 128.84, 
128.87, 130.53, 132.17, 135.71, 191.05 (d, J = 17.4 Hz); 31P NMR (202.45 Hz, CDCl3) 11.10 
(d, J = 71.9 Hz); 19F NMR (282.38 Hz, CDCl3) 130.76 (dd, J = 47.4 Hz, 72.2 Hz); HRMS (ESI) 
m/z calcd for C20H21FO4P [M+H]
+ = 375.1083, found = 375.1156. 
Diethyl (1-fluoro-3,3-dimethyl-2-oxobutyl)phosphonate 
A pale yellow oil; 1H NMR (300 MHz) : 1.24 (s, 9H), 1.33 (t, J = 4.6 Hz, 
3H), 1.37 (t, J = 4.6 Hz, 3H), 4.17-4.28 (m, 4H), 5.45 (dd, J = 14.1 Hz, 47.4 
Hz, 1H); 13C NMR (75.48Hz) : 16.26 (d, J = 1.6Hz), 16.34 (d, J = 1.1 Hz), 25.67 (d, J = 2.7 Hz), 
44.64, 63.85 (d, J = 6.6 Hz), 64.06 (d, J = 7.1 Hz), 88.05, 90.11, 90.70, 92.76, 207.35 (d, J = 
15.9 Hz); 31P NMR (121.49 Hz) : 11.83 (d, J = 71.1 Hz); 19F NMR (282.38 Hz: -128.54 (dd, J 
= 47.3 Hz, 71.7 Hz); HRMS (ESI) m/z calcd for C10H21FO4P [M+H]





IV-3.2. Representative procedure for Michael addition 
 
 
                               
To a sample vial containing the -fluoro--ketophosphonate (0.05 mmol), toluene (0.5 ml) 
was added, followed by the catalyst II-3.9 (0.005 mmol, 3.5 mg) (or II-3.8, 0.005 mmol, 3.4 
mg). The vial was then capped and the reaction mixture was stirred for 5 minutes. Next, the 
nitroalkene (0.06 mmol) was added and the reaction mixture was stirred at room temperature 
for a given period (Table 3). At the end of the reaction, the mixture was subjected directly to 
flash column chromatographic separation using a mixture of hexane/ethyl acetate (10 : 1 to 7 : 
1) as the eluent to afford the Michael addition products (II-3.2ab-ke). 
IV-3.3. Analytical data of the Michael Reaction Products 
 
Diethyl (2-fluoro-4-nitro-1-oxo-1,3-diphenylbutan-2-yl)phosphonate (II-3.2aa);  
 
 
A pale-yellow oil; *α+27D = -18.0 (c 1, CHCl3);  
1H NMR (300 MHz, CDCl3):  1.12-1.17 (t, J = 7.1 
Hz, 3H), 1.25-1.29 (t, J = 7.0 Hz, 3H), 3.91-4.12 (m, 4H), 4.55-4.70 (m, 1H), 5.02-5.05 (m, 2H), 
7.25-7.42 (m, 7H), 7.53-7.58 (m,  1H), 7.78-7.80 (m, 2H); 13C NMR (125.77 Hz, CDCl3)  16.07 
(d, J = 5.5 Hz), 16.34 (d, J = 5.5 Hz), 48.56 (dd, J = 2.7 Hz, 21.1 Hz), 64.40 (d, J = 7.3 Hz), 64.8 
(d, J = 6.4 Hz), 75.6 (t, J = 7.3 Hz), 102.72 (dd, J = 48.6 Hz, 158.6 Hz), 128.29, 128.63, 128.77, 
129.76, 129.83, 129.92, 133.70, 197.66 (dd, J = 1.8 Hz, 22.9 Hz); 31P NMR (121.49 Hz, CDCl3) 
11.57 (d, J = 78.5 Hz); 19F NMR (282.38 Hz, CDCl3) -97.28 (dd, J = 24.8 Hz, 78.4 Hz); HRMS 
183 
 
(ESI) m/z calcd for C20H23FNO6P [M+H]
+ = 424.1247, found = 424.1322; the ee value was 99%, 
tR (major) = 32.8 min, tR (minor) = 34.9 min (Chiralcel IA-H, λ = 220 nm, 5% iPrOH/hexanes, 




A pale-yellow oil; *α+27D = -71 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3):  1.22 (t, J = 6.9 Hz, 
3H), 1.39 (t, J = 6.9 Hz, 3H), 4.09-4.26 (m, 2H), 4.27-4.32 (m, 2H), 5.03-5.08 (m, 1H), 5.04-5.44 
(m, 2H), 7.11-7.14 (m, 1H), 7.17-7.20 (m, 1H), 7.26-7.27 (m, 1H), 7.36 (t, J = 7.5 Hz, 2H), 7.52 
(t, J = 7.6 Hz, 1H), 7.61-7.63 (m, 1H), 7.74 (d, J = 8.1 Hz, 2H); 13C NMR (125.77 Hz, CDCl3)  
16.21 (d, J = 5.5 Hz), 16.47 (d, J = 5.5 Hz), 46.09 (d, J = 22.0 Hz), 64.80 (d, J = 6.4 Hz), 65.35 (d, 
J = 7.3 Hz), 75.90 (d, J = 6.4 Hz), 102.34 (dd, J = 156.7 Hz, 206.2 Hz), 127.54, 127.76, 128.22, 
128.89, 129.83, 129.90, 130.00, 133.59, 133.70, 133.80, 135.66, 197.80 (d, J = 22.9 Hz); 31P 
NMR (121.49 Hz, CDCl3) 11.41 (d, J = 78.5 Hz); 
19F NMR (282.38 Hz, CDCl3) -94.72 (dd, J = 
13.7 Hz, 79.3 Hz); HRMS (ESI) m/z calcd for C20H22BrFNO6P [M+H]
+ = 502.0352, found = 
502.0429; the ee value was 97%, tR (major) = 21.4 min, tR (minor) = 19.3 min (Chiralcel IA-H, 










A pale-yellow oil; *α+27D = -28.1 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.16-1.19 (t, J = 
13.85 Hz, 3H), 1.32-1.35 (t, J = 14.5 Hz, 3H), 4.01-4.24 (m, 4H), 5.03-5.08 (m, 2H), 5.14-5.16 
(m, 1H), 7.04-7.09 (m, 2H), 7.27-7.33 (m, 2H), 7.38-7.41 (m, 2H), 7.54-7.57 (m, 1H), 7.82-7.83 
(d, J = 1.9 Hz, 2H); 13C NMR (125.77 Hz, CDCl3)  16.07 (d, J = 5.51 Hz), 16.28 (d, J = 5.5 Hz), 
29.67, 41.23 (d, J = 21.98 Hz), 64.69 (d, J = 6.4 Hz), 65.09 (d, J = 7.3 Hz), 74.82 (t, J = 5.5 Hz), 
102.39 (dd, J = 157.6 Hz, 206.2 Hz), 116.00 (d, J = 22.9 Hz), 124.28 (d, J = 3.7 Hz), 128.30, 
129.82, 129.88, 130.11, 130.45, 130.52, 133.78, 135.40, 160.51, 162.50, 197.48 (d, J = 24.8 
Hz); 31P NMR (121.49 Hz, CDCl3) 11.22 (d, J = 80.0 Hz); 
19F NMR (282.38 Hz, CDCl3) -38.23 
(m), -97.09 (m). HRMS (ESI) m/z calcd for C20H22F2NO6P [M+H]
+ = 442.1153, found = 
442.1236; the ee value was 98%, tR (major) = 32.5 min, tR (minor) = 35.3 min (Chiralcel IA-H + 




A pale-yellow oil; [α+27D = -33.8 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): t, J = 14.5 
Hz, 3H), 1.41-1.43 (t, J = 14.5 Hz, 3H), 4.08-4.23 (m, 2H), 4.31-4.37 (m, 2H), 5.09-5.14 (d, J = 
8.8 Hz, 2H), 5.74-5.76 (d, J = 8.8 Hz, 1H), 7.31-7.40 (m, 5H), 7.49-7.52 (m, 1H), 7.65-7.66 (d, J 
= 7.6, 2H), 7.72-7.71 (m, 1H); 13C NMR (125.77 Hz, CDCl3)  16.13 (d, J = 6.4 Hz), 16.34 (d, J = 
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5.5 Hz), 43.38 (d, J = 23.8 Hz), 64.96 (d, J = 7.3 Hz), 65.52 (d, J = 7.3 Hz), 76.69, 101.10 (dd, J = 
155.8 Hz, 207.13 Hz), 122.77, 124.96, 127.30, 128.20 (d, J = 1.8 Hz), 128.85, 129.88 (d, J = 8.2 
Hz), 131.15 (d, J = 29.3 Hz), 132.15, 133.00 (d, J = 11.9 Hz), 133.73, 135.93 (d, J = 3.7 Hz), 
198.41 (d, J = 23.8 Hz); 31P NMR (121.49 Hz, CDCl3) 11.68 (d, J = 77.0 Hz); 
19F NMR (282.38 
Hz, CDCl3) 19.12 (d, J = 13.4 Hz), -91.44 (m); HRMS (ESI) m/z calcd for C21H22F4NO6P [M+H]
+ 
= 492.1121, found = 492.1205; the ee value was 96%, tR (major) = 52.7 min, tR (minor) = 57.3 




A pale-yellow oil; [α+27D = -28.5 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.13-1.16 (t, J = 6.9 
Hz, 3H), 1.26-1.29 (t, J = 6.9 Hz, 3H), 3.96-4.02 (m, 2H), 4.04-4.14 (m, 2H), 4.56-4.65 (m, 1H), 
4.96-4.98 (m, 2H), 7.23-7.25 (d, J = 8.2 Hz, 2H), 7.41-7.45 (m, 4H), 7.56-7.59 (t, J = 7.6 Hz, 
1H), 7.85-7.86 (m, 2); 13C NMR (125.77 Hz, CDCl3)    16.05 (d, J = 5.5 Hz), 16.30 (d, J = 5.5 
Hz), 48.05 (d, J = 2.75), 48.21 (d, J = 2.75 Hz), 64.57 (d, J = 6.4 Hz), 64.88 (d, J = 6.4 Hz), 75.37, 
102.64 (dd, J = 49.5 Hz, 158.6 Hz), 123.02, 128.41, 129.91, 129.87, 131.56, 131.58, 131.75, 
132.28, 132.33, 133.95, 197.25 (d, J = 22.9 Hz); 31P NMR (121.49 Hz, CDCl3) 11.24 (d, J = 
77.0 Hz); 19F NMR (282.38 Hz, CDCl3) -98.23 (dd, J = 25.8 Hz, 78.3 Hz); HRMS (ESI) m/z calcd 
for C20H22BrFNO6P [M+H]
+ = 524.0250, found = 524.0254; 526.0242; the ee value was 99%, tR 
(major) = 24.0 min, tR (minor) = 29.9 min (Chiralcel IA-H, λ = 220 nm, 10% iPrOH/hexanes, 






A pale-yellow oil; [α+27D = -10.0 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): t, J = 14.5 
Hz, 3H), 1.27-1.29 (t, J = 13.8 Hz, 3H), 3.96-4.03 (m, 2H), 4.05-4.13 (m, 2H), 4.56-4.64 (m, 1H), 
4.95-4.96 (m, 2H), 7.15-7.18 (t, J = 8.2 Hz, 1H), 7.28-7.30 (d, J = 7.6 Hz, 1H), 7.40-7.43 (m, 
2H), 7.53-7.58 (m, 2H); 13C NMR (125.77 Hz, CDCl3)  15.97-16.02 (d, J = 6.4 Hz), 16.23-16.28 
(d, J = 5.5 Hz), 48.11-48.27 (d, J = 20.2 Hz), 64.51-64.56 (d, J = 6.4 Hz), 64.79-64.85 (d, J = 7.3 
Hz), 75.28-75.39 (t, J = 6.4 Hz, 14.7 Hz), 102.67 (dd, J = 157.6 Hz, 208.1 Hz), 122.45, 128.34, 
128.59, 129.78-129.84 (d, J = 8.3 Hz), 130.01, 131.81, 132.92, 133.88, 135.27, 135.57-135.62 
(d, J = 6.4 Hz), 197.11-197.30 (d, J = 23.8 Hz); 31P NMR (121.49 Hz, CDCl3) 11.11 (d, J = 78.5 
Hz); 19F NMR (282.38 Hz, CDCl3) -98.53 (dd, J = 25.9 Hz, 77.8 Hz); HRMS (ESI) m/z calcd for 
C20H22BrFNNaO6P [M+Na]
+= 524.0250, found = 524.0242; the ee value was 99%, tR (major) = 
43.6 min, tR (minor) = 40.9 min (Chiralcel IA-H, λ = 220 nm, 5% iPrOH/hexanes, flow rate = 
0.75 mL/min). 
Diethyl (2-fluoro-4-nitro-1-oxo-1-phenyl-3-(p-tolyl)butan-2-yl)phosphonate (II-3.2ag); 
 
A pale-yellow oil; [α+27D = -27.8 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.14-1.17 (t, J = 14.5 
Hz, 3H), 1.26-1.29 (t, J = 16.4 Hz, 3H), 2.29 (s, 3H), 3.92-4.14 (m, 4H), 4.53-4.60 (m, 1H), 4.99-
5.07 (m, 2H), 7.09-7.10 (d, J = 7.6 Hz, 2H), 7.22-7.23 (d, J = 7.6 Hz, 2H), 7.37-7.40 (m, 2H), 
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7.53-7.56 (m, 1H), 7.79-7.80 (m, 2H); 13C NMR (125.77 Hz, CDCl3)  16.06 (d, J = 6.4 Hz), 
16.32 (d, J = 5.5 Hz), 21.06, 48.25 (dd, J = 2.7 Hz, 21.0 Hz), 64.38 (d, J = 7.3 Hz), 64.77 (d, J = 
7.3 Hz), 75.70, 102.73 (dd, J = 48.6 Hz, 158.6Hz), 128.25, 129.30, 129.70, 129.75, 129.82, 
129.97, 130.03, 133.64, 138.64, 197.73 (d, J = 21.0 Hz); 31P NMR (121.49 Hz, CDCl3) 11.69 
(d, J = 78.5 Hz); 19F NMR (282.38 Hz, CDCl3) -97.03 (dd, J = 23.7 Hz, 77.3 Hz); HRMS (ESI) 
m/z calcd for C21H25FNNaO6P [M+Na]
+= 460.1401, found = 460.1302; the ee value was 99%, 
tR (major) = 17.1 min, tR (minor) = 18.6 min (Chiralcel IA-H, λ = 220 nm, 10% iPrOH/hexanes, 




A pale-yellow oil; [α+27D = -69.5 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): t, J = 13.9 
Hz, 3H), 1.29-1.31 (t, J = 13.9 Hz, 3H), 3.96-4.14 (m, 4H), 5.20-5.25 (dd, J = 10.8 Hz, 13.9 Hz, 
1H), 5.40-5.44 (dd, J = 3.2 Hz, 13.9 Hz, 1H), 5.71-5.79 (m, 1H), 7.34-7.38 (m, 3H), 7.39-7.56 
(m, 3H), 7.64-7.67 (m, 1H), 7.71-7.72 (d, J = 7.6 Hz, 2H), 7.81-7.83 (d, J = 8.2 Hz, 1H), 7.86-
7.88 (d, J = 8.2 Hz, 1H), 8.34-8.35 (d, J = 8.2 Hz, 1H); 13C NMR (125.77 Hz, CDCl3)  16.09 (d, J 
= 6.4 Hz), 16.30 (d, J = 5.5 Hz), 41.29 (d, J = 22.0 Hz), 64.52 (d, J = 7.3 Hz), 64.88 (d, J = 7.3 
Hz), 76.38 (t, J = 5.5 Hz), 103.03 (dd, J = 157.64 Hz, 206.2 Hz), 123.70, 124.87, 125.82 (d, J = 
1.8 Hz), 126.00, 126.63, 128.19, 128.67, 129.42, 129.85 (d, J = 8.2 Hz), 130.34 (d, J = 8.2 Hz), 
133.08, 133.62, 133.92, 135.67 (d, J = 2.8 Hz), 198.14 (d, J = 22.9 Hz); 31P NMR (121.49 Hz, 
CDCl3) 11.77 (d, J = 79.5 Hz); 
19F NMR (282.38 Hz, CDCl3) 95.83 (dd, J = 18.3 Hz, 79.3 Hz); 
HRMS (ESI) m/z calcd for C24H25FNNaO6P [M+Na]
+= 496.1301, found = 496.1303; the ee value 
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was 98%, tR (major) = 40.1 min, tR (minor) = 35.4 min (Chiralcel IA-H, λ = 220 nm, 5% 
iPrOH/hexanes, flow rate = 1 mL/min). 
Diethyl (2-fluoro-3-(furan-2-yl)-4-nitro-1-oxo-1-phenylbutan-2-yl)phosphonate (II-3.2ai); 
 
A pale-yellow oil; [α+27D = -7.1 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.26-1.29 (t, J = 
13.8Hz, 3H), 1.37-1.40 (t, J = 14.5 Hz, 3H), 4.12-4.30 (m, 4H), 4.70-4.77 (m, 1H), 5.04-5.10 
(dd, J = 13.9 Hz, 1H), 5.19-5.22 (dd, J = 3.8 Hz, 13.9 Hz, 1H), 6.31-6.32 (d, J = 3.8 Hz, 1H), 6.38-
6.39 (d, J = 3.8 Hz, 1H), 7.32 (s, 1H), 7.42-7.45 (t, J = 15.8 Hz, 2H), 7.57-7.60 (t, J = 15.1 Hz, 
1H), 7.84-7.85 (d, J = 6.3 Hz, 2H); 13C NMR (125.77 Hz, CDCl3)  16.16-16.22 (d, J = 6.4 Hz), 
16.34-16.38 (d, J = 5.5 Hz), 29.67, 42.99, 64.79-64.84 (d, J = 7.3 Hz), 65.10-65.16 (d, J = 7.3 
Hz), 74.24, 100.94 (dd, J = 48.6 Hz, 158.6 Hz), 110.73, 111.17, 128.25, 129.69, 129.75, 
133.66, 143.10, 146.83, 146.92, 196.94-197.13 (d, J = 22.9 Hz); 31P NMR (121.49 Hz, CDCl3) 
11.41 (d, J = 78.5 Hz); 19F NMR (282.38 Hz, CDCl3) -93.68 (dd, J = 18.6 Hz, 78.4 Hz); HRMS 
(ESI) m/z calcd for C18H22FNO7P [M+H]
+= 414.1040, found = 414.1112; the ee value was 99%, 
tR (major) = 15.0 min, tR (minor) = 17.2 min (Chiralcel IA-H, λ = 220 nm, 10% iPrOH/hexanes, 









Diethyl (2-fluoro-4-nitro-1-oxo-1-phenyl-3-(thiophen-2-yl)butan-2-yl)phosphonate ( II-
3.2aj); 
 
A pale-yellow oil; [α+27D = -30.1 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.22-1.25 (t, J = 13.9 
Hz, 3H), 1.33-1.36 (t, J = 13.9 Hz, 3H), 4.04-4.24 (m, 4H), 4.93-4.95 (m, 1H), 4.98-5.05 (m, 1H), 
5.13-5.16 (m, 1H), 6.95-6.96 (d, J = 1.85 Hz, 1H), 7.08-7.09 (d, J = 3.8 Hz, 1H), 7.27-7.28 (d, J = 
5.1 Hz, 1H), 7.42-7.45 (m, 2H), 7.57-7.60 (t, J = 7.6 Hz, 1H), 7.88-7.90 (d, J = 8.2 Hz, 2H); 13C 
NMR (75.48 Hz, CDCl3)  16.11 (d, J = 6.0 Hz), 16.36 (d, J = 5.5 Hz), 29.67, 44.45 (d, J = 2.7 Hz), 
44.74 (d, J = 2.7 Hz), 64.81 (q, J = 7.1 Hz, 26.9 Hz), 102.06 (dd, J = 156.4 Hz, 207.0 Hz), 126.58, 
126.80, 128.30, 128.32, 129.01, 129.85 (d, J = 8.2 Hz), 133.82, 134.91 (d, J = 8.8 Hz); 31P NMR 
(121.49 Hz, CDCl3) 11.38 (d, J = 78.5 Hz); 
19F NMR (282.38 Hz, CDCl3) (dd, J = 21.6 
Hz, 77.3 Hz); HRMS (ESI) m/z calcd for C18H22FNO6PS [M+H]
+= 430.0811, found = 430.0889; 
the ee value was 99%, tR (major) = 32.1 min, tR (minor) = 36.6 min (Chiralcel IA-H, λ = 220 




A pale-yellow oil; [α+27D = 4.6 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 0.85-0.86 (d, J = 6.3 
Hz, 3H), 0.88-0.90 (d, J = 6.3 Hz, 3H), 0.91-0.94 (m, 1H), 1.30-1.32 (t, J = 7.0 Hz, 3H), 1.34-1.36 
(t, J = 13.8 Hz, 3H), 3.36-3.46 (m, 1H), 4.17-4.28 (m, 4H), 4.41-4.45 (dd, J = 6.3 Hz, 14.5 Hz, 
1H), 5.18-5.22 (dd, J = 3.8 Hz, 13.8 Hz, 1H), 7.46-7.49 (m, 2H), 7.59-7.60 (m, 1H), 8.02-8.04 
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(d, J = 8.2 Hz, 1H); 13C NMR (125.77 Hz, CDCl3)  16.27 (d, J = 7.33), 16.35, 21.31, 23.33, 
25.51, 38.11 (d, J = 6.4 Hz),   41.11 (d, J = 21.1 Hz), 64.63 (d, J = 7.3 Hz), 64.88 (d, J = 7.3 Hz), 
103.05 (dd, J = 157.6 Hz, 202.6 Hz), 128.42, 129.86, 129.93, 133.81, 197.37 (d, J = 25.7 Hz); 
31P NMR (121.49 Hz, CDCl3) 12.63 (d, J = 80.0 Hz); 
19F NMR (282.38 Hz, CDCl3) (dd, J 
= 16.8Hz, 80.9 Hz); HRMS (ESI) m/z calcd for C18H28FNO6P [M+H]
+= 404.1560, found = 
404.1637; the ee value was 96%, tR (major) = 49.1 min, tR (minor) = 38.7 min (Chiralcel IC, λ = 




A pale-yellow oil; [α+27D = -16.5 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 1.13-1.16 (t, J = 7.0 
Hz, 3H), 1.26-1.28 (t, J = 7.0 Hz, 3H), 3.89-4.12 (m, 4H), 4.58-4.66 (m, 1H), 5.03-5.06 (m, 2H), 
7.29-7.30 (m, 2H), 7.35-7.40 (m, 4H), 7.53-7.56 (m, 1H), 7.78-7.80 (d, J = 8.2 Hz, 2H); 13C NMR 
(125.77 Hz, CDCl3) 16.05 (d, J = 5.5 Hz), 16.32 (d, J = 5.5 Hz), 48.57 (dd, J = 2.74 Hz, 21.1 Hz), 
64.39 (d, J = 6.4 Hz), 64.77 (d, J = 7.3 Hz), 75.60 (t, J = 7.3 Hz), 102.71 (dd, J = 158.6 Hz, 207.1 
Hz), 128.27, 128.61, 128.74, 129.75, 129.82, 129.91, 133.68, 197.63 (d, J = 22.9 Hz); 31P NMR 
(121.49 Hz, CDCl3) 11.57 (d, J = 77.0 Hz); 
19F NMR (282.38 Hz, CDCl3) -97.23 (dd, J = 24.74 
Hz, 78.4 Hz); HRMS (ESI) m/z calcd for C20H22BrFNNaO6P [M+Na]
+= 524.0250, found = 
524.0242; the ee value was 99%, tR (major) = 20.3 min, tR (minor) = 23.1 min (Chiralcel IB, λ = 








A pale-yellow oil; [α+27D = -29.9 (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): 1.12-1.17 (t, J = 7.1 
Hz, 3H), 1.26-1.30 (t, J = 7.0 Hz, 3H), 3.91-4.17 (m, 4H), 4.45-4.60 (m, 1H), 4.96-5.11 (m, 2H), 
7.26 (s, 5H), 7.60-7.63 (d, J = 8.7 Hz, 2H), 7.72-7.74 (m, 2 H); 13C NMR (75.48 Hz, CDCl3) 
16.13 (d, J = 6.0 Hz), 16.38 (d, J = 6.0 Hz), 22.68, 31.23, 48.41 (dd, J = 2.2 Hz, 21.4 Hz), 64.67 
(d, J = 7.1 Hz), 65.24 (d, J = 7.1 Hz), 75.21, 101.12 (dd, J = 157.6 Hz, 204.22 Hz), 117.18 (d, J = 
70.3 Hz), 128.83, 129.02, 129.69, 129.98, 130.09, 131.93, 132.81, 132.92, 138.70, 197.28 (d, 
J = 24.7 Hz); 31P NMR (121.49 Hz, CDCl3) 11.01 (d, J = 78.5 Hz); 
19F NMR (282.38 Hz, CDCl3) 
96.25 (dd, J = 22.7 Hz, 78.4 Hz); HRMS (ESI) m/z calcd for C21H22FN2NaO6P [M+Na]
+= 
471.1097, found = 471.1104; the ee value was 99%, tR (major) = 24.1 min, tR (minor) = 23.1 
min (Chiralcel IB, λ = 220 nm, 20% iPrOH/hexanes, flow rate = 0.5 mL/min). 
Diethyl ((2R,3S)-2-fluoro-1-(4-methoxyphenyl)-4-nitro-1-oxo-3-phenylbutan-2-
yl)phosphonate (II-3.2fa);  
 
Colourless oil; [α+27D = -30.5 (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): 1.11-1.16 (t, J = 7.0 Hz, 
3H), 125-1.29 (t, J = 7.0, 3H), 3.85 (s, 3H), 3.91-4.11 (m, 4H), 4.54-4.69 (m, 1H), 5.01-5.04 (m, 
2H), 6.85-6.88 (d, J = 9.0 Hz, 2H), 7.26-7.36 (m, 5H), 7.86-7.87 (d, J = 2.0 Hz); 13C NMR (75.48 
Hz, CDCl3) 16.09 (d, J = 6.0 Hz), 16.34 (d, J = 5.5 Hz), 48.57 (d, J = 18.7 Hz), 55.49, 64.32 (d, J 
= 7.7 Hz), 64.62 (d, J = 7.1 Hz), 75.75, 100.43, 113.62, 113.64, 128.54, 128.66, 129.95, 129.97, 
132.57, 132.70, 133.31, 164.14, 194.95 (d, J = 22.0 Hz); 31P NMR (121.49 Hz, CDCl3) 11.96 
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(d, J = 77.0 Hz); 19F NMR (282.38 Hz, CDCl3) -96.56 (dd, J = 24.8 Hz, 78.4 Hz); HRMS (ESI) 
m/z calcd for C21H26FNO7P [M+H]
+= 454.1353, found = 454.1434; the ee value was 98%, tR 
(major) = 51.5 min, tR (minor) = 62.6 min (Chiralcel IA, λ = 220 nm, 5 % iPrOH/hexanes, flow 
rate = 1 mL/min). 
 Diethyl ((2R,3S)-2-fluoro-1-(4-fluorophenyl)-4-nitro-1-oxo-3-phenylbutan-2-yl)phosphonate 
(II-3.2da);  
 
A pale-yellow oil; [α+27D = -24.2 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.13-1.18 (t, J = 7.0 
Hz, 3H), 1.27-1.32 (t, J = 7.0 Hz, 3H), 3.98-4.11 (m, 4H), 4.54-4.65 (m, 1H), 5.02-5.07 (m, 2H), 
7.02-7.08 (t, J = 8.7 Hz, 2H), 7.28-7.31 (m, 5H), 7.83-7.84 (m, 2H); 13C NMR (125.77 Hz, CDCl3) 
16.08 (d, J = 5.5 Hz), 16.36 (d, J = 5.5 Hz), 48.48 (t, J = 21.1 Hz), 64.45 (d, J = 6.41 Hz), 64.90 
(d, J = 7.3 Hz), 75.51 (t, J = 6.4 Hz), 102.67 (dd, J = 157.65 Hz, 206.2 Hz), 115.55 (d, J = 11.0 
Hz), 128.66, 128.82, 129.83, 132.76, 132.83, 132.90, 165.99 (d, J = 128.3 Hz), 195.92 (d, J = 
22.9 Hz); 31P NMR (121.49 Hz, CDCl3) (d, J = 77.7 Hz); 
19F NMR (282.38 Hz, CDCl3) -
27.00 (m), -96.25 (dd, J = 23.7 Hz, 78.4 Hz); HRMS (ESI) m/z calcd for C20H23F2NO6P [M+H]
+= 
442.1153, found = 442.1225; the ee value was %, tR (major) = 30.3 min, tR (minor) = 32.6 min 










A pale beige solid; [α+27D = -32.6 (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): (t, J = 7.1 
Hz, 3H), 1.29-1.34 (t, J = 7.1 Hz, 3H), 3.92-4.19 (m, 4H), 4.50-4.64 (m, 1H), 4.99-5.13 (m, 2H), 
7.31 (s, 5H), 7.44-7.46 (d, J = 8.6 Hz, 1H), 7.57-7.80 (m, 1H), 7.81 (s, 1H); 13C NMR (75.48 Hz, 
CDCl3)  16.11 (d, J = 6.1 Hz), 16.37 (d, J = 6.1 Hz), 48.41 (dd, J = 2.3 Hz, 21.3 Hz), 64.57 (d, J = 
7.1 Hz), 65.10 (d, J = 7.1 Hz), 75.28 (t, J = 6.3 Hz), (dd, J = 158.1 Hz, 205.9 Hz), 128.78, 128.90, 
128.97, 129.74 (d, J = 1.1 Hz), 130.41, 131.65, 131.77, 132.83, 132.94, 134.78 (d, J = 3.8 Hz), 
138.54, 195.69 (d, J = 24.1 Hz); 31P NMR (121.49 Hz, CDCl3) (d, J = 77.0 Hz); 
19F NMR 
(282.38 Hz, CDCl3) -96.13 (dd, J = 22.7 Hz, 77.3 Hz); HRMS (ESI) m/z calcd for 
C20H22Cl2FNO6P [M+H]
+= 492.0468, found = 492.0540; the ee value was %, tR (major) = 33.6 
min, tR (minor) = 31.6 min (Chiralcel, ID, λ = 220 nm, 10% iPrOH/hexanes, flow rate = 1 
mL/min). 
Diethyl ((2R,3S)-1-(3,4-dichlorophenyl)-2-fluoro-3-(naphthalen-2-yl)-4-nitro-1-oxobutan-2-
yl)phosphonate (II-3.2im);  
 
A pale beige solid; [α+27D = -24.2 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.10-1.13 (t, J = 6.9 
Hz, 3H), 1.25-1.28 (t, J = 6.9 Hz, 3H), 3.93-4.12 (m, 4H), 4.71-4.80 (m, 1H), 5.15-5.16 (d, J = 
7.5 Hz, 2H), 7.40-7.43 (t, J = 7.5 Hz, 2H), 7.47-7.49 (m, 2H), 7.63-7.65 (d, J = 8.8 Hz, 1H), 7.78-
7.80 (d, J = 8.2 Hz, 4H), 7.88 (s, 1H); 13C NMR (125.77 Hz, CDCl3) 16.02 (d, J = 6.4 Hz), 16.31 
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(d, J = 5.5 Hz), 48.59 (d, J = 21.1 Hz), 64.60 (d, J = 6.4 Hz), 65.11 (d, J = 7.3 Hz), 75.43 (t, J = 6.4 
Hz), 103.53 (dd, J = 188.8 Hz, 205.3 Hz, 126.60 (d, J = 8.2 Hz), 126.74, 127.58, 127.98, 128.52, 
128.89 (d, J = 8.2 Hz), 129.58, 130.24, 130.30, 130.41, 131.72, 131.79, 132.99, 133.20, 
134.68, 138.58, 195.64 (d, J = 26.6 Hz); 31P NMR (121.49 Hz, CDCl3) 11.16 (d, J = 78.5 Hz); 
19F NMR (282.38 Hz, CDCl3) -96.23 (dd, J = 22.7 Hz, 77.3 Hz); HRMS (ESI) m/z calcd for 
C24H23Cl2FNNaO6P [M+Na]
+= 564.0522, found = 564.0527; the ee value was 99%, tR (major) = 





A pale-yellow oil; [α+27D = -8.5 (c 1, CHCl3); 
1H NMR (300.13 MHz, CDCl3): 1.29-1.32 (t, J = 7.0 
Hz, 3H), 1.32-1.35 (t, J = 7.0 Hz, 3H), 1.75-1.89 (m, 1H), 2.09-2.20 (m, 1H), 2.56-2.66 (m, 1H), 
2.69-2.79 (m, 1H), 3.27-3.44 (m, 1H), 4.12-4.30 (m, 4H), 4.52-4.59 (dd, J = 6.1 Hz, 13.5 Hz, 
1H), 5.07-5.13 (dd, J = 3.9 Hz, 14.1 Hz, 1H), 7.10-7.13 (m, 2H), 7.17-7.19 (m, 1H), 7.23-7.27 
(m, 2H), 7.52-7.55 (d, J = 8.6 Hz, 1H), 7.81-7.89 (dt, J = 1.8 Hz, 14.5 Hz, 1H), 8.10-8.11 (t, J = 
1.5 Hz, 1H); 13C NMR (125.77 Hz, CDCl3)   16.26 (d, J = 5.5 Hz),  16.35 (d, J = 5.5 Hz), 30.10, 
30.46 (q, J = 2.8 Hz, 5.5 Hz), 33.12 (d, J = 11.9 Hz), 42.43 (d, J = 22.9 Hz), 64.87 (d, J = 7.3 Hz), 
65.13 (d, J = 7.3 Hz), 75.37, 103.24 (dd, J = 351.9 Hz, 454.8 Hz), 126.34, 128.26 (d, J = 22.9 
Hz), 128.55 (d, J = 6.4 Hz), 129.11 (d, J = 4.6 Hz), 130.57, 131.96 (d, J = 9.2 Hz), 133.15, 134.64 
(d, J = 3.7 Hz), 138.76, 140.19, 195.0 (d, J = 23.8 Hz); 31P NMR (121.49 Hz, CDCl3) 12.0 (d, J = 
81.5 Hz); 19F NMR (282.38 Hz, CDCl3) - 95.43 (dd, J = 18.3 Hz, 80.9 Hz); HRMS (ESI) m/z 
calcd for C22H26Cl2FNO6P [M+H]
+= 520.0781, found = 520.0871; the ee value was 98%, tR 
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(major) = 11.8 min, tR (minor) = 15.1 min (Chiralcel, IA, λ = 220 nm, 10% iPrOH/hexanes, flow 




A white solid; [α+27D = -44.7 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.18-1.20 (t, J = 6.9 Hz, 
3H), 1.32-1.35 (t, J = 6.9, 3H), 4.05-4.21 (m, 4H), 4.65-4.74 (m, 1H), 5.04-5.09 (dd, J = 11.4 Hz, 
14.0 Hz, 1H), 5.16-5.19 (dd, J = 10.1 Hz, 13.9 Hz, 1H), 7.15-7.18 (m, 1H), 7.32-7.34 (d, J = 7.6 
Hz, 1H), 7.42-7.43 (d, J = 8.2, 1H), 7.63-7.66 (m, 2H), 7.73-7.75 (m, 2H), 7.88-7.92 (m, 3H), 
8.04-8.06 (d, J = 2.1 Hz, 1H), 8.60-8.61 (d, J = 8.2 Hz, 1H), 9.17 (s, 1H); 13C NMR (125.77 Hz, 
CDCl3)   16.16 (d, J = 5.5 Hz), 16.41 (d, J = 5.5 Hz), 29.68, 48.30 (d, J =  23.8 Hz), 64.69 (d, J = 
6.4 Hz), 64.99 (d, J = 7.3 Hz), 75.29, 122.70 (d, J = 12.8 Hz), 126.05, 126.17 (d, J = 10.1 Hz), 
126.37 (d, J = 7.3 Hz), 127.37, 127.57, 128.39, 128.63, 128.85, 129.41, 130.19, 130.59, 
130.64, 132.02, 132.09, 133.21, 135.36, 135.65 (d, J = 7.3 Hz), 197.14 (d, J = 22.9 Hz); 31P 
NMR (121.49 Hz, CDCl3) 11.19, 11.82; 
19F NMR (282.38 Hz, CDCl3) -95.67 (dd, J = 22.9 Hz, 
77.8 Hz); HRMS (ESI) m/z calcd for C28H27BrFNO6P [M+H]
+= 602.0665, found = 602.0743; the 
ee value was 99%, tR (major) = 25.8 min, tR (minor) = 21.3 min (Chiralcel, IA, λ = 220 nm, 10% 









A pale yellow oil; [α+27D = 14.0 (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): 1.01-1.06 (t, J = 7.1 
Hz, 3H), 1.20-1.25 (t, J = 7.0 Hz, 3H), 1.31-1.35 (t, J = 7.2 Hz, 3H), 2.69-2.83 (m, 1H), 3.99-4.08 
(m, 3H), 4.10-4.16 (m, 2H), 4.90-4.93 (d, J = 7.7 Hz, 2H), 7.18-7.21 (m, 2H), 7.30-7.44 (m, 2H); 
13C NMR (125.77 Hz, CDCl3)  6.53 (d, J = 2.8 Hz), 16.15 (d, J = 5.5 Hz), 16.38 (d, J = 5.5 Hz), 
33.46, 46.97 (dd, J = 1.4 Hz, 20.2 Hz), 64.45 (d, J = 6.4 Hz), 64.92 (d, J = 6.4 Hz), 74.89 (t, J = 
6.9 Hz), 101.03 (dd, J = 156.7 Hz, 201.6 Hz), 122.62, 128.12, 130.13, 131.93, 132.64 (d, J = 1.8 
Hz), 135.50 (d, J = 7.3 Hz), 207.69 (d, J = 25.7 Hz); 31P NMR (121.49 Hz, CDCl3) 10.69 (d, J = 
80.0 Hz); 19F NMR (282.38 Hz, CDCl3) 103.88 (dd, J = 22.7 Hz, 79.4 Hz); HRMS (ESI) m/z 
calcd for C16H23BrFNO6P [M+H]
+= 454.0352, found = 454.0412; the ee value was 96% for the 
major diastereomer, tR (major) = 19.0 min, tR (minor) = 17.2 min (Chiralcel, IA, λ = 220 nm, 
5% iPrOH/hexanes, flow rate = 1 mL/min); the ee value was 84% for the minor diastereomer, 
tR (major) = 13.3 min, tR (minor) = 10.3 min (Chiralcel, IC, λ = 220 nm, 10% iPrOH/hexanes, 




A pale-yellow oil; [α+27D = -8.7 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.08 (s, 9H), 1.22-1.25 




(m, 2H), 7.16-7.23 (m, 2H), 7.40-7.45 (m, 2 H); 13C NMR (125.77 Hz, CDCl3) 16.15 (t, J = 5.5 
Hz), 16.38 (d, J = 5.5 Hz), 48.50 (t, J = 29.3 Hz), 64.30 (d, J = 7.3 Hz), 64.95 (d, J = 6.4 Hz), 
75.37 (t, J = 7.3 Hz), 103.64 (dd, J = 155.8 Hz, 295.1 Hz), 122.44, 128.88, 130.07 (d, J = 32.1 
Hz), 131.95 (d, J = 8.2 Hz), 133.12, 135.47 (d, J = 7.3 Hz), 211.03 (d, J = 21.1 Hz); 31P NMR 
(121.49 Hz, CDCl3) 12.00 (d, J = 80.0 Hz); 
19F NMR (282.38 Hz, CDCl3) 99.87 (dd, J = 22.9 
Hz, 79.3 Hz); HRMS (ESI) m/z calcd for C18H27BrFNO6P [M+H]
+= 482.0665, found = 482.0732; 
the ee value was 99% for the major diastereomer, tR (major) = 9.5 min, tR (minor) = 7.5 min 
(Chiralcel, IA, λ = 220 nm, 10% iPrOH/hexanes, flow rate = 1 mL/min); 
IV-3.4. Synthesis of -fluoro--hydroxy--nitro phosphonate 
 
 
To a flask containing II-3.2ae (0.1 mmol) in i-PrOH (1ml) NaBH4 (0.3 mmol, 11.4 mg) was 
added in one portion at -5 - 0
o
C, under argon. The reaction was then stirred at this temperature 
for 4h. After the starting material was fully converted (TLC), 2 ml of aqueous saturated 
NH4Cl was added, followed by10 ml of ethyl acetate. The product was then extracted using 
ethyl acetate (3x 10 ml). Combined organic organic phases were than dried over Na2SO4 and 
evaporated. The crude product (9) was then purified by flash chromatography on silica gel 
using ethyl acetate/hexane = 5:1 as eluent.  
Reduction of 3ae leading to 10 was performed analogically, with slight modifications: EtOH 
was used as solvent; LiCl (3 mol equivalents, 0.3 mmol) was added prior to addition of 
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NaBH4; the reaction temperature was slightly higher 0 – 10
o
C and time shorter (2h). 9 and 10 
are very close on TLC. 
Diethyl ((1S,2R,3S)-3-(3-bromophenyl)-2-fluoro-1-hydroxy-4-nitro-1-phenylbutan-2-
yl)phosphonate (II-3.10a);  
 
There are several rotamers of -hydroxyphosphonates, which is reflected on NMR spectrums, 
where the ester group (here - ethyl) differentiates with population proportional to the lifetime 
of each rotamer.
184
 Additionally, both ester groups are not equivalent. In the case of (II-
3.10a), the hydrogen bonding between –OH and the phosphonate oxygen (as evidenced by X-
ray analysis, see the respective chapter) is the cause of noticeable coupling between –OH 
hydrogen and -3‟-Br-C6H4-CH- proton (J~4.5 Hz) and non-equivocality of -CH2-NO2 protons. 
A white solid; [α+27D = -22.5 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 0.86-0.89 (t, J = 13.8 Hz, 
3H), 1.05-1.08 (t, J = 14.5 Hz, 3H), 2.73-2.74 (d, J = 4.4 Hz, 1H, OH), 3.67-3.72 (m, 1H, CH2-
CH3, rotamer), 3.81-3.92 (m, 3H, CH2-CH3, rotamer), 4.68-4.73 (d, J = 25.9 Hz, 1H, -CHOH), 
4.90-5.00 (ddt, J = 4.1 Hz, 10.1 Hz, 29.0 Hz, 1H, 3’-Br-C6H4-CH), 5.09-5.12 (dd, J = 4.1 Hz, 13.9 
Hz, 1H, -CH2NO2), 5.31-5.36 (dd, J = 10.1 Hz, 13.9 Hz, 1H, -CH2NO2), 7.21-7.24 (m, 1H), 7.32-
7.34 (m, J = 8.2 Hz, 5H), 7.46-7.47 (d, J = 7.6 Hz, 1H), 7.56-7.58 (d, J = 7.6 Hz, 1H), 7.80 (s, 1H); 
13C NMR (125.77 Hz, CDCl3)  15.74 (d, J = 6.4 Hz), 15.87 (d, J = 6.4 Hz), 45.70 (d, J = 23.8 Hz), 
62.17 (d, J = 7.3 Hz), 63.98 (d, J = 6.4 Hz), 72.84 (t, J = 9.2 Hz), 75.77 (d, J = 7.3 Hz), 99.65 (dd, 
J = 32.1 Hz, 166.8 Hz), 122.36, 128.11, 128.53 (d, J = 1.83 Hz), 128.76, 129.17, 129.88, 
131.54, 133.04; 31P NMR (121.49 Hz, CDCl3) 15.21 (d, J = 88.9 Hz); 
19F NMR (282.38 Hz, 
                                                          
[
184
]  M. P. Belciug, A. M. Modro, T. A. Modro, P. L. Wessels,  J. Phys. Org. Chem., 1992, 5, 787. 
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CDCl3) -112.88 (ddd, J = 10.7, 26.0 Hz, 90.0 Hz); HRMS (ESI) m/z calcd for C20H24BrFNNaO6P 




A white solid; [α+27D = 26.6 (c 1, CHCl3);  
1H NMR (500 MHz, CDCl3): 0.92-0.95 (t, J = 6.9 Hz, 
3H), 1.36-1.39 (t, J = 6.9 Hz), 3.31-3.39 (m, 1H, CH2-CH3, rotamer), 3.67-3.75 (m, 1H, CH2-CH3, 
rotamer), 3.90-3.92 (d, J = 10.1 Hz, 1H, OH), 4.16-4.25 (m, 2H, CH2-CH3, rotamer), 4.28-4.35 
(dtd, J = 2.5 Hz, 10.7 Hz, 18.3 Hz, 1H, -CHOH), 4.77-4.86 (dt, J = 10.7 Hz, 25.9 Hz, 1H, 3’-Br-
C6H4-CH), 5.25-5.28 (dd, J = 2.5 Hz, 14.5 Hz, 1H, CH2NO2), 5.37-5.42 (dd, J = 10.7 Hz, 14.5 Hz, -
CH2NO2), 7.24-7.28 (m, 2H), 7.32-7.33 (m, 5H), 7.40-7.42 (d, J = 8.2 Hz, 1H), 7.49-7.50 (d, J = 
8.2 Hz, 1H), 7.59 (s, 1H); 13C NMR (125.77 Hz, CDCl3)  15.85 (d, J = 6.4 Hz), 16.18 (d, J = 5.5 
Hz), 48.86 (dd, J = 5.5 Hz, 23.8 Hz), 63.72 (d, J = 8.2 Hz), 64.04 (d, J = 7.3 Hz), 72.46 (dd, J = 
3.7 Hz, 22.0 Hz), 75.49 (d, J = 8.2 Hz), 96.85(dd, J = 158.5 Hz, 196.1 Hz), 122.74, 127.48 (d, J = 
3.7 Hz), 128.12, 128.41, 128.52, 130.11, 131.89, 133.54, 135.38, 135.46, 137.34 (d, J = 3.7 
Hz); 31P NMR (121.49 Hz, CDCl3) 16.03 (d, J = 77.0 Hz); 
19F NMR (282.38 Hz, CDCl3) -94.29 
(d, J = 76.3 Hz); HRMS (ESI) m/z calcd for C20H24BrFNNaO6P [M+Na]










To II-3.2ae (0.1 mmol, 50 mg) in EtOH (absolute, 2 ml) Indium was added (0.12 mmol, 11.4 
mg)
185
  followed by 4Å powdered molecular sieves (freshly activated), Fe (1 mmol, 56 mg) 
and a small drop of HCl (2M aq. solution, strongly acidic conditions or excess of acid must be 
avoided due to de-fluorination; in absence of any acid reaction is slow). The reaction mixture 
was then stirred for 2.5 h at room temperature.  Upon completion (TLC), reaction mixture 
was diluted with ethyl acetate (15 ml) and filtered through a pad of cellite. Then the solution 
was washed with NaHCO3 (satd., aq.), followed by brine, dried over Na2SO4 and evaporated 
to yield crude product. Pure II-3.11 was obtained after flash chromatography on silica gel 
using ethyl acetate/hexane as eluent (5:1 – 4:1).  
Diethyl ((3S,4R)-3-(3-bromophenyl)-4-fluoro-5-phenyl-3,4-dihydro-2H-pyrrol-4-
yl)phosphonate; (II-3.11);  
 
 A colourless oil; [α+27D = 46.2 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 1.19-1.22 (t, J = 7.0 
Hz, 3H), 1.25-1.28 (t, J = 7.4 Hz, 3H), 3.87-3.92 (m, 1H), 4.07-4.14 (m, 3H), 4.19-4.21 (m, 1H), 
4.34-4.38 (m, 1H), 4.43-4.48 (m, 1H), 7.13-7.17 (m, 2H), 7.35 (s, 1H), 7.39-7.46 (m, 4H), 8.06-
                                                          
[
185
] Addition of indium is unnecessary and can be avoided (e.g. from economic reasons), however it 
does facilitate the reaction yield by supressing the formation of hydroxypyrrolidines byproducts (partial 
reduction of NO2 moiety). See also: S. Cicchi, M. Bonanni, F. Cardona, J. Revuelta, A. Goti, Org. Lett. 
2003, 5, 1773.  
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8.07 (d, J = 7.0 Hz); 13C NMR (125.77 Hz, CDCl3) 16.26 (d, J = 5.5 Hz), 51.01 (dd, J = 6.4 Hz, 
18.3 Hz), 63.94 (d, J = 3.7 Hz), 63.99 (d, J = 2.7 Hz), 104.11 (dd, J = 171.4 Hz, 209.0 Hz), 
122.43, 127.36, 128.16, 128.87 (d, J = 3.7 Hz), 129.99, 130.65, 131.00, 131.93, 132.28, 
132.29, 138.64, 138.70, 167.40 (d, J = 16.5 Hz); 31P NMR (121.49 Hz, CDCl3) 15.39 (d, J = 
99.2 Hz); 19F NMR (282.38 Hz, CDCl3) -98.53 (dt, J = 6.1 Hz, 99.2 Hz); HRMS (ESI) m/z calcd 
for C20H23BrFNO3P [M+H]
+= 454.0661, found = 454.0582. 




To MeOH (dry, 1.5 ml) solution of imine (II-3.11, 0.1 mmol, 45 mg) NaBH3CN (1 mmol, 63 
mg) was added in 3 portions in 30 minutes intervals. The reaction mixture was then stirred 
overnight (16-18 h) at room temperature. After that time, despite only partial conversion  
(longer reaction times or larger excess of reducing agent resulted in formation of byproducts), 
reaction was quenched by addition of 1 ml of ice water and diluted with ethyl acetate (15 ml). 
The solution was then washed with NaHCO3 (satd., aq.), followed by brine, dried over 
Na2SO4 and evaporated to yield crude product. Pure II-3.3a was obtained after flash 






To THF/MeOH (4/1, total of 2 ml, dry solvents) solution of imine (II-3.11, 0.1 mmol, 45 mg) 
LiBH4 (1 mmol, 22 mg) was added in 3 portions in 30 minutes intervals. The reaction mixture 
was then stirred for 4h at room temperature. After that time, despite only partial conversion  
(similarly, longer reaction times or larger excess of reducing agent resulted in formation of 
byproducts), reaction was quenched by addition of 1 ml of ice water and diluted with ethyl 
acetate (15 ml). The solution was then washed with NaHCO3 (satd., aq.), followed by brine, 
dried over Na2SO4 and evaporated to yield crude product. Pure II-3.3b was obtained after 
flash chromatography on silica gel using ethyl acetate/hexane as eluent (5:1 – 4:1). 
 
A white solid; [α+27D = -14.3 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 0.84-0.86 (t, J = 7.0 Hz, 
3H), 0.88-0.91 (t, J = 6.9 Hz, 3H); 3.46-3.51 (m, 1H), 3.62-3.73 (m, 4H), 3.85-3.92 (dd, J = 2.7 
Hz, 4.8 Hz), 4.04-4.16 (m, J = 30.2 Hz, 1H), 4.51-4.59 (dd, J = 9.5 Hz, 31.5 Hz, 1H), 5.88 (bs, 
1H), 7.24-7.26 (m, 1H), 7.38-7.41 (m, 3H), 7.47-7.48 (m, 4H), 7.60 (s, 1H); 13C NMR (125.77 
Hz, CDCl3) 15.76 (d, J = 3.7 Hz), 49.02, 56.86 (d, J = 11.00), 63.62 (d, J = 6.4 Hz), 63.76 (d, J = 
7.3 Hz), 74.68 (t, J = 16.5 Hz), 103.51, 122.41, 128.00, 128.67, 128.89, 129.99, 130.03, 
130.27, 131.52, 133.02, 135.44;  31P NMR (121.49 Hz, CDCl3) 11.21 (d, J = 78.5 Hz); 
19F NMR 
(282.38 Hz, CDCl3) 116.51 (dt, J = 32.0 Hz, 79.3 Hz); HRMS (ESI) m/z calcd for C20H23BrFNO3P 






A white solid; [α+27D = -1.0 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 0.89 (t, J = 6.9 Hz, 3H), 
0.93 (t, J = 6.9 Hz, 3H), 3.53-3.62 (m, 1H), 3.64-3.90 (m, 4H), 4.12-4.23 (m, 1H), 4.53 (bs, 1H), 
4.59-4.67 (dd, J = 8.2 Hz, 32.2 Hz, 1H), 7.23-7.26 (m, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.42-7.47 
(m, 6H), 7.61 (s, 1H); 13C NMR (125.77 Hz, CDCl3) 15.82 (d, J = 7.7 Hz), 49.13 (d, J = 22.0 Hz), 
58.34 (d, J = 12.8 Hz), 63.51, 76.12, 101.28, 122.46, 128.62, 128.80, 129.69, 129.72, 130.0, 
131.43, 131.88, 132.81, 135.63; 31P NMR (121.49 Hz, CDCl3) 11.77 (d, J = 81.5 Hz); 
19F NMR 
(282.38 Hz, CDCl3) 116.49 (dt, J = 32.0 Hz, 33.6 Hz, 79.3 Hz); HRMS (ESI) m/z calcd for 
C20H23BrFNO3P [M+H]
+= 456.0661, found = 456.0739. 
IV-3.6. X-Ray crystallographic analysis and determination of 
configurations of products 
The crystal is orthorhombic, space group P2(1)2(1)2(1). The asymmetric unit contains one 
molecule of the compound C20H24NO6FPBr. As the absolute structure parameter is 0.001 with 
esd 0.010, the reported structure is the correct absolute configuration. Final R values are 




  Table 1.  Crystal data and structure refinement for C016. 
Identification code  c016 
Empirical formula  C20 H24 Br F N O6 P 
Formula weight  504.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 7.6675(8) Å = 90°. 
 b = 16.0614(16) Å = 90°. 
 c = 17.4809(18) Å  = 90°. 




Density (calculated) 1.556 Mg/m3 
Absorption coefficient 2.029 mm-1 
F(000) 1032 
Crystal size 0.24 x 0.10 x 0.08 mm3 
Theta range for data collection 1.72 to 27.50°. 
Index ranges -9<=h<=9, -20<=k<=17, -22<=l<=22 
Reflections collected 15621 
Independent reflections 4938 [R(int) = 0.1000] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.5979 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4938 / 0 / 274 
Goodness-of-fit on F2 0.983 
Final R indices [I>2sigma(I)] R1 = 0.0496, wR2 = 0.0715 
R indices (all data) R1 = 0.0767, wR2 = 0.0766 
Absolute structure parameter 0.001(10) 
Largest diff. peak and hole 0.731 and -0.753 e.Å-3 




IV-3.7. Determination of configuration of pyrrolidines 
To assess the configuration of new chiral centre, HMBC, QC and NOESY experiments were 
performed for the pyrrolidines (II-3.3a&b). It was found that in both pyrrolidines, the proton 
at the newly generated chiral centre (C-5) gave positive Overhauser effect with the proton at 
C-3 of known configuration. Therefore, the relationship of C-5 and C-3 protons was 
determined to be cis and configuration of C-5 was assigned as S.  
 
 
The rotation of the phosphonate moiety may be inhibited by the steric hindrance due to the 
presence of the two phenyl groups on the same side of the pyrrolidine ring, perhaps involved 
in - interactions. During the reduction of the imine, the formation of intramolecular H-
bonding between phosphonate and pyrrolidine NH could result in orientation like in II-3.3a. 
On the other hand, Li
+
, present during the reduction step, would coordinate to phosphonate 
and prevent it from forming H-bond with pyrrolidine NH, resulting in the configuration 
observed in II-3.3b.  
207 
 
IV-4. Organocatalytic Michael addition of 2-fluoro-1,3-diketones to 
nitroalkenes: towards fluoro-isosteres of glycerine 
IV-4.1. General procedure and analytical data of the Michael 
reaction products   
Michael addition of 2-fluoro-1,3-diketones to nitroalkenes - representative procedure:  
To a sample vial containing the fluoroketone (0.1 mmol, II-4.7ag) in diethyl ether (1 ml), 
the catalyst II-2.16 (0.01 mmol, 6 mg) was added. The vial was then capped and the reaction 
mixture was stirred for 5 minutes at -70 
o
C. Subsequently nitroalkene (0.11 mmol) was added 
in one portion, under nitrogen protection, the vial was sealed and the reaction mixture was 
stirred at -70 
o
C for the time indicated. Upon completion of the reaction, the mixture was 
passed through a short silica gel column to remove the catalyst (possible recovery of the 
catalyst), evaporated and analyzed by 
1
H NMR. The crude product was then subjected to 
column chromatographic separation eluting with hexane/ethyl acetate (20:1  5:1) to afford 
the pure Michael product (II-4.8aj). 
2-fluoro-2-(2-nitro-1-phenylethyl)-1-phenylbutane-1,3-dione (II-4.8a) 
 
*α+270D = +47.7 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 60(dd, J = 7.2 Hz, 1.6 Hz, 2H), 7.51 
(t, J = 7.6 Hz, 1H), 7.33 (t, J = 7.6 Hz, 2H), 7.25 – 7.20 (m, 5H), 4.87 – 4.75 (m, 3H), 2.37 (d, J = 
4.0 Hz, 3H); 13C NMR (100.62 Hz, CDCl3)  199.77, 192.80, 134.50, 133.83, 132.86, 129.51, 
129.49, 129.13, 129.08, 128.84, 128.68, 128.45, 107.48 (d, J = 206.4 Hz), 75.17, 47.82 (d, J = 
18.3 Hz), 26.27; 19F NMR (376.46 Hz, CDCl3) -137.34 (d, J = 31.2 Hz); HRMS (ESI) m/z calcd 
for C18H15FNO4 [M-H]
- = 328.0991, found = 328.0981; the ee value was 92%, tR (major) = 13.9 












*α+270D = +82.9 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): (d, J = 6.7 Hz, 2H), 7.50 (m, 1H), 
7.31 (m, 2H), 7.22 – 7.18 (m, 5H), 4.91 – 4.66 (m, 3H), 3.14 (m, 1H), 1.09 (d, J = 6.4 Hz, 3H), 
1.02 (d, J = 6.4 Hz, 3H); 13C NMR (125 Hz, CDCl3)  206.15 (d, J = 23.4 Hz), 192.65 (d, J = 23.8 
Hz), 134.70, 134.41, 133.66, 132.73, 129.95, 129.83, 129.54, 129.12, 129.07, 128.79, 128.65, 
128.38, 108.02 (d, J = 206.5 Hz), 75.29 (d, J = 5.9 Hz), 48.03 (d, J = 18.1 Hz), 36.63, 18.66; 19F 
NMR (376.46 Hz, CDCl3) -170.95 (d, J = 30.8 Hz); HRMS (ESI) m/z calcd for C20H19FNO4 [M-
H]- = 356.1304, found = 356.1304; the ee value was 96%, tR (major) = 20.8 min, tR (minor) = 








*α+270D = +9.3 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 9.41 (s, 1H), 8.70 (d, J = 8.4 Hz, 1H), 
8.15 (dt, J = 8.4 Hz, 1.6 Hz, 1H), 7.93 (m, 2H), 7.77 – 7.66 (m, 3H), 7.48 – 7.22 (m, 6H), 
m.89 (m, 2H), 2.02 (d, J = 3.6 Hz, 3H); 13C NMR (125 Hz, CDCl3)  200.01, 
192.52, 138.99, 135.22, 132.99, 132.07, 131.02, 130.61, 129.52, 129.34, 129.08, 128.86, 
128.68, 127.55, 127.41, 125.96, 125.69, 125.64, 125.46, 125.40, 122.61, 107.78 (d, J = 206.1 
Hz), 75.19, 47.94 (d, J = 18.8 Hz), 26.34; 19F NMR (376.46 Hz, CDCl3) -166.30 (d, J = 32.3 Hz); 
HRMS (ESI) m/z calcd for C26H19FNO4 [M-H]
- = 428.1304, found = 428.1302; the ee value was 
96% major diastereomer, tR (major) = 24.8 min, tR (minor) = 26.6 min (Chiralcel IC, λ = 254 








*α+270D = +64.8 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): (s, 4H), 7.24 – 7.21 (m, 5H), 4.85 
– 4.73 (m, 3H), 2.36 (d, J = 4.0 Hz, 3H); 13C NMR (125 Hz, CDCl3)  199.37, 192.20, 133.15, 
133.12, 132.70, 131.82, 130.62, 130.56, 129.45, 128.94, 128.82, 107.67 (d, J = 206.5 Hz), 
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74.98, 47.85 (d, J = 18.9 Hz), 26.24; 19F NMR (376.46 Hz, CDCl3) -167.98 (d, J = 31.9 Hz); 
HRMS (ESI) m/z calcd for C18H14BrFNO4 [M-H]
- = 406.0096, found = 406.0098; the ee value 
was 89% major diastereomer, tR (major) = 14.9 min, tR (minor) = 35.5 min (Chiralcel IC, λ = 








*α+270D = +134.2 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 7.65 (s, 1H), 7.38 (m, 1H), 7.32 – 
7.25 (m, 5H), 6.53 (dd, J = 5.0 Hz, 2.5 Hz, 1H), 4.92 – 4.85m2.40 (d, J = 4.5 Hz, 3H); 13C 
NMR (125 Hz, CDCl3)  199.53, 178.48, 148.53, 132.59, 129.27, 129.09, 128.82, 128.70, 
122.90, 122.80, 112.73, 105.68 (d, J = 204.6 Hz), 75.05, 47.25, 26.18; 19F NMR (376.46 Hz, 
CDCl3) -171.43 (d, J = 31.2 Hz); HRMS (ESI) m/z calcd for C16H13FNO5 [M-H]
- = 318.0783, 
found = 318.0778; the ee value was 95%, tR (major) = 30.1 min, tR (minor) = 23.4 min 







*α+270D = +46.8 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 7.66 – 7.61 (m, 3H), 7.53 – 7.57 (m, 
4H), 7.36 (d, J = 7.6 Hz, 2H), 4.97 – 4.76m 4.72 – 4.66 (m, 1H), 3.16 (m, 1H), 1.11 (d, J 
= 6.8 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H); 13C NMR (75 Hz, CDCl3)  205.83, 191.60, 138.37, 
134.35, 132.63, 132.46, 130.40, 129.98, 129.88, 129.17, 129.08, 128.74, 117.95, 112.81, 
108.11 (d, J = 198.5 Hz), 74.89, 47.80 (d, J = 18.1 Hz), 36.57, 18.78, 18.32; 19F NMR (376.46 
Hz, CDCl3) -170.58 (d, J = 31.2 Hz); HRMS (ESI) m/z calcd for C21H18FN2O4 [M-H]
- = 381.1256, 
found = 381.1255; the ee value was 94%, tR (major) = 18.8 min, tR (minor) = 21.8 min 








*α+270D = +53.1 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 7.60 (m, 2H), 7.50 (m, 1H), 7.32 (t, J = 
8.0 Hz, 2H), 7.10 (d, J = 6.8 Hz, 2H), 6.99 (d, J = 8.0 Hz, 2H),  4.91 – 4.64m 3.14 (m, 
1H), 2.22 (s, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H); 13C NMR (125 Hz, CDCl3)  
206.41, 192.71, 138.45, 134.75, 134.36, 133.60, 129.96, 129.90, 129.70, 129.60, 129.47, 
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129.38, 129.19, 128.36, 108.05 (d, J = 206.3 Hz), 75.45, 47.75 (d, J = 18.4 Hz), 36.60, 20.98, 
18.69; 19F NMR (376.46 Hz, CDCl3) -170.78 (d, J = 30.5 Hz); HRMS (ESI) m/z calcd for 
C21H21FNO4 [M-H]
- = 370.1460, found = 370.1462; the ee value was >99% major 
diastereomer, tR (major) = 8.9 min, tR (minor) = 12.3 min (Chiralcel IC, λ = 254 nm, 10% 







*α]270D = +100.0 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): (d, J = 8.4 Hz, 2H), 7.53 (m, 
1H), 7.38 – 7.30 (m, 4H), 7.16 (d, J = 6.8 Hz, 1H), 7.06 (t, J = 7.6 Hz, 1H), 4.85 – 4.65 (m, 3H), 
3.15 (m, 1H), 1.09 (d, J = 6.8 Hz, 3H) 1.02 (d, J = 7.2 Hz, 3H); 13C NMR (125 Hz, CDCl3)  
205.99, 192.28, 135.16, 134.59, 133.96, 132.54, 131.86, 130.27, 129.90, 129.17, 129.11, 
128.89, 128.56,122.75, 107.78 (d, J = 207.3 Hz), 75.07, 47.50 (d, J = 18.9 Hz), 36.66, 18.73, 
18.35; 19F NMR (376.46 Hz, CDCl3) -170.75 (d, J = 30.8 Hz); HRMS (ESI) m/z calcd for 
C20H18BrFNO4 [M-H]
- = 434.0409, found = 434.0409; the ee value was 95%, tR (major) = 7.8 









*α+270D = +100.3 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): (d, J = 10.5 Hz, 2H), 7.53 (t, J = 
9.5 Hz,  1H), 7.35 (m, 3H), 7.22 – 7.15 (m, 1H), 7.03 (t, J = 9.5 Hz, 1H), 6.93 (t, J = 10.5 Hz, 1H), 
5.24 (ddd, J = 36.5 Hz, 13.5 Hz, 5.0 Hz, 1H), 4.97 (dd, J = 17.0 Hz, 13.0 Hz, 1H), 4.73 (dd, J = 
18.5 Hz, 5.0 Hz, 1H), 3.15 (m, 1H), 1.06 (d, J = 8.0 Hz, 3H) 1.02 (d, J = 8.0 Hz, 3H); 13C NMR 
(125 Hz, CDCl3)  206.17, 192.22, 162.03, 160.04, 133.99, 130.62, 130.55, 130.20, 129.31, 
129.26, 128.53, 124.61, 116.11, 115.93, 107.27 (d, J = 206.8 Hz), 74.58, 36.71, 35.92, 18.72, 
18.67; 19F NMR (376.46 Hz, CDCl3) -168.73 (dd, J = 28.6 Hz, 12.0 Hz); HRMS (ESI) m/z calcd 
for C20H18F2NO4 [M-H]
- = 374.1209, found = 374.1206; the ee value was 95%, tR (major) = 8.1 













*α+270D = +142 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3) (diastereomeric mixture): 7.99 (m, 
4H), 7.65 – 7.60 (m, 2H), 7.51 – 7.46 (m, 4H), 4.63 – 4.59 (m 2H), 4.45 (dd, J = 11.2 Hz, 5.2 Hz, 
1H, CH2NO2 diastereomer 1), 4.41 (dd, J = 10.8 Hz, 5.2 Hz, 1H, CH2NO2 diastereomer 2), 3.60 
– 3.48 (m, 2H), 3.20 – 3.11 (m, 2H), 1.31 – 1.22 (m, 2H), 1.09 – 1.06 (m, 4H), 0.98 (d, J = 6.8 
Hz, 2H), 0.92 – 0.83 (m, 6H); 13C NMR (125 Hz, CDCl3) 207.33 (d, J = 28.3 Hz), 207.11 (d, J = 
29.8 Hz), 193.57 (d, J = 24.6 Hz), 193.26 (d, J = 24.5 Hz), 134.62, 134.59, 134.45, 134.42, 
134.28, 134.18, 129.79, 129.74, 129.68, 128.78, 108.16 (d, J = 203.0 Hz), 108.05 (d, J = 203.9 
Hz), 75.50 (d, J = 3.5 Hz), 75.19 (d, J = 3.6 Hz), 41.03 (d, J = 18.1 Hz), 40.85 (d, J = 14.5 Hz), 
37.34, 37.31, 36.81, 36.48, 25.40, 25.39, 23.53, 23.41, 21.08, 21.05, 19.15, 18.80, 18.62, 
18.49; 19F NMR (376.46 Hz, CDCl3) -166.52 (d, J = 21.8 Hz), -168.68 (d, J = 24.8 Hz); HRMS 
(ESI) m/z calcd for C15H17FNO4 [M-H]
- = 294.1174, found = 294.1172. 
IV-4.2. Reduction and analytical data of fluoroglycerines 
 
Experimental procedure: 
To the Michael addition product II-4.8b (0.2 mmol, 35.5 mg) in MeOH (4 ml) at 0 
o
C was 
added sodium borohydride (0. 5 mmol, 19 mg). The reaction mixture was allowed to warm to 
room temperature, and stirring was continued for additional 1.5 h. The reaction was then 
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placed in an ice bath and quenched by adding saturated aqueous solution of ammonium 
chloride (5 mL). The mixture was extracted with ethyl acetate (3 x 10 ml), and the combined 
organic layers were dried over Na2SO4. After filtration and concentration, the residue was 
purified by column chromatography (hexane/chloroform = 5:1 to 2:1) to yield II-4.16a as a 
white solid (41 mg, 57%) and II-4.16b as a white solid (27 mg, 38%). 
2-fluoro-4-methyl-2-(2-nitro-1-phenylethyl)-1-phenylpentane-1,3-diol (II-4.16a) 
 
*α+270D = - 108.4 (c 1, CHCl3); 
1H NMR (500 MHz, CDCl3): 7.49 (d, J = 7.0 Hz, 2H), 7.38 (t, J = 
7.5 Hz, 2H), 7.35 – 7.25 (m, 6H), 5.42 (dd, J = 13.9 Hz, 12.0 Hz, 1H), 5.25 (m, 1H), 4.80 (m, 
1H), 4.34 (ddd, J = 14.8 Hz, 11.9 Hz, 2.9 Hz, 1H), 3.76 (m, 1H), 3.34 (td, J = 9.0 Hz, 3.4 Hz, 1H), 
2.81 (m, 1H), 2.09 (dt, J = 8.1 Hz, 6.6 Hz, 1H), 0.97 (d, J = 6.6 Hz, 3H), 0.94 (m, 3H); 13C NMR 
(125 Hz, CDCl3) 138.50, 134.53, 129.97, 128.58, 128.23, 128.16, 128.06, 126.89, 126.87, 
95.66 (d, J = 181,0 Hz), 78.80 (d, J = 27.8 Hz), 75.55 (d, J = 6.8 Hz), 75.40 (d, J = 12.0 Hz), 
48.13 (d, J = 23.4 Hz), 29.75, 20.02, 19.12; 19F NMR (376.46 Hz, CDCl3) -154.83 (bs); HRMS 
(ESI) m/z calcd for C20H23FNO4 [M-H]
- = 360.1617, found = 360.1619. 
X-ray analysis  
The crystal is triclinic, space group P-1. The asymmetric unit contains  one molecule of the 
compound C20h23FNO4. As P-1 is a centro space group, the crystal is a racemic mixture. 






Table 1.  Crystal data and structure refinement for D652. 
Identification code  D652 
Empirical formula  C20 H24 F N O4 
Formula weight  361.40 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 9.5306(7) Å = 98.5360(10)°. 
 b = 10.0139(7) Å = 106.7890(10)°. 
 c = 10.8100(8) Å  = 
108.1950(10)°. 
Volume 905.46(11) Å3 
Z 2 
Density (calculated) 1.326 Mg/m3 
Absorption coefficient 0.817 mm-1 
F(000) 384 
Crystal size 0.400 x 0.360 x 0.200 mm3 
Theta range for data collection 4.427 to 68.222°. 
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Index ranges -10<=h<=11, -12<=k<=12, -13<=l<=13 
Reflections collected 22331 
Independent reflections 3284 [R(int) = 0.0160] 
Completeness to theta = 67.679° 99.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3284 / 2 / 243 
Goodness-of-fit on F2 1.089 
Final R indices [I>2sigma(I)] R1 = 0.0358, wR2 = 0.0901 
R indices (all data) R1 = 0.0360, wR2 = 0.0903 
Extinction coefficient n/a 




[α]270D = + 24.6 (c 1, CHCl3); 
1H NMR (400 MHz, CDCl3): 7.51 (d, J =  2.0 Hz, 2H), 7.40 – 7.33 
(m, 3H), 7.33 – 7.25 (m, 5H), 5.33 (dd, J = 12.9 Hz, 3.5 Hz, 1H), 4.86 (dd, J = 12.8 Hz, 11.3 Hz, 
1H), 4.51 (bs, 1H), 4.45 (ddd, J = 32.0 Hz, 10.8 Hz, 3.2 Hz, 1H), 3.96 (dt, J = 14.7 Hz, 4.8 Hz, 
1H), 2.27 (m, 1H), 2.08 (m, 1H), 1.22 (m, 1H), 0.83 (d, J = 6.8 Hz, 3H), 0.52 (d, J = 6.8 Hz, 3 H); 
13C NMR (75 Hz, CDCl3) 137.90, 136.68, 129.87, 128.81, 128.14, 127.83, 127.00, 126.96, 
100.22 (d, J = 189.9 Hz), 78.02 (d, J = 7.7 Hz), 74.87 (d, J = 22.7 Hz), 73.60 (d, J = 30.6 Hz), 
47.13, 29.55, 21.02, 16.92; 19F NMR (376.46 Hz, CDCl3) -173.23 (dd, J = 29.7 Hz, 13.5 Hz); 
HRMS (ESI) m/z calcd for C20H23FNO4 [M-H]
- = 360.1617, found = 360.1619. 
X-ray analysis  
The crystal is triclinic, space group P-1. The asymmetric unit contains  one molecule of the 
compound C20H23FNO4. NO2 group of one of the molecules was disordered into two 
positions with occupancy ratio=66:34. Restraints in bond length and thermal parameters were 
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applied to the disordered atoms. As P-1 is a centro space group, the crystal is a racemic 
mixture. Final R values are R1=0.0763 and wR2=0.2693  for 2-theta up to 55º. 
  Table 1.  Crystal data and structure refinement for D687. 
Identification code  D687 
Empirical formula  C20 H24 F N O4 
Formula weight  361.40 
Temperature  298(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 9.1094(6) Å = 89.156(2)°. 
 b = 11.3084(8) Å = 88.332(3)°. 
 c = 18.2603(14) Å  = 88.251(2)°. 
Volume 1879.2(2) Å3 
Z 4 
Density (calculated) 1.277 Mg/m3 




Crystal size 0.26 x 0.16 x 0.08 mm3 
Theta range for data collection 2.106 to 27.499°. 
Index ranges -11<=h<=11, -14<=k<=14, -23<=l<=23 
Reflections collected 35873 
Independent reflections 8618 [R(int) = 0.0549] 
Completeness to theta = 25.242° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.6930 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8618 / 65 / 513 
Goodness-of-fit on F2 1.081 
Final R indices [I>2sigma(I)] R1 = 0.0763, wR2 = 0.2397 
R indices (all data) R1 = 0.1525, wR2 = 0.2693 
Extinction coefficient n/a 




IV-5. Asymmetric Mannich reaction - towards fluorinated amino 
acids, lactones and -lactams 
IV-5.1. Preparation and analytical data of acid, lactam and lactone 
 
 
(2S, 3S)‐Ethyl 3‐(tert‐butoxycarbonylamino)‐2‐fluoro‐2‐((S) hydroxy(phenyl) methyl)‐3‐p‐ 
tolylpropanoate (II-5.15)  
To a solution of Mannich product I-166k (100 mg, 0.23 mmol) in absolute EtOH (8 mL) at 0 
o
C was added sodium borohydride (0.56 mmol, 34 mg). The reaction mixture was allowed to 
warm to room temperature, and stirring was continued for additional 1.5 h. The reaction was 
then placed in an ice bath and quenched by adding saturated aqueous solution of ammonium 
chloride (25 ml). The mixture was extracted with ethyl acetate (3 x 15 ml), and the combined 
organic layers were dried over Na2SO4. After filtration and concentration, the residue was 
purified by column chromatography (hexane:ethyl acetate = 9:1 to 4:1) to yield 5 as a white 
solid (83 mg, 83%).  
1H NMR (300 MHz, CDCl3) δ 0.63‐0.68 (t, 3H), 1.38 (s, 9H), 2.19 (s, 3H), 3.62‐3.73 (m, 
2H), 4.66 (bs, 1H), 4.99‐5.07 (d,1H), 5.24‐5.30 (t, J = 9.5 Hz, 1H), 5.86‐5.89 (d, J = 10.5 Hz, 
1H), 6.99‐7.07 (m, 4H), 7.15‐7.17 (m, 3H), 7.26‐7.28 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 
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13.36, 20.91, 28.18, 54.72 (d, J = 31.29 Hz), 61.28, 73.68 (d, J = 18.67 Hz), 81.23, 97.34, 
100.10, 127.33, 127.35, 127.70, 127.71, 127.86, 128.18, 128.99, 132.56, 136.87, 137.93, 
156.52, 169.04 (d, J = 21.96 Hz).  
 
(3S, 4S)‐3‐Fluoro‐3‐((S)‐hydroxy(phenyl)methyl)‐4‐p‐tolylazetidin‐2‐one (I-168).  
 
To  a  solution  of  II-5.15  (60  mg,  0.14  mmol)  in  dichloromethane  (4  mL)  at  0 
o
C  was  
added trifluoroacetic acid (0.4 mL). The ice bath was then removed and the reaction mixture 
was allowed to warm up to room temperature and stirred for 2 h. Saturated aqueous 
ammonium chloride (10 mL) was added to quench the reaction, and the resulting mixture was 
extracted with dichloromethane (3 x 10 mL). The combined organic extracts were dried over 
sodium sulfate, after filtration, the filtrate was concentrated to yield the crude free amine, 
which was used directly for the next step without further purification. Grignard reagent was 
prepared from isopropyl chloride (5 mmol, 392 mg) and magnesium (10 mmol, 240 mg) in 
dry THF (10 mL), initiated with a few crystals of iodine. To a solution of the crude amine in 
dry THF (2 mL) at 0 
o
C, freshly prepared Grignard reagent was added (10 eqiv., 2.5 ml of 
THF solution). The reaction mixture was then allowed to warm to room temperature and 
stirred overnight.  The  reaction  was  quenched  with  the  addition  of  saturated  aqueous  
ammonium chloride (10 mL). The mixture was extracted with ethyl acetate (3 x 10 mL), and 
the organic extracts were combined, dried over Na2SO4 and concentrated. The residue was 
purified by column chromatography (hexane:ethyl acetate = 9:1 to 4:1) to afford the β‐lactam 
as a white solid (20 mg, 58%).  
 [α]D25 = 43.2 (c = 0.6, CHCl3); 1H NMR (300 MHz, CDCl3) δ 2.31 (s, 3H), 3.37 (s, 1H), 
5.04‐5.07 (d, J = 4.92 Hz, 1H), 5.27‐5.29 (d, J = 8.22 Hz, 1.0H), 6.59‐6.61 (d, J = 6.06 Hz, 
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1H), 6.79‐6.82 (d, J = 8.07 Hz, 2H), 7.06‐7.09 (d, J = 7.89 Hz, 2H), 7.37‐7.46 (m, 3H), 7.53‐
7.56 (d, 2H); 
13C NMR (75 MHz, CDCl3) δ 20.99, 29.61, 58.35 (d, J = 23.46 Hz), 70.33 (d, J 
= 27.82 Hz), 104.2 (d, J = 226.4 Hz), 126.66 (d, J = 1.64 Hz), 126.77, 128.35, 128.52, 129.02, 
130.88 (d, J = 1.64 Hz), 137.35, 138.14, 166.86 (d, J = 35.45 Hz); HRMS (IT‐TOF) m/z calcd 
for C17H16FNO2 [M+Na]
+
 = 308.1063, found = 308.0962. Crystal obtained for X‐ray 
diffraction was recrystallized from a mixture of EtOAc/Hexane.  
(2S,3S)‐3‐(tert‐Butoxycarbonylamino)‐2‐fluoro‐2‐((S)‐hydroxy(phenyl)methyl)‐3‐p‐
tolylpropanoic acid (II-5.17)  
 
To a solution of II-5.15 (100 mg, 0.232 mmol) in THF (2 mL) and MeOH (1 mL), 3M 
aqueous NaOH was added (2 mL). The reaction mixture was stirred at room temperature for 
2.5 h. Upon completion, ethyl acetate (10 mL) was added to the reaction mixture, followed by 
slow addition of 2M aqueous solution of HCl until pH 1‐2 was reached. The phases were then 
separated and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined 
organic layers were dried over Na2SO4 and evaporated to yield crude product, which was 
purified by chromatography (ethyl acetate/hexane = 1:4 to 1:1) to afford acid II-5.17 as a 
white solid (80 mg, 85%) 
1
H
 NMR (300 MHz, CDCl3) δ 1.53 (s, 9H), 2.36 (s, 3.0 H), 5.15‐5.23 (d, J = 24 Hz, 1H), 
5.38‐5.44 (t, J = 9.0 Hz, 1H), 5.98‐6.01 (d, J = 9.0 Hz, 1H), 6.82 (bs, 1H), 7.14‐7.22 (m, 4H), 
7.30‐7.34 (m, 3H), 7.42‐7.43 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 21.01, 28.23, 54.88 (d, J 
= 30.9 Hz), 73.53 (d, J = 18.1 Hz), 81.73, 99.1 (d, J = 203.8 Hz), 127.44, 127.74, 128.11, 
128.42, 129.28, 132.15, 136.38, 138.22, 156.69, 171.4 (d, J = 24.1Hz); HRMS m/z calcd for 
C22H26FNO5 [M+Na]
+
 = 426.1693, found = 426.1511.   
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tert‐Butyl (S)‐((3S, 4S)‐3‐fluoro‐2‐oxo‐4‐phenyloxetan‐3‐yl)(p‐tolyl)methylcarbamate (I-169) 
 
To a solution of acid II-5.17 (77 mg, 0.19 mmol) in dry CH2Cl2 (3.5 mL), DMAP was added 
(0.02 mmol, 4.9 mg), followed by a solution of DCC (59 mg, 0.3 mmol) in dry CH2Cl2 (1.5 
mL). The reaction mixture was stirred at room temperature for 6 hours. Upon completion 
(judged by TLC), DCU was removed by filtration,  and  the  filtrate  was  washed  with  
CH2Cl2  and  the  organic  layers  were  combined  and concentrated. The crude product was 
purified by chromatography using silica gel (ethyl acetate/hexane = 1:10) to afford lactone I-
169 as white solid (43 mg, 59%).  
1
H NMR (300 MHz, CDCl3) δ 1.46 (s, 9H), 2.29 (s, 3.0 H), 5.07‐5.24 (m, 2H), 5.57‐5.61 (d, J 
= 12.0 Hz, 1H), 6.54‐6.57 (d, J = 7.08 Hz, 2H), 6.90‐6.92 (d, J = 7.89 Hz, 2H), 7.20‐7.23 (d, J 
= 7.41 Hz, 2H), 7.32‐7.45 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 20.94, 28.16, 52.47 (d, J = 
19.76 Hz), 80.48, 82.75 (d, J = 24.7 Hz), 105.48 (d, J = 226.70 Hz), 126.65, 128.09, 128.13, 
128.67, 128.86, 129.60, 130.90, 131.52, 131.56, 138.03, 154.54, 164.29 (d, J = 25.24 Hz); 
HRMS m/z calcd for C22H24FNO4 [M+Na]
+




IV-5.2. Experimental procedure for Mannich addition of 
fluoromalonate and analytical data of the product 
 
 
Ethyl fluoromalonate I-170 (18 mg, 0.1 mmol) was added to a mixture of the catalyst Trp-1 
(5 mg, 0.01 mmol) and imine I-164a (16.43 mg, 0.15 mmol) in toluene (2.0 - 1.0 mL) in a 
sample vial. The vial was then capped and the reaction mixture was stirred at -50 
o
C for 72 h. 
The reaction mixture was than filtered through short silica gel column to remove the catalyst. 
Solvent was evaporated and the crude product was purified by column chromatography on 
silica gel (hexane: ethyl acetate = 30:1 to 10: 1) to afford I-171a as a pale yellow oil (39 mg, 
98%). The enantiomeric excess of product was determined by chiral HPLC analysis.  




H NMR (300 MHz, CDCl3): d= 7.31–7.20 (m, 2 H), 7.17–7.07 (m, 2 H), 5.71 
(d, J= 10.2 Hz, 1 H), 5.55 (dd, J= 10.2, 10.0 Hz, 1 H), 4.38–4.21 (m, 2 H), 4.21–4.02 (m, 2 
H), 2.30 (s, 3 H), 1.38 (s, 9 H), 1.31 (t, J= 7.0 Hz, 3 H), 1.13 (t, J= 7.0 Hz, 3 H). The ee value 
was determined as 93% (Chiralcel AD-H, λ= 220 nm, 10% iPrOH/hexane, flow rate = 1 
mL/min, tR = 15.0 min, 17.2 min). 





IV-5.3. Preparation of malonate Mannich adduct halfester and 
analytical data 
 
To a stirred solution of I-171a in mixed solvent (0.5 mmol, 195 mg in 10 ml of solvent: 
THF/MeOH/H2O = 1/0.5/1), was added 1M aqueous solution of NaOH (0.5 ml) dropwise at 0 
o
C. The reaction was then allowed to warm to room temperature and stirred for additional 1.5 
h - 2 h. Upon completion (TLC analysis), slight excess of solid citric acid was added until pH 
reached 3-4. The reaction mixture was then extracted with CH2Cl2 (4x 10 ml), dried over 
Na2SO4 and evaporated. The crude product was purified on silica gel column, eluting with 





H NMR (400 MHz, CDCl3, diastereomeric mixture 1:1): = 10.0 (s, 1H), 7.72 - 7.69 (m, 
1H), 7.54 - 7.52 (m, 1H), 7.36 - 7.35 (m, 1H), 7.12 - 7.10 (m, 6H), 5.63 - 5.53 (m, 3H), 4.96 
(dd, J = 16 Hz, 28Hz, 0.5H, CHArN), 4.95 (dd, J = 16 Hz, 28Hz, 0.5H, CHArN), 4.30 (m, 
2H, CH2O), 4.26 (m, 2H, CH2O), 2.31 (s, 1.5 H, PhCH3), 2.30 (1.5 H, 1.5 H, PhCH3), 1.33 (s, 
4.5 H, t-Bu), 1.28 (s, 4.5 H, t-Bu), 0.92 (t, J = 7.0 Hz, 1.5 H, CH3), 0.90 (t, J = 7.0, 1.5 H, 
CH3); 
13
C NMR (125 Hz, CDCl3): = 186, 184, 172, 171, 130.9, 129.0, 128.8, 128.1, 126.1, 
125.8, 124.4, 124.0, 119.0, 77.2, 68.2, 68.0, 53.4, 53.2, 31.9, 31.4, 23.7, 23.0, 14.0, 14.1; 
19
F 





IV-5.4. Representative procedure for decarboxylation/protonation 
and analytical data of the product. 
 
To a solution of halfester II-5.26 (0.05 mmol, 18.4 mg) in DMF (0.5 ml) was added the base 
(0.01 mmol) at room temperature. The reaction mixture was then stirred at 40 - 45 
o
C the 
duration indicated in the table. Upon completion (TLC analysis) the reaction mixture was 
diluted with ethyl acetate (10 ml) and washed with water (10 ml x 3), brine (10 ml), dried 
over sodium sulphate and evaporated. The crude product was then analyzed by 
1
H NMR and 
subsequently purified by column chromatography on silica gel, eluting with hexane/ethyl 
acetate (30:1 - 20/1) to yield the product as a colorless oil. 
1
H NMR (400 MHz, CDCl3, 2:1 mixture of diastereomers): =  7.24 – 7.12 (m, 6 H), 5.37 – 
5.04 (m, 3H), 4.30 – 4.24 (m, 1H, OCH2 minor dr), 4.14 – 4.06 (m, 2H, OCH2 major dr), 2.34 
(s, 1.5 H, PhCH3 minor dr), 2.32 (s, 3H, PhCH3 major dr), 1.30 (t, J = 7.1 Hz, 1.5 H, CH3 
minor dr), 1.14 (t,  J = 7.1 Hz, 3H, major dr); 
13
C NMR ():  167.54 (d, J = 25.1 Hz), 167.01 
(d, J = 23.7 Hz), 138.3, 137.8, 129.4, 129.3, 127.6, 126.6, 90.29 (dd, J = 191.1, 76.6 Hz, 80.2, 
80.1, 61.76 (d, J = 51.2 Hz, major), 55.65 (d, J = 18.7 Hz, minor), 28.3 (major), 28.2 (minor), 
21.1 (major), 21.0 (minor), 14.0 (minor), 13.9 (major); 
19
F NMR (376 MHz, CDCl3):  =  -
203.4 (dd, J = 27.4, 49.8 Hz, major), -203.5 (dd, J = 26.8, 48.8 Hz, minor); the ee value was 
determined as 93% (Chiralcel IA, λ= 220 nm, 1% iPrOH/hexane, flow rate = 1 mL/min, tR 




IV-6. Preliminary results and future perspective:  decarboxylative 
additions of fluoromalonate halfester 
IV-6.1. Preparation of malonic acid half-ester 
 
To a solution of diethyl fluoromalonate (1 mmol, 178 mg) in a mixed solvent system 
THF/EtOH/H2O (1/0.5/1, 5 ml total) was added 1 M solution of KOH in EtOH (1 equiv., 1 
ml) dropwise at 0 
o
C under vigorous stirring. The reaction was then allowed to warm up to 
room temperature gradually and was stirred for an additional 1.5 - 2 h. Upon completion, the 
reaction mixture was cooled to 0 
o
C and the pH was adjusted to 2 with 1 M aqueous solution 
of HCl. The product was than extracted with CH2Cl2 (4 x 10 ml); the organic phase was dried 
and evaporated to yield the pure desired product as pale-yellow oil.  
3-Ethoxy-2-fluoro-3-oxopropanoic acid (III-2.6) 
 
1
H NMR (300 MHz, CDCl3):  1.33 (t, J = 7.1 Hz, 3H), 4.33 (d, J =7.0 Hz, 2H), 5.41 (d, J = 
40.0 Hz, 1H), 10.16 (bs). 
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IV-6.2. Experimental procedure for decarboxylative addition to 
nitroalkene and analytical data of the product 
 
To a solution of malonate half-ester (III-2.6, 0.1 mmol, 15 mg) in DMSO (1 ml) was added 
the catalyst (I-194b, 0.2 equiv., 6 mg), followed by nitroalkene (1.2 equiv., 18 mg). The 
reaction vial was flushed with argon, capped and stirred at 40 - 45 
o
C for 7 days, with 
occasional TLC analysis. After 7 days, the reaction mixture was cooled to room temperature 
and quenched with satd. aqueous NH4Cl solution (2 ml) and extracted with ethyl acetate (2 x 
5 ml). The organic layer was then washed with water (3 x 10 ml) dried over Na2SO4 and 
evaporated to yield the crude product. After 
1
H NMR analysis of the crude reaction mixture, 
the product was purified on silica gel column eluting with hexane:ethyl acetate (40:1 - 10:1) 
to yield pure product as a pale-yellow oil.  
  Ethyl 2-fluoro-4-nitro-3-phenylbutanoate (III-2.7) 
1
H NMR (300 MHz, CDCl3):  7.34 - 7.22 (m, 5H), 4.74 (dd, J = 7.0, 
12.5 Hz, 1H), 4.64 (dd, J = 7.7, 12.5 Hz, 1H), 4.08 (q, J = 7.0, 14.3 Hz, 
2H), 4.01 - 3.96 (m, 1H), 2.76 (d, J = 7.2 Hz, 1H), 1.17 (t, J = 7.0 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3):  170.6, 138.3, 129.0, 128.0, 127.3, 79.5, 64.3 (d, J = 231 
Hz), 60.9, 40.2, 14.0; 
19
F NMR (376 MHz, CDCl3):  -108.8 (-108.9) m.  
 
 
 
 
 
